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ABSTRACT 
Dengue fever and dengue hemorrhagic fever (DF IDHF) are caused by the dengue 
viruses, which belong to family Flaviviridae. DHF incidence has been increasing 
globally in the last 40 years. Over half the world's population lives in areas 
potentially at risk for dengue transmission, making dengue the most important 
human viral disease transmitted by arthropod vectors in terms of morbidity and 
mortality. Recently, the age distribution of DHF cases in Asia has changed. The 
number of adults with DHF has increased since the 1990s in Southeast Asian 
countries including Viet Nam. 
A series of studies were conducted in the Hospital for Tropical Diseases, Ho Chi 
Minh City, Viet Nam on clinical manifestations, cytokine production in acute 
infection and T cell responses in adult dengue patients. 
A high proportion of adult dengue patients had bleeding and abdominal symptoms. 
DSS were observed in 45% of the in-patient study population. The existing WHO 
classification system and case definitions were inadequate to distinguish between 
adult Vietnamese patients with or without severe bleeding. Therefore, it is 
suggested that a reassessment of the dengue classification scheme is needed for use 
2 
by clinicians, epidemiologists, public-health authorities, vaccine specialists, and 
scientists involved in dengue pathogenesis research. 
The in-vivo cytokine profile in dengue patients strongly implicated the role of 
vaso-active cytokines such as TNFa, soluble TNF receptors, IFNy, IL-2, IL-6, IL-
10 and possibly, the imbalance between these proinflammatory and anti-
inflammatory cytokines in the pathogenesis of dengue infection. 
Six candidate HLA-A * 11 restricted dengue serotype 2 - specific CD8+ T 
lymphocyte epitopes were identified with freshly collected PBMC from secondary 
dengue patients using motif-based predicted peptides. The cross reactivity of 
NS3 133-141 peptides against PBMC from patients infected with all four serotypes 
was studied further by using ELISpot assays and cell surface tetramer staining. 
Short-term CD8+ CTL lines and clones were expanded by stimulating with the 
different variants of the immunodominant NS3133-141 peptide from acute and 
convalescence PBMCs of DHF patients with secondary dengue. The functional 
phenotype of these cross-reactivity CD8+ CTL lines and clones were then 
evaluated and characterized by cytotoxic activity and cytokine secretion. Our 
major finding was that highly cross-reactive CTL clones produce higher levels of 
inflammatory cytokines than serotype - specific clones and this might have 
implications in the pathogenesis of dengue. The fact that cross-reactive immune 
responses between dengue serotypes may playa part in the pathogenesis of severe 
disease should be considered in dengue vaccine development. 
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Chapter) Introduction 
Dengue fever and dengue hemorrhagic fever (DFIDHF) are caused by dengue 
viruses, which belong to the genus Flavivirus, family Flaviviridae. There are four 
antigenically related, but distinct, dengue virus serotypes (DEN-I, DEN-2, DEN-3 
and DEN-4), all of which can cause DF IDHF. Classically, dengue virus infections 
cause a spectrum of illness ranging from asymptomatic, mild undifferentiated 
fever, to classical DF, dengue fever with haemorrhagic manifestations, or dengue 
hemorrhagic fever (DHF). This chapter reviews the history of dengue infection, the 
current situation of DF IDHF as "a global public health problem in the twentieth 
century", clinical manifestations of dengue infection and the pathogenesis of the 
diseases. 
1.1. Dengue infections 
1.1.1 History of dengue 
Because dengue fever has nonspecific clinical features, the interpretation of 
historical records for evidence of past epidemics is open to speculation. The origin 
of the dengue viruses has been controversial. Some early authors speculated on an 
African origin and subsequent distribution around the world with the slave trade 
(Hirsch 1883) (Ehrenkranz, Ventura et al. 1971). 
Dengue viruses are highly adapted to their mosquito hosts and responsible for 
forest cycles, with periodic amplification in lower primates. Such forest cycles 
have been documented in South-East Asia and Africa, and involve several species 
of lower primates and three subgenera (Stegomyia, Finlaya and Diceromyia) of 
canopy-dwelling mosquito species of the genus Aedes (Rudnick 1967) (Comet 
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1993). Biologically, the persistence of dengue virus in the successive generations 
of mosquitoes infected through vertical transmission (i.e., from one generation to 
another) was reported with transmission rates (the percentage of parent females 
transmitting to one or more progeny) ranged up to 95% (Fauran, Laille et al. 1990) 
(Freier and Rosen 1988). These observations suggest that vector mosquitoes may 
play an important role in the maintenance of virus in nature, and that mosquitoes 
may act as reservoirs of dengue viruses (Joshi, Mourya et al. 2002). 
A 1780 Philadelphia epidemic described by Benjamin Rush was perhaps the 
earliest description in English of so-called break-bone fever (Rush 1789). 
However, the earliest clinical and epidemiologic description of a potential dengue 
- like illness found to date is in a Chinese "encyclopedia of disease symptoms and 
remedies", first published during the Chin Dynasty (AD 265 - 420) (Nobuchi 
1979). The disease was called "water poison" by Chinese and was thought to be 
somehow connected with flying insects associated with water. It was characterized 
by fever, rash, eye pain, arthralgias, myalgias and hemorrhagic manifestations, 
including pharyngeal, gingival, intestinal and vaginal bleeding. 
Subsequently, significant numbers of sporadic outbreaks of hemorrhagic disease 
were reported in continental United States through the early decade of the 20th 
century. Clinical descriptions of dengue complicated by hemorrhages, shock and 
death were reported in outbreaks in Australia in 1897, Greece in 1928, and Taiwan 
in 1931 (Hare 1898) (Copanaris 1928); (Akashi 1932). 
Mosquito - borne transmission of the dengue infection by the Aedes aegypti 
mosquito was demonstrated in 1903 (Graham 1903). Sabin and his colleagues 
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isolated viruses from US soldiers in India, New Guinea and Hawaii in 1944 (Sabin 
1945) (Sabin 1952) 
After World War II, dengue cases complicated by haemorrhage and shock (DHF 
and DSS) were increasingly documented in Southeast Asia. Between 1954 and 
1963 outbreaks of a newly recognized severe infectious disease of children were 
reported successively from the Philippines, Thailand, (Hammon, Rudnick et al. 
1960), Singapore (Chew, Leng et al. 1961), and India (Ramakrishnan, Gelfand et 
al. 1964). In Viet Nam, Mihov and co-workers reported an outbreak of 
hemorrhagic fever in Hanoi, North Viet Nam, which appears to be the earliest 
observation of this disease on the east coast of the Dong Duong (Indo-China 
Peninsula). These authors reported clinical findings in 68 patients hospitalized at 
the Pediatric Clinic of the University of Hanoi during the rainy season of 1958. 
Although the total number of cases was unknown, it was estimated that many 
hundreds were involved. The disease affected children and was characterized by 
collapse, gastrointestinal hemorrhage and a mortality rate of 7%. Patients usually 
had thrombocytopenia, mild leukocytosis and hepatomegaly, but no urinary 
abnormalities. The authors did not mention whether dengue-like disease occurred 
simultaneously in the community (Mihov 1959). 
According to available records and personal communication, Halstead et al. 
realised that the first recognized outbreak of hemorrhagic fever in South Viet Nam 
occurred between April and July 1960 in the town of C"i Be, Ti~n Giang Province. 
C"i Be is located approximately 90 Kms southwest of Ho Chi Minh City (Saigon). 
Nearly 50 deaths were attributed to this outbreak. A few cases were admitted to the 
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Provincial Hospital at My Tho, but most cases were not hospitalized; thus, no 
accurate estimate of morbidity could be made (Halstead, V oulgaropoulos et al. 
1965). The first virologically studied outbreak of mosquito-borne hemorrhagic 
fever occurred in the Mekong River delta (Cai L~y) and the city of Saigon, South 
Viet Nam, in the rainy season of 1963. Clinically, the disease resembled that 
described in other outbreaks in Southeast Asia. Three dengue viruses identified 
tentatively as type 2 were recovered, two from patients and one from Aedes 
aegypti captured in Saigon. Serologic data strongly suggested dengue VIruS 
etiology in clinically diagnosed cases (Halstead, Voulgaropoulos et al. 1965). 
Epidemic activity of DHF intensified but remained confined to Southeast Asia 
through the 1970s. However, in the 1980s and 1990s, epidemic DHF spread west 
into India, Pakistan, Sri Lanka, and the Maldives and reemerged in China (Fan, Yu 
et al. 1989). 
In the Americas, dengue was not considered a major public health problem until 
recent years. In 1981, the first major DHF epidemic in the Americas occurred in 
Cuba. During that outbreak, an estimated 344,000 dengue infections occurred and 
over 116,000 hospitalized patients and 10,000 cases of DHF were reported from 
May to October (Kouri, Mas et al. 1983). Moreover, by 1997, DHF had emerged as 
a disease entity in several major and many minor epidemics in tropical and 
subtropical countries of the Americas. 
In summary, DHF incidence has increased in Southeast Asia, the Americas, 
Oceania and world widely over the last 40 years. The reasons for the dramatic 
global emergence of DFIDHF as a major public health problem in the twentieth 
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century are complex and not fully understood. However, several important factors 
can be identified, such as reinfestation of the American tropics by Ae. aegypti 
(Gubler and Trent 1993), ineffective mosquito control (Gubler 1989) (Newton and 
Reiter 1992), major global demographic changes with uncontrolled population 
growth, unplanned urbanization, and massive increase in global travel and trade 
particularly by airplane (Sutherst 2004) (Braks, Honorio et al. 2003) (Friel, 
McMichael et al. 2004). 
1.1.2 Current dengue situation 
Today an estimated 50-100 million cases of dengue fever and 500,000 cases of 
DHF, resulting in around 24,000 deaths, occur annually, depending on the 
epidemic activity (Rigau-Perez, Clark et al. 1998) «WHO) 1997). Over half the 
world's population lives in areas potentially at risk for dengue transmission, 
making dengue the most important human viral disease transmitted by arthropod 
vectors in terms of morbidity and mortality. 
In South East Asia, the total number of reported cases and deaths from DFIDHF in 
nine countries of the SEA Region for the period 1985-2006 ranged from 46,458 
(1986) to 218,821 (1998) and 188,684 (2006). Since 2003 the trend of reported 
dengue cases is rising although the case fatality rate is maintained below 1 % 
.Unfortunately, despite the increase in the reported cases ofDFIDHF, it is generally 
accepted that the incidence of the infection is largely under-reported (Gibbons and 
Vaughn 2002). Poor surveillance systems for dengue (Gubler 2002) and the non-
specific clinical presentation were considered to be the reason for the 
underestimation of the infection (Hoang Lan Phuong 2006). 
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Figure 1.1: Dengue situation in the world (Source: World Health Organization - lOlNoy/2006) 
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The dengue disease burden in Viet Nam is almost certainly under-reported. The 
total disease burden is extracted from the routine health infonnation system (HIS). 
The HIS of the public health services in Viet Nam reports at three levels: 
community, district and province. At community level, health data are recorded in 
a Health Examination Notebook (HEN) in which all patient consultations are being 
recorded. Routine surveillance of dengue is based on an algorithm upplied by the 
National Dengue Control Program that basically follows the guidelines of WHO, 
but does not require haematology support (haematocrit and/or platelets count). By 
u ing this algorithm, in principle, only dengue haemorrhagic fever and dengue 
shock syndrome are notified and uncomplicated dengue fever is not recognized. 
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Serological confirmation is only performed in the relatively mall number of 
complicated cases that need referral to the provincial ho pitals. Sometimes serum 
samples are transferred to National In titute of Hygiene and Epidemiology, Ha Noi 
(in the North) and Institute Pasteur, Ho Chi Minh City (in the South) for isolation 
of dengue virus, but not on a systematic basis. The surveillance data of Institute 
Pasteur, Ho Chi Minh City was shown in Figure 1.2. 
Figure 1.2: Incidence of Dengue Haemorrhagic Fever and serotypes in the South of Viet Nam 
from 1996 - 2007 (Source: Pasteur In titute, Ho Chi Minh City, Viet Nam) 
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Result of tudy in central of Viet Nam, Binh Thuan province (total population = 
1.12 million), in 2003 showed that every year, approximately 1.8% to 3.7% of the 
total population suffered from acute primary dengue, the total number of cases with 
acute primary or secondary dengue should range from 5.5% to ] 1.0% of the total 
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population (Hoang Lan Phuong 2006). Therefore, dengue is highly endemic III 
southern Viet Nam and leads to ignificant costs to the health care system. 
1.1.3 Adult with Dengue infection at the Hosp ital for Tropical Diseases. 
The number of DHF adult cases has increased during the 1980s and the 1990 III 
the Hospital for Tropical Diseases (HTD), Ho Chi Minh city, Viet Nam. 
Figure 1.3: Dengue Haemorrhagic Fever in the Hospital for Tropical Disease (Source: Hospital 
for Tropical Diseases, Ho Chi Minh City, Viet Nam) 
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1.2. Clinical Manifestation and Management of dengue infection 
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The World Health Organization has defined strict criteria for the classification of 
dengue, based on observations made in children during epidemics that occurred in 
Thailand during the 1970s (Fig. 1.4)((WHO) 1997). 
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Figure 1.4: Manifestation of the dengue syndrome (Source: CAB International 1997. Dengue 
and Dengue Haemorrhagic Fever. OJ. Gubler and G. Kuno) 
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1.2.1. Dengue Fever (DF) 
1.2.1.1 Clinical manifestation: 
Classically, DF is described as a non-fatal febrile illness of older children and 
adults of about 5 to 7 days duration associated with sudden onset, extreme malaise, 
and pain of the muscles, back, limbs and eyes; rash is common as are other non-
specific constitutional symptoms such as nausea, vomiting and headache. DF may 
be confused clinically with any other initially non-specific syndromes such as 
influenza measles, malaria, typhoid or leptospirosis. A definitive diagnosis of DF, 
therefore, can only be made by specific laboratory tests. 
Dengue fever is associated with hemorrhage in 5 to 30 percent of cases. Variable 
degrees of bleeding may occur at any site, most commonly petechiae, purpura, 
epistaxis, gingival bleeding or menorrhagia, and usually on days 5 to 8 of the 
illness; hematuria, intracranial and gastrointestinal bleeding have also been 
reported in dengue fever. Unusually severe bleeding may cause shock and death 
due to blood loss (Hayes, Manaloto et al. 1988). 
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Other non-specific constitutional signs and symptoms which may occur include 
photophobia, drenching sweats, cough, sore throat, epistaxis, dysuria, 
hyperesthesia of the skin, pain in the groin and. testicles, delirium, alteration in 
taste, lethargy, anorexia, lymphadenopathy and constipation or diarrhea (Neff, 
Morris et al. 1967) (Liu, Ho et al. 1989) (Chungue, Burucoa et al. 1992). 
1.2.1.2 Laboratory findings 
Clinical laboratory findings associated with classic dengue fever include an early 
neutropenia with subsequent lymphocytosis, often marked by atypical 
lymphocytes. Leucopenia is seen in 50 to 90 percent of OF cases. 
Thrombocytopenia has been reported in 35 to 50 percent of confirmed cases (Dietz, 
Gubler et al. 1996). The WHO defines thrombocytopenia as a platelet count less 
than 100,000 mm-3 for DHF IDSS. Dietz et al. (1987) found that hemorrhage was 
associated with platelet counts below 50,000 mm-3• The hematocrit and 
hemoglobin are normal in uncomplicated classical dengue fever. Likewise, 
prothrombin and partial thromboplastin times are normal and there are no fibrin 
split products present. 
1.2.2. Dengue Haemorrhagic Fever (DHF) 
1.2.2.1 Clinical manifestation: 
Dengue hemorrhagic fever (DHF) is the most severe form of dengue infection with 
hemorrhagic diatheses and a tendency to develop shock (dengue shock syndrome -
DSS) in addition to acute febrile illness «WHO) 1997). The major 
pathophysiologic hallmarks that determine disease severity and distinguish OHF 
from DF are plasma leakage, due to an increase in vascular permeability, and 
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abnormal hemostasis. Hypovolemic shock occurs as a consequence of, and 
subsequent to, critical plasma volume loss selectively into serious spaces (i.e. 
pleural and peritoneal cavities). Abnormal hemostasis, including increased 
capillary fragility (positive tourniquet test and tendency to bruise), 
thrombocytopenia, impaired platelet functions and in the most severe form, 
disseminated intravascular coagulation (DIC), contributes to varying degrees of 
hemorrhagic manifestations. Typically, DHF is characterized by four major clinical 
manifestations, in order of their appearance and declining frequency as follows: 
• High continuous fever of 2 to 7 days 
• Hemorrhagic diathesis 
• Hepatomegaly 
• Circulatory disturbances (as shock in the most severe case) 
Following the incubation period of 5 to 8 days, the illness usually begins abruptly 
with high fever accompanied by facial flushing, skin erythema, headache and 
muscle pain. The body temperature may reach 40 to 41°C, and febrile convulsions 
may occur, particularly in infants. Some patients may complain of sore throat, but 
rarely have rhinitis or cough. Anorexia, vomiting and abdominal pain are common. 
During the acute febrile phase, which usually lasts 2 to 7 days, DHF resembles DF 
in many respects. Hemorrhagic manifestations are usually mild and frequently 
found as tiny, scattered, petechial hemorrhages on the skin or occasionally in the 
buccal cavity and sub conjunctivae, and a tendency to bruise. Early in the febrile 
phase, a positive tourniquet test (more than 10 petechiae per 2.5 cm2) is frequently 
observed. Bleeding from the nose, gums and gastrointestinal tract may be severe. 
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Massive gastrointestinal hemorrhage may occur and is usually found later in 
association with prolonged shock. 
The liver is often enlarged and palpable a few days after onset of fever. It is usually 
soft and tender, but jaundice is rarely observed (Agarwal, Kapoor et al. 1999). 
Splenomegaly is reported in 5 to 15% of cases.(Nimmannitya, Halstead et al. 1969) 
(Setiawan, Samsi et al. 1998) (Singh, Jhamb et al. 2005). 
The critical stage is reached by the end of the febrile phase of illness. 
Accompanying or shortly after a rapid drop in temperature, varying degrees of 
circulatory disturbances develop. The patient is often sweating, restless and has 
cold extremities. In mild DHF cases, the changes in vital signs are minimal and 
transient, patients recovering spontaneously or shortly after a brief period of 
treatment. In more severe DHF cases, the disease progresses rapidly into a stage of 
shock. The onset of shock is acute and generally occurs at the time of 
defervescence, which is usually on or after the fourth day of illness and is acute. 
The patient usually complains of acute abdominal pain and becomes restless. Often 
with subnormal temperature, the skin is cold and clammy, and the pulse becomes 
rapid and weak. The pulse pressure is narrow (:S 20 mmHg), with characteristic 
high diastolic pressure (e.g. 100/90, 110/90 mmHg) in the early stage of shock. It is 
noteworthy that patients who are in shock usually remain conscious almost to the 
terminal stage. The course of shock is short, but life threatening. If proper 
resuscitation is not given, the patient deteriorates rapidly into the stage of profound 
shock, the pulse and/or blood pressure become undetectable, and usually die within 
12 to 24 h after shock ensues. Prolonged shock is often complicated with metabolic 
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acidosis that may precipitate the occurrence of, or enhance the ongoing, DIC to the 
point that massive bleeding may occur. The most common severe bleeding is in the 
gastrointestinal tract, which usually presents as hematemesis (with dark-colored 
blood) and/or melena. The least common hemorrhagic manifestation is intracranial 
bleeding, but these patients have the highest fatality rates. (Sumarmo, Wulur et al. 
1983) (George and Duraisamy 1981). Convulsions and coma are rare in patients 
with DHF in Thailand, but may be more frequently observed in other countries 
such as Indonesia and Malaysia (Lum, Lam et al. 1996). 
Convalescence in patients with DHF, even in shock cases, is usually short and 
uneventful. Diuresis ensues as shock terminates and the patient rapidly regains 
appetite. Some patients may have a confluent petechial rash with characteristic, 
scattered, round areas of pale skin (without petechiae) on the extremities, more 
frequently on the lower extremities; occasionally it may be itchy. Bradycardia is a 
common finding during convalescence. This type of confluent petechial rash and 
bradycardia were originally described during convalescence in patients with DF 
(Sabin 1952). The course of uncomplicated DHFIDSS is about 7 to 10 days in most 
cases. 
1.2.2.2 Laboratory findings 
Some significant laboratory changes occur in patients with DHF, and 
understanding these is critical for clinical diagnosis and management of the 
disease. 
In the peripheral blood, normal white blood-cell counts or leucopenia with 
predominant neutrophils is common initially, and the majority of neutrophils are 
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young fonns. Towards the end of the febrile phase, there is a reduction in the 
number of total white cells and neutrophils, simultaneously with an increase in the 
number of lymphocytes. A relative lymphocytosis with about 15 to 20 percent 
atypical lymphocytes is usually observed 1 to 2 days before defervescence 
(Thisyakom, Nimmannitya et al. 1984). 
Moderate to marked thrombocytopenia is a constant finding in DHF. The platelet 
count drops rapidly to a very low level « 100,000 mm-3) shortly before or 
simultaneously with a rise in hematocrit level, which reflects a leakage of plasma. 
Hct detenninations should be made more frequently after the platelet count has 
fallen. Clotting abnonnalities are common, and laboratory evidence of DIe 
appears to be correlated with disease severity (Srichaikul, Nimmanitaya et al. 
1977) (Srichaikul 1987). 
Evidence of plasma leakage includes a rise m hematocrit leading to 
hemoconcentration during the period of leakage. The hematocrit levels could 
correlate with plasma volume loss and disease severity. However, the levels of 
hemoconcentration may be equivocal when there is frank hemorrhage early and 
excessive volume replacement, or untimely hematocrit determinations. Right-sided 
or bilateral pleural effusion is commonly found at the peak of plasma leakage by 
chest radiography. In cases of mild leakage, hydrothorax can be detected by right 
decubitus view. Hypoproteinemialhypoalbuminemia and other evidence of plasma 
leakage are common, and a reverse albumin to globulin ratio is noted in about two-
thirds of the patients (Nimmannitya 1987). Liver function tests show that most 
patients with DHF have elevation of aspartate aminotransferase (AST) and alanine 
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aminotransferase (AL T) (Uu, Ho et al. 1989) (Kuo, Tai et al. 1992) (Qiu, Gubler et 
al. 1993). 
1.2.3. Clinical Diagnosis 
The severity of DHF has been arbitrarily classified into four grades according to 
the clinical hallmarks of shock and bleeding (Nimmannitya, Halstead et al. 1969). 
It is important to emphasize that cases are classified first as DHF with the presence 
of thrombocytopenia and concurrent hemoconcentration. 
Grade I and grade II are non-shock DHF. In grade I the only hemorrhagic 
manifestation is a positive tourniquet test or tendency to bruise, while in grade II 
there is spontaneous bleeding, usually in the form of petechiae, ecchymoses, 
purpura, bleeding from the nose or gums, hematemesis and melena. 
Grades III and IV are cases ofDHF with shock (dengue shock syndrome). In grade 
III, signs of shock may include cold clammy skin, restlessness, rapid and weak 
pulse, narrow pulse pressure (20 mmHg or less) or hypotension. Grade IV cases 
are those with profound shock with undetectable pulse and/or blood pressure. 
Occasionally, DF cases, particularly those with unusual hemorrhages or with 
thrombocytopenia, are misclassified as DHF grade I or grade II. It should be 
emphasized that thrombocytopenia with concurrent hemoconcentration or rising 
hematocrit are constant findings in DHF that differentiate non-shock cases of DHF 
from DF and other diseases. 
1.2.4. Laboratory Diagnosis 
Laboratory diagnosis of dengue relies on the recovery of the virus by culture or on 
the detection of antibodies to the dengue virus «(WHO) 1997). Although culture is 
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the definitive diagnostic test, several practical considerations limit its use. First, 
virus isolation is mainly successful when attempted using clinical samples obtained 
during the acute phase of disease. Second, samples obtained for the detection of 
dengue virus by culture require proper handling. Third, not all laboratories are 
capable of culturing dengue viruses due to financial and safety reason. 
Several promising laboratory techniques have been introduced in recent years with 
which either viral RNA or viral antigen can be detected in samples obtained from 
infected patients. Amplification of dengue RNA by reverse transcriptase 
polymerase chain reaction (RT-PCR) has proved successful (Lanciotti, Calisher et 
al. 1992) (Morita, Maemoto et al. 1994) (Warrilow, Northill et al. 2002). Using 
RT-PCR, dengue RNA in human samples can be quantified (Sudiro, Zivny et al. 
2001). Recently, it was found that the nonstructural protein NS 1 was circulating 
during the acute phase of infection (Young, Hilditch et al. 2000). Capture enzyme-
linked immunosorbent assays (ELlSAs) have been developed to detect the NS 1 
protein, and several reports indicate that detection of the NS 1 protein may allow 
early diagnosis of infection (Young, Hilditch et al. 2000; Koraka, Burghoorn-Maas 
et al. 2003). Although an antigen detection kit is commercially available, and early 
studies suggest it is specific and reasonably sensitive, further studies are required to 
evaluate this assay are required (Koraka, Burghoorn-Maas et al. 2003) (Dussart, 
Labeau et al. 2006). Serological assays are most widely used in routine practice to 
confirm dengue virus infections and to differentiate between a primary and a 
secondary infection ((WHO) 1997; Vaughn, Green et al. 1997). Primary infections 
are characterized by an increase in the levels of dengue-virus-specific 
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immunoglobulin M (IgM) antibody 3-5 days after the onset of fever. IgM antibody 
titres continue to rise for 1-3 weeks and remain detectable for up to 6 months. 
Dengue-virus-specific immunoglobulin 0 (IgO) antibodies increase shortly after 
the initial rise in IgM antibodies to a modest degree and remain detectable for life 
((WHO) 1997) (Vaughn, Oreen et al. 1997). In secondary infections, the IgM 
antibody level is generally lower than in primary infections, while IgO antibody 
levels rise rapidly from 1 to 2 days after the onset of symptoms (Vaughn, Oreen et 
al. 1997). The most commonly used serological techniques for the diagnosis of 
dengue infection are an ELISA that detects IgO or IgM antibodies and the 
haemagglutination-inhibition test. Traditionally, the haemagglutination-inhibition 
test has been used for the diagnosis of dengue and requires paired acute and 
convalescent sera collected 1 week or more apart for definitive diagnosis. 
However, this test requires samples to be pretreated, and the variability in methods 
used in different laboratories has compromised its general applicability. Today, 
many laboratories rely on other immunosystems for the diagnosis of dengue 
infections: ELISAs, immunochromatographic assays, or dot-blot assays (Vaughn, 
Nisalak et al. 1998) (Vaughn, Nisalak et al. 1999) (Cuzzubbo, Vaughn et al. 2000). 
The most widely used are an IgM antibody-capture enzyme-linked immunosorbent 
assay (MAC-ELISA) or a combination of IgM-capture and IgO-capture ELISAs. 
The interpretation of serological test results may be complicated by the occurrence 
of cross-reactive antibodies to antigenic detenninants shared by other members of 
the flavivirus family (i.e. Japanese encephalitis virus). Commercial kits for the 
detection of IgO as well as IgM antibodies have become available and seem to be 
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useful and reliable for serodiagnosis of dengue virus infection but more evaluation 
is required (Report of the Scientific Working Group on Dengue, 2006. 
TDRJSWG/08). 
1.2.5. Management of Dengue Infection 
Treatment for DF is supportive. Patients with DF may be treated as out-patients 
(Chin, Kang et al. 1993). 
The major pathophysiologic changes that determine disease severity seen in DHF 
include leakage of plasma with resultant hypovolemia/shock and abnormal 
hemostasis that may cause severe bleeding. These changes occur before the fever 
falls and before onset of shock. The duration of plasma leakage is 24 to 48 h in 
most cases. Therefore, therapy in DHF is directed at replacement of lost plasma 
and maintenance of adequate circulatory volume for the 24 to 48 hours period of 
increased vascular permeability and management is essentially supportive and 
symptomatic. The prognosis depends mainly on the early recognition and treatment 
of shock. The key to success is frequent monitoring and changing strategies. 
Patients with DHF grade I and II should be closely monitored for signs of shock. 
The management of DSS (grade III and IV) is a medical emergency needing 
prompt and adequate fluid replacement for the rapid and massive plasma losses 
through increased capillary permeability. Although volume replacement is 
recognized as the critical therapeutic intervention, World Health Organization 
management guidelines remain empirical rather than evidence-based. Initial 
resuscitation with Ringer's lactate is indicated for children with moderately severe 
dengue shock syndrome. Colloidal fluids are indicated in patients with massive 
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plasma leakage and in whom a large volume of crystalloids has been given. 
Dextran 70 and 6 percent hydroxyethy I starch perform similarly in children with 
severe shock, but given the adverse reactions associated with the use of dextran, 
starch may be preferable for this group (Wills, Nguyen et al. 2005). The best 
regiment of fluid resuscitation in DSS is still controversial and further large-scale 
studies, stratified for admission pulse pressure, are indicated (Dung, Day et al. 
1999; Ngo, Cao et al. 2001). 
Frequent recording of vital signs and determinations of the patient's platelet count 
and hematocrit level are important in evaluating the results of treatment. Therefore, 
the haematocrite centrifuge is needed bedside in Intensive Care Unit. Apart from 
correction of electrolyte and metabolic disturbances, oxygen is mandatory in all 
patients of shock. Some patients develop DIC and need supportive therapy with 
blood products (blood, FFP and platelet transfusions). Pleural effusion and ascitis 
are common in cases of DSS, and if possible, drainage should be avoided as it can 
lead to severe hemorrhages and sudden circulatory collapse. 
There is insufficient evidence to justify the use of corticosteroids in managing 
dengue shock syndrome. There were 2 prospective, randomized, controlled trials 
with small samples sizes (97 and 63) showed that a single dose of corticosteroids 
(hydrocortisone hemisuccinate, 50 mg/kg in one trial, methylprednisolone (30 
mg/kg) in other) does not reduce mortality in DSS which does not respond to 
conventional critical care (Sumarmo, Talogo et al. 1982) (Tassniyom, 
Vasanawathana et al. 1993). As corticosteroids can potentially do harm, clinicians 
should not use them unless they are participating in a randomized controlled trial 
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comparing corticosteroids with placebo (Panpanich, Somchai et at. 2006) and 
further investigation on the use of corticosteroids in DHFIDSS is needed. 
1.3. Pathogenesis of Dengue Infection 
Major manifestations of DHF include (i) plasma leakage through elevated vascular 
permeability, (ii) hemorrhage, and (iii) thrombocytopenia. Dengue shock 
syndrome (DSS) is a potentially lethal complication of dengue virus infection 
associated with hypotension and leakage of plasma fluid into the extravascular 
space. 
The pathogenesis of DHF and DSS is still controversial. Two main factors, which 
are frequently cited to explain the pathogenesis changes that occur in DHF and 
DSS, are virus factors and host factors. 
1.3.1 Virus factors 
The dengue virus belongs to genus Flavivirus (family Flaviviridae) that includes 
about 70 distinct viruses, all of which are serologically related and in majority of 
cases, maintained in nature by transmission from hematophagous arthropod 
vectors (mosquito or ticks) to vertebrate hosts. More than 50% of the flaviviruses 
have been associated with human diseases, and of these, the most important in 
terms of disease incidence are dengue virus, yellow fever virus, Japanese 
encephalitis virus, and tick borne encephalitis virus. Dengue virus is present in 
tropical and subtropical areas around the world, as these provide the ecological 
conditions required for maintaining the natural cycles of the virus. There are four 
antigenically-related serotypes, dengue virus types 1, 2, 3, and 4.(Monath 1996). 
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Dengue virus is a single stranded, positive sense RNA virus with 11 kb 
unfragmented genome surrounded by a lipid bilayer envelope. The uninterrupted 
open reading frame codes for three structural proteins and seven non-structural 
proteins. Three structural proteins are C (nucleocapsid), M (membrane associated 
protein) and E (envelope protein) and the seven structural proteins have been 
named as NS 1, NS2, NS3, NS4, NS5, NS6 and NS7 (Lindenbach 2001). Dengue 
virion has a spherical shape with 40-50 nm in diameter. The nucleocapsid is about 
30 nm in diameter and covered by envelope. The envelope is a lipid bilayer 
containing two envelope-associated proteins: the E and M proteins. The E protein 
is glycosylated and responsible for attachment to the cellular receptors and fusion 
with endosomal membranes. The E protein contains the main epitopes recognized 
by neutralizing antibodies. These epitopes can be dengue virus-specific or cross-
reactive with other flaviviruses. It is suggested that neutralizing antibody plays a 
key role in protective immunity against dengue viruses. It is generally believed, 
but not proven, that infection with one DENY serotype provides lifelong immunity 
to that serotype of virus, but limited or negligible cross-protective immunity to the 
other serotypes (Monath 2002). 
The pathology of DHF and DSS has been well studied (Bhamarapravati, Tuchinda 
et al. 1967) (Bhamarapravati 1989). Gross and microscopic pathologic studies of 
tissues taken at autopsy in Thailand have shown diffuse petechial haemorrhages of 
most organs, as well as serous effusions in the pericardial, pleural, and peritoneal 
cavities. Microscopically, perivascular edema and loss of integrity of endothelial 
junctions are found. 
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Dengue antigen can be demonstrated in endothelial cells, but there is no apparent 
damage to the blood vessels or endothelial cells. Dengue antigen has been detected 
in Kuffer cells, alveolar macrophages, mononuclear phagocytes in the skin, and 
circulating monocytes (Bhamarapravati 1997). The viruses have been isolated or 
detected in organs such as lymphoid organs, liver, spleen, kidney, and brain 
(Guzman, Alvarez et al. 1999). There is increased proliferation of 
reticuloendothelial cells in the bone marrow, spleen, lymph nodes, and lungs. 
Dendritic cells could be the early, primary targets of dengue viruses in natural 
infection and could play an important part in the pathogenesis of dengue infection 
through an increase in virus load and cell activation (Wu, Grouard-Vogel et al. 
2000) (Libraty, Pichyangkul et al. 2001). 
It has been assumed that virulence of the virus contributes to the development of 
DHF, virulent dengue virus strains cause DHF while avirulent dengue virus strains 
cause DF. This hypothesis assumes that dengue viruses, like all animal viruses, 
vary and change genetically as a result of selection pressures as they replicate in 
humans and/or mosquitoes and that there are some virus strains that have greater 
epidemic potential. Phenotypic expression of genetic changes in the virus genome 
may include increased virus replication and viremia, severity of disease 
(virulence), and epidemic potential (Gubler, Reed et al. 1978). There has been 
some evidence that support for this theory. Two important genotypes for dengue 2 
virus have been identified, one, from southeast Asian origin, related to most of the 
DHF epidemics in southeast Asia and the Americas; and the other, the American 
genotype, only related to DF epidemics in the American region (Leitmeyer, 
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Vaughn et al. 1999) (Guzman, Deubel et al. 1995) (Watts, Porter et al. 1999). The 
1981 Cuban epidemic has been considered one of the most severe DHF epidemics 
to date in the Americas (Kouri, Guzman et al. 1989). The genomic study of Cuban 
dengue 2 strains and the RNA from a liver sample of a fatal case demonstrated 
their similarity with southeast Asian strains, at least at the studied fragment 
(Guzman, Deubel et al. 1995) (Sarlol, Pelegrino et al. 1999). Thus, the introduction 
of the Southeast Asian genotype coincided with the appearance of DHF in 
different countries in the Americas, while the original American genotype was 
only associated with DF, but not with DHF (Rico-Hesse, Harrison et al. 1997) 
(Rico-Hesse, Harrison et al. 1998). 
A similar epidemiological situation to that in Cuba was reported in Iquitos, Peru. A 
dengue 1 epidemic occurred in 1990 followed 5 years later by a dengue 2 epidemic 
with DF; no DHF cases were observed in Peru. The dengue 1 viruses that affected 
Cuba in 1977 and Peru in 1990 were similar; but, the 1981 Cuban dengue 2 strain 
belonged to an Asian genotype and the Peruvian dengue 2 virus belonged to the 
American genotype (Watts, Porter et al. 1999). These results suggest that the Asian 
genotype possess one or more virulence determinants that are absent from viruses 
originating in the Americas. 
The relation of specific genotypes with severe disease has also being observed for 
dengue 3 virus (Figueroa and Ramos 2000) (Briseno-Garcia, Gomez-Dantes et al. 
1996). 
Classically, the strains that were isolated from patients with DHF or DSS are often 
called "virulent strains". However, their virulence cannot be confirmed because of 
39 
Chapter 1 Introduction 
a lack of adequate animal models of disease. It has not been determined whether 
some strains are virulent because they grow well in vivo with or without enhancing 
antibodies, because they are highly cytopathic, or because they induce high levels 
of cytokines. Further studies are needed to elucidate the molecular basis 
underlying these possible different phenotypes. 
It has been reported that viral titers in peripheral blood are higher in patients who 
develop DHF than in those with DF (Vaughn, Green et al. 2000). However, it is 
not determined why and how higher levels of viremia lead to unique clinical 
manifestations: plasma leakage, hemorrhagic manifestations seen in DHF. 
Recently, Libraty et al showed that maximum plasma viremia levels of DEN-3 
correlated with the degree of plasma leakage and thrombocytopenia (Libraty, Endy 
et al. 2002), although the level of correlation was not particularly strong. 
1.3.2 Host factors and Immunopathogenesis 
A well-established epidemiologic feature of DHF lOSS is age. In the Cuban DHF 
lOSS outbreak of 1981, where everyone from 2 to 40 years of age experienced the 
same sequence of exposure (DEN-l in 1977-78 and DEN-2 in 1981), hospitalized 
patients peaked at age 8 to 11 years and then fell dramatically nearly to the baseline 
among mid-teens (Kouri, Guzman et al. 1989). In addition, children are in higher 
risk of DHF than adults, as have been reported in Thailand and some others 
Southeast Asian countries. These studies showed that age-specific DHF incidence 
was bimodal, with severe cases peaking at 7 months of age and again at 3-5 years 
of age (Nimmannitya 1987). (Halstead 1970) (Guzman, Kouri et al. 1984). It has 
been suggested that baseline microvascular permeability of capillaries in children 
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is considerably greater than that of adults and this could explain, at least partly, 
why dengue shock syndrome is more frequently observed in children (Bethell, 
Gamble et al. 2001). Age associated immune status of the population can also 
govern the severity of outbreaks. When a single dengue serotype has been endemic 
for a generation or more, most adults will be solidly immune. A highly immune 
adult popUlation and a semi-immune population of children would be expected to 
create an epidemiologic situation, in which there is little or no reported disease of 
any kind. This is what was noted during the era of European colonization of 
tropical Asia; dengue fever attacked the newcomers, but without obvious disease 
among the local population (Halstead 1994). 
The interactions between pre-existing pathology and dengue infections are also 
contribute to the severity of illness. The best documented example is the severe 
gastrointestinal bleeding which accompanies dengue infections (primary or 
secondary) in individuals with peptic ulcer disease (Tsai, Kuo et al. 1991). Severe 
menorrhagia has also been described in women during dengue infections (Tai, 
Chee et al. 1999) (McGready, Paw et al. 2000). Individuals with open mucosal 
lesions, whether pathologic (peptic ulcer) or physiologic (menstruation), who 
suffer dengue infections may bleed. Blood loss may be catastrophic and life 
threatening. 
Host immunopathogenesis is an alternatively hypothesis for the pathogenesis of 
dengue infection. This hypothesis implies that patients experiencing a second 
infection with a heterologous dengue virus serotype have a significantly higher risk 
for developing DHF and DSS (Halstead 1970) (Halstead 1988). 
41 
Chapter 1 Introduction 
Antibody levels may have a dominant role in driving dengue infection to more or 
fewer infected cells. Epitopes present on E protein are able to induce neutralizing 
antibodies, both homologous and heterologous. People infected with one serotype 
maintain a life-long protective immunity to infection by the homologous virus, 
although protective immunity to infection with heterologous serotypes is short-
lived. Cross-reactive antibodies that lack neutralizing activity are also induced in 
the primary infection. Upon secondary infection with a heterotypic virus, these 
preexisting heterologous dengue antibodies recognizes the infecting virus and 
forms virus-antibody complexes, which then bind to Fcy receptors on target cells, 
especially macrophages. Because the antibody is heterologous, however, the virus 
is not neutralized, and the non-neutralizing, cross-reactive antibodies markedly 
augment dengue virus infection of Fcy receptor-positive cells (Mady, Erbe et al. 
1991). This phenomenon is called antibody-dependent enhancement (ADE). Thus, 
it is hypothesized that prior infection, through a process known as ADE, enhances 
the infection and replication of dengue virus in cells of the mononuclear cell 
lineage (Halstead and O'Rourke 1977) (Halstead and O'Rourke 1977) (Brandt, 
McCown et al. 1982) (Halstead 1988). It is thought that these cells produce and 
secrete vasoactive mediators in response to dengue infection, which causes 
increased vascular permeability leading to hypovolemia and shock. Infants born to 
the mothers develop DHF in the primary infections. The levels of maternal dengue 
virus antibodies in the infants needed to decline to the levels that can enhance 
dengue virus infection and lead to DHF (Kliks, Nisalak et al. 1989) (Kliks, 
Nimmanitya et al. 1988). These observations are consistent with the idea that 
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enhancing antibodies increase the number of dengue virus-infected cells and the 
levels of viremia and lead to DHF. 
Activation of complement is another important clinical manifestation in DHF and 
thus it has been assumed that complement activation is also responsible for the 
pathogenesis of DHF. It was reported that the complement system is activated in 
DHFIDSS (Ward 1973) (Nishioka 1974). The peak of activation and the presence 
of C3a and C5a coincided with the onset of shock and leakage. The levels of C3a 
correlated well with disease severity (Malasit 1987). The mechanism of 
complement activation in DHF is not completely understood. Circulating immune 
complexes are present in the DHF patients, and it has been assumed that the 
complement is activated by the immune complexes (Malasit 1987). High levels of 
secreted NS 1 and pre-existing cross-reactive antibody may also mediate 
complement activation (A virutnan, Punyadee et al. 2006). Further, it was reported 
that dengue virus-infected monocytes and endothelial cells activate complement 
via classical and alternative pathways (A virutnan, Malasit et al. 1998). It is likely 
that complement is activated by various mechanisms in DHF patients, and that 
complement activation also contributes to the pathogenesis of various clinical 
features, especially plasma leakage. 
The cellular immune response may also be important in the pathogenesis of 
dengue. Circulating dengue virus-specific CD4+ and CD8+ T lymphocytes were 
detected in individuals after a primary dengue virus infection (Bukowski, Kurane 
et al. 1989) (Kurane, Innis et al. 1989). It has been demonstrated that memory 
dengue T lymphocyte response after a primary infection includes both serotype-
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specific and serotype-cross-reactive CD4+CD8( -)T lymphocytes and CD4(-
)CD8+ T lymphocytes. The predominant response in PBMC was to the serotype of 
dengue virus with which the donors had been infected, but cross-reactive responses 
to one or more of the other (heterologous) serotypes of dengue virus were detected 
in all subjects. (Kurane, Innis et al. 1990). Heterogeneous dengue virus-specific 
CD4+ cytotoxic T cells are stimulated in response to infection with a dengue virus 
and that a nonstructural protein, NS3, contains multiple dominant T-cell epitopes 
(Kurane, Brinton et al. 1991). NS3 protein seems to be the major target for CD4+ 
and CD8+ T cells, although some T cell epitopes have been recognized in other 
proteins such as envelope and capsid (Kurane, Zeng et al. 1998) (Spaulding, 
Kurane et al. 1999). 
The pattern and magnitude of the cross-reactive response to heterologous dengue 
serotypes is variable between subjects, even among those who were infected with 
an identical virus (Dharakul, Kurane et al. 1994), depending on different factors 
such as the serotype causing the primary infection and the ethnicity of the 
individual (Rothman and Ennis 1999). Both CD4+ and CD8+ dengue virus-
specific T lymphocyte clones are able to lyse dengue virus-infected target cells in 
vitro (Gagnon, Zeng et al. 1996) (Kurane, Innis et al. 1989) (Livingston, Kurane et 
al. 1995). 
A series of studies have suggested that plasma leakage is caused by malfunction of 
vascular endothelial cells induced by cytokines or chemical mediators rather than 
by destruction of the small vessels and cytokines that may induce plasma leakage 
such as interferon y, interIeukin (IL) 2, and tumour necrosis factor (TNF) a are 
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increased in DHF cases (Kurane and Ennis 1992) (Bethell, Flobbe et al. 1998) 
(Hober, Nguyen et al. 1998) (Rothman and Ennis 1999). 
Cytokines could be released either directly from monocytes/macrophages as a 
result of infection or after interactions between infected and immune cells, or both 
(Kurane and Ennis 1992) (Hober, Nguyen et al. 1998). CD4+ T lymphocytes 
produce a number of cytokines, including interferon y (IFNy), interleukin (IL) 2, 
IL-4, IL-5, IL-6, IL-lO, and lymphotoxin. Moreover, monocytes/macrophages 
which are infected by dengue viruses produce tumour necrosis factor (TNF) a, IL-
l, IL-IB, IL-6, and platelet-activating factor (PAF). Finally, cytokine and chemical 
mediator production is induced by other cytokines. Thus, once cytokines are 
produced, a complex network of induction may further increase the levels of 
cytokines and chemical mediators, resulting in even higher levels with synergistic 
effects on vascular permeability (Kurane 1997). Interferon y enhances uptake of 
dengue particles by target cells through increasing Fc cell receptors (Kontny, 
Kurane et al. 1988). Others cytokines such as IL-6, IL-8, and IL-I0 are also 
increased (Green, Vaughn et al. 1999). 
It has been, however, difficult to attribute the pathogenesis of DHF to a sole 
cytokine. It is more likely that the multiple cytokines function in a synergistic and 
additive fashion, and induce the pathology and the clinical manifestations of DHF. 
Further studies are still needed for a better understanding of the precise 
contribution of cytokines to dengue pathology. 
It has been demonstrated that dengue infected peripheral blood monocytes in ADE 
conditions generate soluble mediators that activate endothelial cells through the 
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enhanced expression of adhesion molecules such as VCAM-I and ICAM-I 
(Anderson, Wang et al. 1997). At the same time, high levels ofTNFa (induced by 
infected monocytes and by T-cell activation or both) could be responsible in part 
for transient vascular damage. The role ofTNFa in the pathogenesis of the disease 
is critical, and it probably initiates several processes relating to plasma leakage and 
haemorrhage (Anderson, Wang et al. 1997). Avirutnan and colleagues have shown 
that infection of human endothelial cells with dengue virus induces the secretion of 
RANTES and IL-8, and in the presence of anti-dengue Abs, the formation of 
nonlytic complement complexes. Furthermore, dengue virus infection of 
endothelial cells in vitro caused apoptosis. Complement activation, chemokine 
induction, and apoptotic cell death may act in concert to cause the fulminant but 
short-lived vascular leakage that is characteristic of DHF lOSS (A virutnan, Malasit 
et al. 1998). 
The potential role of mast cells/basophils in the pathogenesis of the disease also 
has been reported. Mast cell/basophile KU812 cells are permissive to dengue virus 
infection with the production of viral particles and vasoactive cytokine 
production.(King, Marshall et al. 2000). 
1.3.3 Integrated hypothesis to explain pathogenesis 
Overall, there are many epidemiologic and laboratory-derived data to support 
important roles for both virus factors and host response to the overall clinical 
phenotype. These two theories have been considered as opposing each other for a 
long period of time. However, it appears that they are not mutually exclusive, and 
both are likely to be valid. Excellent reviews have recently been published on both 
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viral pathogenesis and immunopathogenesis (Kurane 1997) (Rothman and Ennis 
1999) (Guzman and Kouri 2002),. In essence the overall clinical outcome likely 
depends on a very complex interaction between virus, host, and host immune 
response An integrated hypothesis for the development of DHF epidemics was 
proposed in 1987 (Kouri, Guzman et al. 1987). The intersection of three groups of 
factors (host, viral, and epidemiological factors) determine the nature of a DHF 
epidemic (Fig 1.4). 
Figure 1.5: Risk factor for DHFIDSS: an integral hypothesis 
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(From Guzman et al. Lancet Infectious Di eases 2002) (Guzman and Kouri 2002) 
In general, the epidemiological and viral factors are the determinants for an 
epidemic of disease. Individual risk factors such age, chronic diseases are 
predi posing factors that make the disease more frequent in a certain age group 
(Nimmannitya 1987). (Halstead 1970) (Guzman, Kouri et al. 1984). However, the 
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pre-existence of immune response is the main individual risk factor, but not the 
only one, for the occurrence of severe disease. Individual risk factors are the ones 
that determine the appearance of the disease in a particular person in a given 
population. The presence or absence of these individual risk factors, in the matrix 
of epidemiological and viral factors, determines whether or not all persons with a 
secondary type of infection present the clinical picture of DHF. 
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1 Study site 
The Hospital for Tropical Diseases (HTD) (former name: Cho Quan Hospital) in 
Ho Chi Minh City is referral hospital for patients with infectious diseases, and 
serves the Ho Chi Minh City area (8 million population) and southern provinces of 
Viet Nam (population approximately 35 million). The hospital has 500 beds, 
including two intensive care units (paediatric and adult) and nine wards for non-
complicated infectious diseases (malaria, DHF, diphtheria, HIV/AIDS, viral 
hepatitis, central nervous infections (encephalitis and meningitis), respiratory 
infections, acute diarrhea. The hospital staff have places in The National 
Committee of DHF Control, AIDS control, Malaria Control, Hospital infection 
Control and are collaborating with WHO on several aspects of dengue clinical 
management and diagnosis. Laboratories of HTD are supported by the Oxford 
University Clinical Research Unit to provide routine clinical haematology, 
biochemistry, microbiology, serology, immunology and molecular biology 
investigations. The HID Laboratory is also involved in the TDRlPDVI network of 
laboratories for dengue diagnostic evaluations. 
The Oxford University Clinical Research Unit (OUCRU) opened in 1991, funded 
by the Wellcome Trust of Great Britain. The OUCRU, located within the HTD, 
serves as a collaborative centre between HTD and Oxford University and started as 
an 8-bed ward for the treatment of patients with severe malaria. Over 10 years the 
Unit has expanded and now performs research on many areas including dengue, 
influenza, central nervous system infection. 
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To explore the factors those contribute to the pathogenesis of dengue 
infection in Vietnamese adults. 
Specific objectives: 
11 to describe clinical features and immunological responses of adult 
patients with dengue infection admitted to the Hospital for Tropical Diseases, Ho 
Chi Minh City, Viet Nam. 
2/ to investigate dengue-specific and cross - reactivity T Lymphocyte 
responses during acute disease and convalescence, in a population of naturally 
immune individuals, in a dengue-endemic region. 
3/ to study the specificity and cross reactivity of short-term CD8+ CTL 
lines and clones stimulated with different variants of the identified epitope from 
acute and convalescence PBMCs of secondary DHF patients. The functional 
phenotype of these cross-reactivity CD8+ CTL lines and clones are also evaluated. 
2.3 Patient and Study procedure 
Adult patients who admitted to the Hospital for Tropical Diseases with suspected 
dengue were recruited to prospective clinical descriptive and immunology studies. 
HTD Scientific and Ethical Committee approved all study protocols, and informed 
consent was obtained from each patient or accompanying relative. 
2.3.1 Patient recruitment 
Consecutive adult cases (~ 15 year-old) presenting to the Hospital for Tropical 
Diseases in Ho Chi Minh city, Viet Nam who were suspected of having dengue 
51 
Chapter 2 Materials & Methods 
were invited to participate in the study between 2002 and 2004 and informed 
consent was obtained. 
The case definition of a patient with suspected dengue included acute fever or 
history of acute fever (less than 7 days) with one or more of the following 
symptoms and signs: headache, retro-orbital pain, myalgia, arthralgia, rash, 
hemorrhagic phenomena, including a positive tourniquet test; exclusion of 
alternative diagnoses, such as malaria, by clinical examination and appropriate 
laboratory tests. 
The World Health Organization (WHO) definitions and criteria were used to 
classify dengue disease «WHO) 1997). DSS was defined as a case of DHF with 
either a narrow pulse pressure (~ 20 mm Hg) or unrecordable blood pressure 
«WHO) 1986); typically these were accompanied by signs of circulatory 
insufficiency, such as cold extremities and thready pulse. 
In parallel to the DHFIDSS classification, severe clinical manifestations of dengue 
were defined as internal hemorrhage, plasma leakage, shock, and/or platelet count 
< 50,000/mm3• Internal hemorrhage consisted of melena, hematemesis, hematuria, 
and/or menorrhagia. Plasma leakage was indicated by the presence of pleural 
effusion, ascites, and/or haemoconcentration (haematocrit values (~ 20% of the 
baseline value). Because baseline value was not known for most patients and only 
a small percentage of patients came back for follow-up to provide autologous 
baseline Hct values, haemoconcentration in adults for practical reasons was 
defined as haematocrit ~ 45% (normal value of Hct in adult in Viet Nam is 38%, 
range from 35 - 41 % (source: Ministry of Health of Viet Nam). 
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The confirmation of acute dengue virus infection by elevated dengue virus-
specific serum IgM titers as measured by capture ELISA (using a commercial 
PANBIO Dengue duo IgM and IgG test) and / or virology (using RT -PCR) (see 
2.4). 
2.3.2 Clinical procedure 
On admission to the study, following informed consent, patients were examined 
and results documented on a standardized Case Record Form (CRF) that also 
recorded the subject's demographic and epidemiologic characteristics as well as 
information regarding their illness. Clinical evolution of hospitalized patients was 
monitored daily using these CRF. 
Venous blood was taken on admission for testing full blood count, blood glucose, 
serum creatinin, blood urea nitrogen and transaminases in the hospital laboratory, 
and serum was taken for serologic and virological testing. Patients were reassessed 
every 6 hours daily for vital signs as axillary temperature, pulse, blood pressure 
during febrile period until discharge. As per routine hospital procedure, blood 
samples were collected daily from patients hospitalized for dengue for monitoring 
of hematocrit and platelet levels until normal levels were obtained post-
defervescence. 
An extra sample for cytokine measurement was collected from consented patient 
as soon as possible after admission onto EDTA (1 mg/mL) and separated 
promptly, and plasma was stored at -700C. A second blood sample, taken upon 
hospital discharge, served as the convalescent phase sample. 
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For cellular immune response studies, peripheral blood samples were collected 
from venous blood of patients between 8 and 11 am on the first morning after 
admission (study day 1), and again on study day 5 unless the patient was 
discharged earlier. Convalescent samples were taken at 14 days and I month after 
admission. Peripheral blood mononuclear cells (PBMCs) then were separated 
using Lymphoprep (Axis-Shield Poc AS, Oslo, Norway). Separated PBMCs were 
cryo-preserved in liquid nitrogen container for future immune assays. 
Supportive therapy for all patients was given following the WHO guidelines and 
Viet Nam National Guideline for Dengue Heamorrhagic Fever. All patients who 
developed dengue shock syndrome were kept under close observation, including 
hourly measurements of pulse and blood pressure, hematocrit measurements every 
2 to 6 hours with the bedside centrifuge by experienced physicians and nurses in 
intensive care unit. Fluid resuscitation was carried out immediately for these 
patients until they were no longer clinically hypovolemic. Fresh whole blood with 
matched group was given in the case of suspected internal bleeding whose had 
persistent shock even after initial resuscitation with plasma expanders and 
continuing decline of the haematocrit. Other appropriate treatments such as 
inotropic agents, mechanical ventilator were also applied if it is indicated. U suaUy, 
patients who had been resuscitated from shock rapidly recovered. Patients with 
dengue hemorrhagic fever discharged from the hospital after their clinical 
condition was stable, or at least 48 hours since recovery from shock in dengue 
shock syndrome. All patients were asked to come back to the hospital for follow 
up 2-4 weeks after discharge from hospitaL 
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2.3.3 Routine Clinical Laboratory investigation 
Full blood counts were performed every day during hospitalisation. Blood glucose, 
creatinine were tested on admission and re-tested until the results were normal or 
the patient fully recovered from shock status. Chest X ray and ultrasound were 
performed for indicated severe cases. All routine clinical laboratory tests were 
performed followed standard operating procedures at the hospital laboratory . 
2.4 Laboratory Methods 
2.4.1 Serology confirmation for acute dengue infection 
Dengue virus infectious cases were confirmed via serological testing of acute and 
early convalescent phase plasma with a commercial capture-immunoglobulin M 
(lgM) and IgG enzyme-linked immunosorbent assay (ELISA) (Panbio, Brisbane, 
Australia). The ELISA was performed and results were interpreted according to 
the manufacturer's instructions. Results were determined by comparison with IgM 
and IgG reference sera provided (cut-off calibrators). A positive sample was 
defined as having a calibrator absorbance ratio ~ 1.0 and a negative sample with a 
ratio ~ 1.0. Dengue virus infection was characterized by the elevation of either 
IgM or IgG, with a negative sample being defined as having both IgM and IgG 
ratios of <1.0. The Panbio ELISA has been calibrated against HAl units previously 
(Vaughn, Nisalak et al. 1999); an IgG level greater than 40 units has been defined 
as highly suggestive of secondary dengue. This P ANBIO Dengue duo capture-IgM 
and IgG ELISA assay has been proven to be a reliable, rapid, sensitive, and 
specific diagnostic test to diagnose primary and secondary dengue infection on 
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single or paired samples (Cuzzubbo, Vaughn et al. 1999) (Vaughn, Nisalak et al. 
1999). 
2.4.2 Dengue virus molecular serotyping methods 
2.4.2.1 RNA Extraction 
Dengue RNA was extracted from plasma using the Boom method (Boom, Sol et at. 
1990). 
Preparation of reagents: 
~ Buffer L6: add 120 g of guanidinium isothiocyanate to 100 mL of 0.1 M 
TrislHCI pH 6.4 and 22 mL of 0.2 M EDTA pH 8.0, and 2.6 g of Triton x-
100; stir overnight in the dark to dissolve. Store in the dark. 
~ Buffer L2: add 120 g of guanidinium isothiocyanate to 100 mL of 0.1 M 
TrislHCI pH 6.4 and stir overnight in the dark to dissolve. Store in the dark. 
~ Size fractionated silica, add 60 g of silicon dioxide to 500 mL of distilled 
water in a measuring cylinder and allow standing for 24 h at room 
temperature. Discard 430 mL of supernatant and re-suspend solids in 500 
mL of distilled water. Allow to stand at room temperature for 5 hand 
discard 440 mL of supernatant. Add 600 ilL of concentrated HCl pH 2.0 
and aliquot into 1.5 mL volumes. Sterilize by autoclaving (151bs for 
15min) and store in the dark. 
Protocol: 50-200JlI of serum, plasma or culture supernatant was added to a tube 
containing 1 ml of L6 lysis buffer and 20Jll of a suspension of size-fractionated 
silica particles, then briefly vortexed. After incubation for 10 min at RT, the tube 
was vortexed for 5 seconds and centrifuged for 1 min at 13,000 x g. Supernatant 
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was then discarded and 1 ml of washing buffer L2 added to the silica-nucleic acid 
complex, followed by vortexing (5 sec) and two washes with buffer L2 (1 min at 
13,000 x g), followed by two washes with 70% (vol/vol) ethanol and one wash 
with 1 ml of acetone (Merck). After disposal of the acetone, the tube was dried at 
56°C with open lid in a heating block for 10 min. The pellet was resuspended in 
IOOIlI of 1 x TE buffer, vortexed for 5 seconds, and left at 56°C for 10 min to elute 
the nucleic acids. After incubation, it was vortexed again and centrifuged for 2 min 
at 13,000 x g. Only 70 III of the supernatant containing viral RNA were gently 
pipetted to a new O.5ml eppendorf to avoid disturbing the pellet. In most cases, 
RNA was immediately used for synthesis of eDNA, otherwise it was stored at 
minus 800C until used. 
2.4.2.2 Oligonucleotide primers 
Dengue virus consensus primers Dl and D2 that were designed for maximum 
homology to the four serotypes, high melting temperature, and nonhomology to 
other regions of dengue virus genomes are shown in Table 2.1, along with their 
genome positions and product sizes when used in enzymatic amplifications. The 
type-specific primers shown in Table 2.1 (TS1, TS2, TS3, and TS4) were designed 
to anneal specifically to each of their respective genomes. 
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Table 2.1: Oligonucleotide primers for amplification and serotyping dengue virus 
Primes Sequence Genome Size 
position (in bp) 
01 5'-TCAATATGCTGAAACGCGCGAGAAACCG-3' 134-161 511 
02 5'-TTGCACCAACAGTCAA TGTCTTCAGGTTC-3' 616-644 511 
TSI 5'-CGTCTCAGTGATCCGGGGG-3' 568-586 482 
(01 and TSl) 
TS2 5'-CGCCACAAGGGCCATGAACAG-3' 232-252 119 
(01 and TS2) 
TS3 5'-TAACATCATCATGAGACAGAGC-3' 400-421 290 
(01 and TS3) 
TS4 5'-CTCTGTTGTCTTAAACAAGAGA-3' 506-527 392 
(01 and TS4) 
2.4.2.3 Lanciotti seminested RT -peR 
A seminested RT-PCR, targets the C and preM region has been developed 
(Lanciotti, Calisher et al. 1992). It uses universal outer dengue primers D 1 and 02, 
followed by a subsequent serotype-specific seminested PCR combining primer Dl 
with one of the following internal primers: TSI, TS2, TS3, or TS4. 
Target viral RNA was converted to a DNA copy (cDNA) prior to enzymatic DNA 
amplification by use of reverse transcriptase (R T) and the dengue virus 
downstream consensus primer (D2), homologous to the genomic RNA of the four 
serotypes as following: RNA pellet was resuspended in 30 III of RNase-free water 
and incubated for 10 min at 55°C, and then 5 III was used in an RT reaction in a 
IS-Ill mixture containing 500 J.LM deoxynucleoside triphosphate (dNTP) , 0.25 ~ 
D2 primer, 20 U of RNasin (Promega), 5 U of avian myeloblastosis virus reverse 
transcriptase (Promega). 5x RT buffer, and RNase-free water. RT was carried out 
at 42°C for 1 h. 
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The first-round PCR was carried out in a 50-~1 volume containing 2.5 mM MgCI2, 
0.2 mM (each) dNTPs (Boehringer Mannheim, Mannheim, Germany), 0.2 ~M 
(each) 01 and 02 outer primers, 1 x Taq buffer, 2 U ofTaq polymerase (Promega), 
5 ~l of the RT product, and PCR-grade water. The PCR program started with 5 
min of denaturation at 95°C, followed by 35 cycles consisting of 94°C for 1 min, 
55°C for 1 min, and 72°C for 1 min, and ended with a noc final extension step for 
10 min. The second-round PCR was performed in a 50-~1 reaction mixture 
containing 2.5 mM MgCI2, 0.2 mM (each) dNTPs, 0.2 ~ (each) Dl, TS1, TS2, 
TS3, and TS4 primers, lOx Taq buffer, 2 U of Taq polymerase, and 5 ~l of the 
diluted first-round PCR product (1 : 1 00 in PeR-grade water). The cycling program 
started with a 5-min denaturation step at 94°C, followed by 25 cycles each at 94°C 
for 1 min, 55°C for 1 min, and noc for 1 min, and ended with a 72°C final 
extension step for 10 min. Positive (dengue viral RNA) and negative (no template) 
controls were included for each step of the process (extraction, RT, and first- and 
second-round PCR). 
This assay is known to have the good sensitivity and is widely used for diagnosis 
and surveillance of dengue, particularly in Southeast Asian countries (Nguyen, 
Tran et al. 1997) (Solomon, Oung et al. 2000) (Vaughn, Green et al. 2000). 
2.4.3 Separation of peripheral blood mononuclear cells from peripheral blood. 
Peripheral blood mononuclear cells (PBMCs) were separated using Lymphoprep 
(Axis-Shield Poc AS, Oslo, Norway). Whole blood was placed on the Iymphoprep 
(ratio I: 1 to 1: 1.5) using a pipette and applying the sample gently to the sides of 
SOml Falcon tube already containing the right amount of Ficoll. This tube was 
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centrifuged at 2000x g (Relative centrifugal force) for 20-25 minutes at room 
temperature with no brake. After centrifugation, the milky - white - cloudy layer 
(PBMC layer) at the interface between the Ficoll (transparent) and the remaining 
plasma (yellow) was transferred into other another 50ml tube by aspiring gently 
with a sterile pipette. PBMCs were washed twice with RPMI (normally 10-20 mL 
are used). PBMCs were re-suspended in RlIO (RPMI 1640 medium containing 
10% HI-FCS, 2mM L-glutamine, IOOllg/ml Streptomycin, 100U Penicillin) for 
direct use in immune assay or future use in cryo-preservation. 
2.4.4 Cryopreservation of PBMCs. 
PBMC were cryopreserved at a cell concentration of 5-1 Ox 1 06 viable cells/mL in 
cold freezing medium (heat inactivated FCS + 10% Dimethylsulfoxide - DMSO) 
and ali quoted to cryovials (Coming Incorporated, CORNING, Mexico). The 
cryovials were immediately placed in a slow-freeze container (e.g. "Mr Frosty") 
which was then placed in a -70°C freezer for 4 to 24 hours. After 4-24 hours, the 
cryovials were transferred into a liquid nitrogen tank (-135°C) for long-term 
storage. 
2.4.5 Thawing of cryopreserved PBMCs. 
Cryovials containing frozen PBMC were removed from liquid nitrogen storage and 
quickly defrost by immersion and gentle shaking in a 37°C water bath until the 
majority of the suspension had thawed. The suspension was then transferred to a 
15rnL centrifuge tube with sterile pastette. Immediately add warm (37°C) RlIO 
medium (RPM! 1640 medium containing 10% HI-FCS, 2mM L-glutamine, 
IOOIlg/ml Streptomycin, 1000 Penicillin); initially slowly with gentle shaking, 0.5 
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mLimin for the first 2 minutes, followed by 2 mLimin for the next 2 minutes, and 
then top up with 5 mL. The thawed cells then were washed twice with RPM!. The 
supernatant was discarded; the pellet was flicked and re-suspended in cRPMI and 
ready for use. 
2.4.6 Establishing CTL lines and CTL clones 
Short-term CTL-cell lines are produced by direct stimulation PBMCs with epitope 
peptide. PBMCs were divided according to the number of peptides to be used and 
centrifuged at 600g for 5 minutes at room temperature in separate tubes. The pellet 
was resuspended in 100J..lL concentrated sterile peptide solution, to a final 
concentration of 20 - 50J..lM and incubated at 3 ~C, 5% C02 for 1-2 hours. The 
cells then were resuspended into 1-2 x 106/mL in RlIO (RPMI 1640 medium 
containing 10% HI-FCS, 2mM L-glutamine, 100 J.lg/ml Streptomycin, 100U 
Penicillin) and plated out in 24-well plates, i.e. 2-4 x 105 /well. IL2 was added on 
day 3 to a final concentration of 10%. After 6 - 10 days in culture, the cells were 
splitted if they look overcrowded, and maintained in RlI0 containing IL2. 
Although some CTL activity can often be detected as early as day 7 - 10, specific 
killing is maximal after 12 - 14 days. The cultures were usually maintained 
specific CTL activity for up to 3-4 weeks without restimulation. Clones also were 
set up at this stage. 
Epitope peptide specific Cytotoxic T Lymphocyte clones were generated by the 
limiting dilution of CTL cell lines. Briefly, CTL lines were plated out in flat -
bottom 96-well microtitre plate at a concentration of 1 cell/well in cloning mixture 
containing irradiated mixed allogeneic PBMCs, irradiated autologous peptide -
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pulsed BCLs, phytohaemagglutinin and 10% pooled human AB serum in RPM! 
(RJlO) supplemented with 25 ng of IL-7/ml. On day 4, 50 U of recombinant IL2 
per ml of RJlO was added. Wells demonstrating sufficient growth and cell density 
(very obvious on microscopy of flat-bottomed plate) at each 7-day period were 
screened for their specificity using tetramer staining and selected clones were 
expanded into 48-well (then 24-well) plates tissue culture plates with autologous, 
irradiated, peptide-pulsed EBV-transformed B-lymphoblastoid cells (B-LCL). The 
expanded clones were cultured for 14 days and were screened for their specificity 
using tetramer staining. Specific clones were maintained by weekly restimulation 
with autologous, irradiated, peptide-pulsed EBV -transformed B-Iymphoblastoid 
cells (B-LCL) and also were kept frozen and stored in liquid nitrogen. 
2.4.7. peR using Sequence-Specific Primers (peR-SSP) for HLA typing 
PCR-SSP for HLA typing was kindly performed by Tim Rostron from Institute of 
Molecular Medicine - Oxford. Briefly, typing of HLA class I and class II alleles 
was performed using the amplification refractory mutation system PCR (ARMS-
PCR) with sequence specific primers, as described previously (Bunce, O'Neill et 
al. 1995). One hundred and ninety two peR reactions were performed to genotype 
~A-A, B, Cw, DRBI and DQB1 alleles peR was performed using 96-well 
polycarbonate plates (Thermo-Fast 96, Low profile, ABgene, UK), and a Peltier 
thermal cycler machine (DNA Engine Tetrad 2, BIO-RAD). Each well of a 96-
well peR plate contained a unique set of allele-specific peR-primers, and a set of 
internal control primers (amplifying a conserved region from the third intron of the 
HLA-DRB 1 locus). The presence of an allele is defined as when the allele-specific 
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PCR product is present and negative when only the internal control product is 
present. 
2.4.8 Methods for measuring Cytotoxic T Lymphocyte Activity 
There are a number of different assays of CTL activity, which assess different 
aspects of their function. The full details of these methods are described in the 
following sections. 
The best-known assay that looks at the killing efficiency of CTLs is so called CTL 
lysis assay. This conventional method aims to examine the lysis of appropriate 
target cells expressing the correct HLA restriction molecule and presenting the 
specific antigen. This chromium release assay has been mainstay of this approach 
to measuring CTL activity for over two decades. The target cells are labeled with 
radioactive slchromium for 1 h before use, and then incubated with cultured CTLs 
in vitro. Specific CTL activity is calculated from the excess release of chromium in 
the presence of a specific antigen compared to that released from the target cells 
without CTL or without antigen. These assays are usually carried out using several 
dilutions of CTLs (i.e. varying the effector:target (E:T) ratio) or of antigen (e.g. 
peptide titration) in order to demonstrate that this is a titratable response. In 
addition, measuring those CTLs that are capable of expanding and growing over 2-
3 weeks in culture, which are then assayed for antigen-specific cytotoxicity using 
CTL lysis assay is a principle of Limiting Dilution Analysis (LDA). LDA was the 
'gold standard' assay for many years for quantitation of antigen-specific T cells. 
In other hand, most CTLs release a variety of cytokines and chemokines, most 
commonly IFNy and TNFcx, on antigen-specific contact (Lin and Askonas 1981) 
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(Morris, Lin et al. 1982). It is therefore possible to use the antigen-specific release 
of IFNy or 1NFa. as an indication of CTL recognition. The Enzyme-Linked 
Immuno - Spot (ELI Spot) method has been adapted to provide a simple and rapid 
assay for the identification and enumeration of CTLs, on the basis of their antigen-
specific secretion of TNFa (Herr, Schneider et al. 1996) or IFNy (Lalvani, Brookes 
et al. 1997). The ELI Spot assay detects cytokines produced by an individual cell, 
which are then captured by binding to a specific antibody immobilized on the base 
of a micro titre well. When the assay is developed using a biotinylated second-
layer antibody, followed by the addition of streptavidin conjugated to alkaline 
phosphatase, the use of a chromogenic alkaline phosphatase substrate stains the 
area of cytokine release as a blue 'footprint' for each secreting cell. The spots in 
wells with and without antigen, and at different input cell numbers, are then 
counted by eye or using a dissecting microscope, and the results presented as the 
number of specific spot -forming cells (SFCs) per 106 PBMCs. The assays 
originally used a target-cell population to present the antigen, but when using 
sufficient numbers of PBMCs, the cells will present antigen to one another. The 
ELISpot assay has been most commonly used to screen for peptide-specific 
responses and to quantify these from PBMCs (Lalvani, Brookes et al. 1998) 
(Jameson, Cruz et al. 1998). 
More recently, the use of peptide-HLA tetrameric complexes has provided a way 
of enumerating CTLs, based on the expression by CD8+ T cells of a T-cell 
receptor (TCR) capable forming a stable interaction with that particular HLA-
peptide complex. Peptide-HLA tetrameric complexes allow the direct visualization 
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of antigen specific T cells by flow cytometry (Altman, Moss et al. 1996) (Ogg, Jin 
et al. 1998). Therefore, by itself, this method does not provide any information 
about the functional phenotype of the tetramer-staining population. However, the 
majority of sorted tetramer-positive cells will produce IFNy in an ELISpot assay 
(Dunbar, Ogg et al. 1998) (Murali-Krishna, Altman et al. 1998), and many of them 
will also expand as clones (Dunbar, Ogg et al. 1998). 
These different methods have been directly compared in a study of EBV specific 
CTLs in 13 people chronically infected with EBV (Tan, Gudgeon et al. 1999). In 
terms of the hierarchy of epitopes recognized within an individual, each method 
gave similar results; however, the absolute frequency differed substantially 
according to the method used. There was good correlation between ELI Spot 
assays and both other methods. 
The choice between these different methods will depend both on practical 
circumstances and on the aspect of CTL function under scrutiny. The CTL lysis 
assay remains a robust method of examining cytotoxic function, but requires the 
use of radioisotopes and usually necessitates the expansion of CTLs in culture over 
several weeks. The limiting dilution assay has been the 'gold standard' for 
enumerating antigen-specific CTLs for many years, but is a very time-consuming 
and exacting procedure, and appears to underestimate significantly the true 
frequency of circulating antigen-specific CTL effectors. The ELISpot assay is 
simple and quick, so it is a very useful procedure for screening potential CTL 
responses and new CTL epitopes. It also uses very few cells, so is valuable when 
samples are limited. However, once the assay is complete, the cells are lost and 
65 
Chapter 2 Materials & Methods 
cannot be manipulated any further. Moreover, only one secreted factor can be 
examined in each assay, so this provides only limited information about CTL 
phenotype. The tetramer assay has the advantage of providing phenotypic as well 
as quantitative information, since co-staining with other antibodies provides the 
opportunity to look at surface markers of activation, T-cell receptor usage, and 
cytokine and chemokine production (using intracytoplasmic staining). Moreover, 
the cells can be sorted directly from the F ACS machine and expanded as CTL 
populations or individual clones (Tan, Gudgeon et al. 1999). However, this method 
does not provide directly any information about the functional phenotype of the 
tetramer-staining population. 
2.4.9 IFN'y ELISPOT assay 
The IFNy ELISPOT assay was performed according to the manufacturer's 
instructions (Mabtech AB, Stockholm, Sweden). 96-well polyvinylidene difluoride 
(PVDF)-backed plates (MAIP, Millipore, USA) were coated with coating antibody 
I-DIK (50ul at 15ul/ml), incubated at room temperature for 2 hours or overnight at 
40C. The capture antibody was discarded and the wells were then washed 6 times 
with 200ul of sterile phosphate-buffered saline (PBS) or RPM!. The blocking 
solution was applied at 200J.LlIwell (R/I0) for at least one hour at room 
temperature. PBMC samples (5xI04 to I x 10scells/weU) then were plated out in 
100J.LLlwell of serum-containing medium (R/IO) and stimulated with solution of 
individual peptides or peptide pools at required concentration (usually individual 
peptides were used at 20J.LM final concentration, peptide pools were used at a final 
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concentration of 5J..lM for each peptide). PBMC were incubated overnight with 
peptides at 37°C in a humidified incubator containing 5% C02. The plate should 
not be disturbed at this stage of the assay. After overnight incubation, the cells and 
medium were discarded, the wells then were washed six times with PBS 
containing 0.05% Tween-20 (Sigma). The detection monoclonal antibody, 7-B6-1-
biotin (Mabtech, Sweden - diluted 1: 1 000 in sterile - filtered PBS at 50J..lI per well) 
was added to each well for 2-4 hours at 370C. The wells were washed again 6 
times with PBS containing 0.05% Tween-20 before incubating with SOul of 
conjugate antibody (Mabtech, Sweden - at a dilution of 1: 1 ,000 in PBS) for one 
hour at 37°C. After washing again 6 times with PBS + 0.05% Tween-20, 
chromogen was added at 100J..lI per well. The plate was left at room temperature 
until the blue color appears. The reaction was terminated by washing the plate 
under running tap water. The number of spot-forming units (SFU) in each well was 
counted with the aid of a dissecting microscope, and the background (no antigen 
stimulation) was subtracted. For each assay, the phytohemagglutinin (Sigma, 
Poole, UK) was used as the positive control. At the time of this study, an 
automated ELI SPOT reader was not available. Therefore, ELI SPOT counting was 
done manually. This approach may have limitations in terms of observer bias. 
2.4.10 FLow cytometry and MHC Class I Tetramer staining 
2.4.10.1 FLow cytometry 
Fluorochrome-conjugated monoclonal antibodies were used to stain whole blood, 
CTL lines and clones and all analyses were performed on a F ACSCalibur flow 
cytometer (Becton Dickinson). Absolute and percentage counts of leukocyte 
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subsets were obtained by flow cytometry using a F ACSCalibur four-color flow 
cytometer (Becton Dickinson, San Diego, USA). The surface phenotype of T cells 
was determined using panels of mAb such as CD8+, CD38+ and other tetrameric-
peptide complexes. Briefly, 100ul of whole blood or 10ul of CTLs pellet were 
stained with each mAb cocktail at room temperature in the dark, fixed by Facs-
lyse, and then washed twice by PBS. Cells were resuspended in 1 % Para 
formaldehyde and analyzed by flow cytometry 
2.4.10.2 Tetramer staning 
Tetrameric HLA - All/peptide complexes ("tetramers") were synthesized as 
previously described (Altman, Moss et al. 1996). Briefly, the HLA molecule heavy 
chain cDNAs were modified by substitution of the transmembrane and cytosolic 
regions with a sequence encoding the BirA biotinylation enzyme recognition site, 
These modified HLA heavy chains, and B2-microglobulin, were synthesized in a 
prokaryotic expression system (pET, R&D Systems), purified from bacterial 
inclusion bodies, solubilised in the presence of denaturant (4M Urea) and allowed 
to refold with the relevant peptide by dilution. Refolded monomeric complexes 
were purified by FPLC and biotinylated using BirA enzyme (Avidity), then 
combined with either phycoerythrin (PE)-labeled streptavidin (Sigma) or Quantum 
red (Sigma) at a 4: 1 molar ratio to form tetrameric HLA/peptide complexes 
("tetramers "). 
Cell surface staining was carried out on whole blood (200Ill), freshly separated 
PBMCs, thawed cryo-preserved PBMCs or cell clones. Cells were incubated with 
conjugated peptide - MHC class I tetramers (phycoerythrin fluorophore conjugated 
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or quantum-red conjugated) for 30 min in the dark. Sample was stained with an 
APC-conjugated anti-CD8 antibody for 15 min at room temperature in the dark. 
Red cells (if whole blood staining) were then lysed by 1 X lysing buffer (BD 
Immunocytometry Systems) for IOmin at room temperature. Cells were then 
washed three times with PBS and stored in Cell Fix ™ buffer (Becton Dickinson) 
at 4°C until flow cytometry analysis was performed. Samples were analyzed on a 
Becton Dickinson F ACSCalibur. 
2.4.11 Cytotoxic T Lympbocyte lysis assay 
After 14 days of culture, cells were harvested and used as effectors in a SICr-
labeled release assay. Target cells in the chromium release assay consisted of a 
51Cr-Iabeled B-cellline (BCL) that was autologous or Class 1 HLA-matched with 
effectors. The BCL was pulsed for 1 hour with the epitope peptide, washed, and 
ali quoted in duplicate in 96-well round-bottomed microtitre plates (5x 103 to 1 x 104 
cells/well),. Then effector cells were added in a range of effector-to-target ratios 
(50-100:1 for short-term CTL line, lower ratio for clones such as 1: 1). The control 
wells were plated out for background SICr release (target cells plus IOOJlL RlIO) 
and total SICr release (target cells plus 100J..lL detergent - 5% Triton XIOO in 
water) for each target in quadruplicate. Detergent was added last of all and 
avoiding splashing it into any of other wells. Nonspecific killing of un-pulsed 
target cells will be subtracted from that of pulsed target cells. The plates were 
incubated for 4-6 hours at 37°C in 5% C02. 20J..lL of the supernatant of each well 
were carefully removed (without disturbing the cells) onto beta-plate and count in 
beta counter. 
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The 51 Cr release was calculated from the following equation: 
%lys is = exper~mental release - spontaneous release 
maxImum release - spontaneous release 
These assays are carried out using several dilutions of CTLs (i.e. varying the 
effector:target (E:T) ratio) or of antigen (e.g. peptide titration) in order to 
demonstrate that this is a titratable responses. 
2.4.12 Cytokine assays 
2.4.12.1 Cytokine measures by sandwich ELISA 
Cytokine assay were performed by sandwich ELISA in 96-well microtiter plates 
following the manufacturer's instructions. This assay employs the quantitative 
sandwich enzyme immunoassay technique. A monoclonal antibody specific for 
cytokine has been pre-coated onto a microplate. Standards and samples were 
pipetted into the wells and any cytokine present is bound by the immobilized 
antibody. After washing away any unbound substances, an enzyme-linked 
poly clonal antibody specific for cytokine was added to the wells. Following a wash 
to remove any unbound antibody-enzyme reagent, a substrate solution was added 
to the wells. After an incubation period, an amplifier solution was added to the 
wells and color was developed in proportion to the amount of cytokine bound in 
the initial step. The color development was stopped and the intensity of the color 
was measured. The average of the duplicate readings for each standard and sample 
were subtracted the average zero standard optical density. The optical density for 
the standards versus the concentration of the standards was plotted and the best 
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curve was drawn. The data was linearized by using log/log paper and regression 
analysis was applied to the log transformation. 
The concentration of each mediator was estimated with reference to recombinant 
standards included on each plate. The detection limits were 10 pg/mL for TNFa, 
IL-6 and IL-1O; 100 pg/mL for sTNFR-55 and smFR-75. 
2.4.12.2 Cytokine measurement by Cytometric Bead Array 
Cytokine and chemokine concentrations release from clones were measured using 
a Cytometric Bead Array (Becton Dickinson, San Diego, USA). The BD CBA 
system used the sensitivity of amplified fluorescence detection by flow cytometry 
to measure soluble analytes in a particle-based immunoassay. Each bead in a CBA 
provided a capture surface for a specific protein and is analogous to an individually 
coated well in an ELISA plate. The BD CBA capture bead mixture was in 
suspension to allow for the detection of multiple analytes in a small volume 
sample. The broad dynamic range of fluorescence detection via flow cytometry 
required fewer sample dilutions and substantially less time overall (compared to 
conventional ELISA) to establish the value of an unknown. The BD Human 
ThllTb2 Cytokine CBA Kit was used to measure Interleukin-2 (lL-2), Interleukin-
4 (IL-4), Interleukin-5 (lL-5), Interleukin-lO (lL-10), Tumor Necrosis Factor a 
(mF -a ) and Interferon-g (IFN-g ) protein levels in a single sample. 
The experiment was followed the assay procedure which was recommended by 
manufacturer. A mix of distinct fluorescence intensities beads from brightest to 
dimmest and recombinant standards or test samples were incubated together and 
then the sandwich complexes were detected by PE - conjugated anti-human 
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antibodies. Standard curves were set in every experiment for cytokine/chemokine 
concentration analysis. 
2.4.13 Intracellular Cytokine Surface staining 
Staining for intracellular cytokines, followed by flow cytometry analysis, was 
provided single-cell information about a cell population that one cannot obtain 
from surface staining or ELISA. CTLs were direct stimulated with epitope peptide 
for cytokine producing. GolgiPlug™ (BDB-Pharmingen; containing brefeldin A) 
was used for blocking intracellular transport processes and results in the 
accumulation of most cytokine proteins in the rough endoplasmic reticulum or 
Golgi complex. These activated cells then were suspended and distributed to 
plastic tubes or microwell plates for immunofluorescent staining. Cell surface was 
stained with fluorochrome-conjugated monoclonal antibody specific for a cell 
surface antigen, such as, CD3, CD8, tetramer (15-30 min, 4°C). As some 
antibodies, which recognize native cell surface markers may not bind to 
fixed/denatured antigen, it is recommended that the staining of cell surface 
antigens be done with live, unfixed cells PRIOR to flxation/permeabilization and 
staining of intracellular cytokines. Cells were fixed by adding 1001-11 of 4% 
Formaldehyde and mixed well. The cells were washed twice with ice-cold 
PBSIBSAI Azide buffer and resuspended in 150 ml of permeabilization buffer 
(perm/WashTM) for 15 min. Intracellular Cytokines were stained with respective 
fluorochrome-conjugated anti-cytokine antibody. The cells then were washed 2 
times with IX PermlWash™ solution (1 mVwash for staining in tubes) and 
resuspended in Staining Buffer prior to flow cytometric analysis. 
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2.5 Statistical analysis 
Most of the data were not normally distributed and therefore nonparametric tests 
(Mann-Whitney V-test, Wilcoxon signed rank test for pairs) were used. Wilcoxon 
signed rank test for pairs was used to compare paired data from each individual 
(level of cytokine in acute and convalescent phase in same patients). The Chi-
square test with Yate's correction or the Fisher's exact test was used to compare 
proportions. The software package SPSS was used for all analyses 
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3.1 Introduction 
During the past few years, the characteristics of dengue in Viet Nam appear to 
have changed. For instance, a decade ago, children were predominantly affected, 
but in recent years, clinicians have seen increasing numbers of adult dengue 
patients, with both significant morbidity and increasing numbers of adult deaths 
due to dengue. 
The rise in dengue among Vietnamese adults adversely affects development of 
economy as it affects the most economically productive people in the population. It 
also affects health planning, and is further compounded by the general lack of 
systematically collected information on the natural history of dengue in such 
patients. This lack often leads health planners and clinicians to base their decisions 
regarding resource allocation and clinical management on personal experiences of 
dengue management in children, rather than on prospective evidence from this 
population. 
This study, conducted at the Hospital for Tropical Diseases ofHo Chi Minh City in 
Viet Nam, was designed to recruit consecutively admitted adult patients with 
dengue in order to systematically describe the clinical features and immunological 
responses. The study was approved by the Scientific and Ethical Committee of the 
Hospital for Tropical Diseases. 
Consecutive adult cases (2: 15 year-old) presenting to the Hospital for Tropical 
Diseases in Ho Chi Minh City, Viet Nam who were suspected of suffering from 
dengue underwent the informed consent process and were invited to participate in 
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the study between 2002 and 2004. Clinical procedures in the study were described 
in Chapter 2. Briefly, all information for study of patients was recorded in their 
separate CRF. Blood samples were taken for routine and research investigation. 
Supportive therapy for all patients were followed the WHO guideline and Viet 
Nam National guideline for Dengue Heamorrhagic Fever. All patients were asked 
to come back to the hospital for following up. Cytokine assay were performed by 
sandwich ELISA in 96-well microtiter plates, by use of previously described 
techniques (chapter 2). The concentration ofTNFu, IL-6 and IL-lO, sTNFR-55 and 
sTNFR-75 were measured with reference to recombinant standards included on 
each plate. Appropriate statistic analyses such as Wilcoxon signed rank tests for 
paired samples were performed using SPSS software. 
3.2 Results 
3.2.1 Clinical findings 
Between June 2002 and April 2004, 182 patients with laboratory-confirmed 
dengue infections were analyzed among a total of 198 adults presenting to the 
HTD. Serologic responses could be defined as secondary in all 182 patients. There 
were 100 (55%) with dengue without shock and 82 (45%) with DSS. RT-PCR 
results were positive in 101 patients (55%), 71 % of whom presented before the day 
5 of the illness. DEN-I was detected in 12 patients, DEN-2 in 65, DEN-3 in 6 and 
DEN-4 in 17 cases. There was one DHF grade II patient infected by serotypes 1 
and 2. All 4 serotypes of dengue virus are responsible for all spectrum of clinical 
severity of dengue infection in this study (Table 3.1). 
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Table 3.1 : Serotype Features of all patients 
DFIDHF I DHF II 
DEN-I 0 8* 
DEN-2 3 31* 
DEN-3 0 4 
DEN-4 0 9 
·one DHF 1/ patient was co-mfected by DEN-l and DEN-2. 
3.2.1.1. Demographic characteristics 
DHF III DHFIV Total 
4 0 12 
30 I 65 
2 0 6 
7 1 17 
The male (n = 98) to female (84) ratio was 1.2: 1. The mean age was 20 years 
(SD=5.5), the range of age from 15 to 52 years. The distribution of ages in the 
patient population is shown in Figure 3.1, note that the left skewed deviation of 
age with the peak. of age at 17 years could be seen in this chart. Note that an adult 
is defined as > 14 years of age. 
Amongst the 182 patients, 148 patients (81 %) lived in districts in Ho Chi Minh 
City, with the majority living in District 8, 6, II, 5 and 4, an area south-west of 
the city and generally an area oflower socioeconomic development (Figure 3.2). 
Together with 129 patients admitted directly to HTO, 19 patients were referred to 
HTD from another hospitals in Ho Chi Minh city and 34 patients who lived in 
other provinces were admitted to Provincial Hospital where they received 
treatment with an average hospital stay of 1 day (N= 53 SO=I.I, range: 0 - 4 days) 
until they were referred to the HID. There were 28/53 patients (53%) had been 
received intravenous infusions with saline solution in provincial hospitals, three 
received colloid solutions and one had a blood transfusion. 
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Patients presented at the HTD after a mean 5 (SD= 1.2) days of illness and were 
hospitalized for a mean duration of 8 (SD= 2.4) days. The distribution of illness 
lengths prior to admi sion into HTD is showed in Figure 3.3. 
Figure 3.1: Oi tribution of age 
Age 
Age 
Figure 3.2: Location of patients in Ho Chi Minh City 
o No patient 
o From 1-10 patients 
• From 11 -15 patients Can Gio 
• Over 15 patients 
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Figure 3.3 : Duration of illne s (days) prior to admis ion to HTD. 
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3.2.1.2. Symptoms and Signs 
The classic symptom of dengue, such as fever, headache, vomiting, abdominal 
pain and bleeding (skin, nose, gum) were present in the history of more than 50% 
of adults with confirmed dengue (Table 3.2). Fever and bleeding including 
petechia were the two main symptoms, which brought the patients to the hospital. 
The spectrum of clinical signs is shown in Table 3.3. Extemal bleeding (petechiae, 
epistaxis, gingival bleeding) were also present in more than 80% of patients by 
physical examination. Gastrointestinal bleeding (melena orland hematemesis) 
were present in 17% patients with DSS and 21 % in DHF without shock. Usually, 
patients with DHF without shock were treated in the Department of Infection; 
however, patients with complications, sllch as gastrointestinal (OT) bleeding were 
kept under clo e observation in Intensive Care Unit of our hospital. 
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In this study, it was necessary to give blood products to nine patients. Two 
patients, both with severe GI bleeding, prolonged shock, anemia with an Hct drop 
to below 20%, were transfused by more than 5000 mL of fresh blood. All except 
one of these patients recovered completely. 
There was one patient in the study who died (case fatality =0.5%). This was a man 
(BC409), 23 yrs, with 4 days of fever, headache, abdominal pain. On day 4, he had 
melena and admitted to Thong Nhat Hospital in Dong Nai Province for treatment. 
He was referred to HID on day 7 with fever, headache, melena, pleural effusion 
and moderate ascite but with normal blood pressure. Hct was 44%, platelet count 
37900 x 106/dL, leucocyte 4100 x 103 /dL, AL T 50 UIL, AST 40 UIL. The 
diagnosis of DHF grade II was made. One day later, he suddenly became 
unconscious with apnea. Cerebral spinal fluid (CSF) shown uncoagulated blood. 
He was mechanically ventilated for the next 4 days but could not be resuscitated. 
The final diagnosis was dengue heamorrhagic fever grade II complicated by 
intracranial bleeding. 
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Table 3.2: Patients characteristics on history ofsymtomps and signs before admission 
All groups DFIDHF DHFII DHFIII DHFIV 
I 
Number N=182 N=4 N=96 N=76 N=6 
Gender MalelFemale 98/84 212 51145 42/34 313 
Fever No(%) 182 (100%) 4 (100%) 96 (100%) 76 (100%) 6 (100%) 
Headache No(%) 92 (51%) 2 (50%) 47 (49%) 42 (55%) 1 (17%) 
Muscle pain No(%) 22 (12%) 0(0%) 13 (14%) 9 (12%) 0(0%) 
Vomiting No(%) 113 (62%) 2 (50%) 57 (59%) 49 (64%) 5 (83%) 
Diarrhea No(%) 26 (14%) 0(0%) 15 (16%) 10(13%) 1 (17%) 
Abdominal pain No(%) 92(51%) 2 (50%) 47 (49%) 40 (53%) 3 (50%) 
Bleeding· No(%) 154 (85%) 0(0%) 92 (96%) 58 (78%) 4 (67%) 
*Any kinds of haemorrhage that patient described to doctor, or revealed by exammatlOn, 
including petechia. 
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Table 3.3: Clinical features during admission 
All groups DFIDHFI DHFII DHF III DHFfV 
Number N=182 N=4 N=96 N=76 N=6 
Fever on admission 60 (33%) 1 (25%) 32 (33%) 27 (36%) 0(0%) 
Rash 78 (43%) 0(0%) 44 (46%) 32 (42%) 2 (33%) 
Petechia 159 (87%) 0(0%) 87(91%) 67 (88%) 5 (83%) 
Gum bleeding 51 (28%) 0(0%) 33 (34%) 17 (22%) 1 (17%) 
Epitaxis 21 (12%) 0(0%) 12 (13%) 9 (12%) 0(0%) 
Bruising 48 (26%) 1 (25%) 24 (25%) 22 (29%) 1 (17%) 
GI Bleeding 34 (19%) 0(0%) 20 (21%) 13 (17%) 1 (17%) 
Menorrhagia 17 (9%) 0(0%) 10 (\0%) 7 (9%) 0(0%) 
Hepatomegaly 144 (79%) 2 (50%) 71 (74%) 67 (88%) 4 (67%) 
Pleural effusion 73 (40%) 2 (50%) 25 (26%) 42 (55%) 4 (67%) 
Pulmonary Edema 2 (1%) 0(0%) 0(0%) 2 (3%) 0(0%) 
Hematocrit· % 46 42 45 46 50 
Mean (9S%C.I) (45 - 47) (29 - 55) (43 - 46) (45 - 48) (42 - 58) 
Platelet· lO6/dL 47000 65333 45739 47139 42600 
Mean (95%C.f) (41625 - 52460) 20292 - 110373) (38797 - 52680) (37580 - 56690) (25378 - 59821) 
Lymphocyte· lO6/dL 1546 952 1486 1650 1690 
Mean (95%C.I) (1308 - 1785) (344 - 1842) (1260 - 1712) (1153-2149) (744 - 2638) 
* Result on admission 
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3.2.2 Laboratory results 
Serum creatinine was in the normal range (mean 71)lmollL, 95%C.I: 67 - 75) in 
all patients on admission. During hospitalization, blood transaminase levels, 
alanine transaminase (ALT) and aspartate transaminase (AST) increased greater 
than upper limits of normal (50 UIL) in 46% and 60% of patients without and with 
shock syndrome respectively. 
The mean haematocrit on admission tended to be greater in DSS patients than in 
DHF I & II (Table 3.3). The trend ofHct was increased from day 2 of the illness to 
day 3, 4 and up to the peak at day 5 then dropped in recovery phase (figure 3.4). In 
term of criteria of haematocrit threshold of plasma leakage by WHO, there were 
only 43% of patients with DHF grade I and II, 63% of patients with grade III and 
IV meet that criteria in our study (who had haematocrit on admission greater than 
45%) . 
Means of platelet count on admission tented to be lower in DSS groups than in 
DHF I & II (Table 3.3). On admission, thrombocytopenia (platelet count < 
lOO,000/mm3) was present in 91% of patients without shock and in 89% patients 
with shock syndrome. Therefore, there were approximately 10% of patients who 
did not meet WHO criteria for thrombocytopenia on admission, even in the DSS 
group. Platelet counts generally declined from day 1 of the illness to day 5, then 
recovered slowly in almost of the patients, platelet count bounced back to the 
normal range within 2 weeks of illness onset (figure 3.4). During hospitalization, 
marked thrombocytopenia (platelet count < SO,000/mm3) occurred in 72% of 
patients without shock and in 71 % patients with shock syndrome. 
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Figure 3.4: Distribution of Heamatocrit and Platelet counts by day of illness of all patients. 
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Leucocytes, neutrophils had trend of the decline from day 1 of the illness over first 
week then recovered slowly in recovery phase. Leucocyte counts were still lesser 
than 8000 I mm3 at day 14 after the onset. Lymphocyte counts that were low on 
admission with mean was 1546 Imm3 (95%C1= 1308 - 1785), tented to be 
increased over acute phase (figure 3.5). 
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Figure 3.5 : Evolution of Leucocyte, neutrophil and lymphocyte counts by day of illness 
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3.2.3 Cytokine investiga tion 
A subset of patient that included 5 DHF grade I and II patients and 18 DSS 
patients had plasma samples for cytokine measurements. An acute blood sample 
was collected into EDTA from patients who gave con ent as soon as possible after 
enrolment into the study. Blood was separated promptly and plasma was stored at -
70°C. A second blood sample, taken upon hospital di charge, served as the 
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convalescent phase sample. Concentrations of TNFa, soluble TNF receptors, IL-6 
and IL-IO from acute and convalescent samples were measured and the results are 
shown in Table 3.4. 
Mean TNFa levels on admission were 38 pg/mL (95% CI, 32 to 44) in DHF grade 
I & II group and 54 pglmL (95% CI, 17 to 91) in DSS group. In comparison 
between acute and convalescent paired samples from each individual, TNFa 
plasma levels declined to significantly lower levels in convalescent samples 
irrespective of disease severity (p <0.05). The concentration of soluble TNF 
receptor p55 and p75, IL6 and ILlO showed a positive trend (as shown in Figure 
3.6) between mild diseases (DHF 1&11) to more severe diseases (DSS), although 
there was not a statistically significantly difference between two groups. Except 
for soluble 1NF receptor p55 in the DSS group, there were elevated concentrations 
of all studied cytokines in the acute phase (on admission) in compared with its 
concentrations from convalescent samples (at discharge of the hospital) in each 
individual (Table 3.4). 
Of the 58 patients with DHF 1&11,29 (50%) had detectable levels of IL-6 and IL-
lOin serum. There were significantly higher levels ofIL-6 (mean, 37 pg/ml; 95% 
C.I, 24 to 50 pg/ml) and IL-IO (mean, 38 pg/ml; 95% C.I, 26 to 50 pg/ml) in acute 
samples than in convalescent phase (mean, 13 pg/ml, and 95%C.I, 10 to 18 pg/ml) 
and (mean, 18 pglml, and 95%C.I, 10 to 25 pg/ml), respectively. 
Of the 18 patients with DSS, 11 (61 %) and 9 (50%) had detectable levels of IL-6 
and IL-IO in serum, respectively. Acute levels ofIL-6 (mean, 53 pg/ml; 95% C.I, 
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15 to 92 pg/ml) and IL-lO (mean, 34 pg/ml; 95% C.I, 13 to 54 pg/ml) were 
significantly higher than in convalescent samples. 
Table 3.4: Levels ofCytokines & Chemokines in DHF 1&11 group versus DSS groups 
DHF I&II (N=58) p* DSS 
Acute Convalescent Acute 
TNF (pglmL) 38 25 <0.01 54 
Mean (95%C.I) (32 - 44) (19 - 30) (17-91) 
sTNFR55 (pglmL) 1882 1466 <0.01 2351 
Mean (95%C.I) (1723 - 20411 (l325 - 1606) (1644 - 3057) 
sTNFR75 Cng/mL) 12.8 7.6 <0.01 21.1 
Mean (95%C.I) (10.9-14.6) 15.9 -9.2) (12.9-29.2) 
IL 6 CpglmL) 37 13 <0.01** 53 
Mean (95%C.I) (24 - 50) (10-18) (15 - 92) 
IL 10 (pg/mL) 38 18 <0.01** 34 
Mean (95%C.I) (26 - 50) (10 - 25) (13 - 54) 
P value *: WIlcoxon sIgned rank test. 
**: comparison 29-paired values that were above detection limit (10 pg/mL). 
***: comparison II-paired values that were above detection limit (lO pg/mL). 
*+*: comparison 9 paired values that were above detection limit (10 pg/mL). 
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23 <0.05 
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1967 NS 
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11.5 <0.05 
(7.4 - 15.5) 
17 <0.01*** 
(10 - 26) 
10 <0.05*+* 
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Figure 3.6: Levels of Cytokines 
Figure 3.6.a: TNFa levels. 
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Figure 3.6.b: Soluble TNF receptor 55 levels. 
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Figure 3.6.c: Soluble TNF receptor 75 levels. 
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Figure 3.6.d: Interleukin 6 levels. 
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Figure 3.6.e: Interleukin 10 levels. 
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3.2.4 Management and Outcome: data from all death in the Hospital for 
Tropical Diseases (1997 - 2006) 
There was one patient with DHF grade II complicated by intracranial bleeding died 
in this descriptive study. A this is not intervention trial, it i difficult to interpret 
the management measure . 
However, we had kindly perrnis ion of having the data of28 adults with DHF/DSS 
who died in HTD between 1997 to 2006 (in those, 61 % had serological evidence 
of dengue infection). In this period, there were 10861 adults who admitted to HTD 
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with OHFIDSS, therefore the in-hospital case fatality was 0.26%, was higher than 
in children in the same period of 0.09% (source: HID). 
There were 12 males and 16 females (ratio was 0.75:1). The mean age was 25 
years (SO=8), the range of age from 16 to 49 years. Amongst the 28 patients, 9 
patients (32%) lived in Ho Chi Minh City and 19 (68%) in other provinces of 
Southern Viet Nam. 
Only 4 patients admitted directly to HTO on the 4.5 th day after onset (SO: 0.6; 
range: 4 - 5). The majority of 24 patients were referred to HTD from another 
hospital. The average stay in other district / provincial hospitals where they 
received treatment was 34 hours (SO: 36 hrs; range: 2 - 144 hrs). Therefore, those 
86% of this study population admitted to HTO on the 6th day after onset (SD: 1.6; 
range: 4 - 10). There were 23 patients had sustained shock before admission at the 
HTD, these patients were treated at previous hospital (district / provincial levels) 
during 35 hours (range: 2 - 44y hrs). On admission at the HTD, there were 13 
patients who had fluid overloading, in those 6 patients with OSS and 7 without 
shock syndrome. 
Patients were treated in HID for a mean duration of 34 hours (range: 1 - 96). 13 
patients were necessary of blood transfusion, minimum amount was 250 mL and 
maximum amount was 3750 mL of fresh whole blood. 
Complication of metabolic acidosis were in 5 patients with prolong DSS, in 5 
patients with suspected intracranial bleeding, in 16 with severe bleeding such as 
gastrointestinal bleeding, disseminated intra-vascular coagulopathy. There were 11 
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patients had the combination of shock and severe bleeding on admission. 8 patients 
died very quickly after admission (from 1 to 5 hours). 
3.3 Discussion 
3.3.1 Clinical features 
DHF has been primarily a disease of children ((PAHO) 1994) ((WHO) ]997). 
Reports from 1975 to 1978 from Southeast Asia where DHF is endemic revealed 
only eight of 629 patients in Indonesia and 18 of 694 in Thailand to be older than 
15 years (Nimmannitya 1987) (Sumarmo, Wulur et a1. 1983). 
In the outbreaks in the 1980s in Cuba and Venezuela, the disease occurred in all 
age groups, although about two-thirds of the fatalities were among children (Kouri, 
Guzman et a1. 1989) (Guzman, Alvarez et a1. 1999). Similar observations have 
been made in Brazil and Puerto Rico in the 1990s (Zagne, Alves et a1. 1994) 
(Rigau-Perez 1997). 
Recently, the age distribution of DHF cases in Asia has changed progressively. 
The number of DHF adult cases has been increased during the 1980s and the 1990s 
in Southeast Asia countries such as Philippines, Malaysia (Capeding, Paladin et al. 
1997) (Ibrahim and Cheong 1995). 
The ratio of adult:children DHF cases has increased since the 1990s in the Hospital 
for Tropical Diseases (HTD), Ho Chi Minh city, Viet Nam (Figure 1.3). Data from 
HID showed that between 1997 to 2006, the in-hospital case fatality rate of adults 
was higher than in children (0.26% vs. 0.09%). As a referral hospital for the south 
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of Viet Nam, the population being studied in this project may not be representative 
of the case burden in the whole of Southern Viet Nam. 
In this present study, a high proportion of patients with DHF had abdominal 
symptoms: vomiting (62%), diarrhoea (14%), and abdominal pain (51 %). This 
features is more similar to data from Cuba in 1997 that showed 100% adult DHF 
patients had vomiting and 51 % had abdominal pain (Guzman and Kouri 2002). 
Sometimes, abdominal pain simulated an acute surgical abdomen. Patients who 
had severe abdominal pain, vomiting associated with little amount of ascite were 
misdiagnosed as acute surgical abdomen and were initially treated in a surgical 
hospital until they later developed skin bleeding and severe hypotension. Those 
misdiagnosed cases with high mortality due to severe bleeding had been reported 
in some hospitals in Viet Nam (data from HTD). Dengue infections presenting 
with predominantly gastro-intestinal symptoms also have been reported recently in 
outbreak 2002 in Singapore (Seet, Ooi et a1. 2005) and therefore, highlight the 
need for medical personnel to consider the possibility of dengue when assessing 
patients from areas where it is common, especially during a major dengue 
epidemic. 
Bleeding is other important sign of DHF. In our current study, bleeding site 
included petechia (87%), gums (28%), bruising (26%), gastro-intestinal tract 
(19%), nose (12%) and vaginal (9%). In other studies of hospitalized patients in 
Malaysia, haemorrhagic manifestations were observed in 62% to 68.8% (Wallace, 
Lim et a1. 1980) (Shekhar and Huat 1992). Recent studies from Taiwan revealed 
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that the incidence of gastrointestinal bleeding varied from 11.1 % to 58.5% (Wang, 
Tseng et a1. 1990) (Tsai, Kuo et a1. 1991). 
The fact that internal bleeding with a huge volwne occurred acutely but without 
obvious external blood loss might causes recurrent or persistent shock, whereas the 
haematocrit may not decline due to haemoconcentration, adds to the difficulty of 
making a diagnosis and giving the appropriate treatment. It is thus recommended 
that blood transfusion should be given promptly if there is suspected internal 
heamorrhage even though the haematocrit may remain apparently stable. 
One patient in the present study died with the dramatic clinical picture of intra-
cranial haemorrhage. Encephalopathy in DHF could result from cerebral anoxia, 
oedema, intracranial haemorrhage, and vessel occlusion. In a previous study in our 
hospital of 378 Vietnamese patients with suspected central nervous system 
infections, 4.2% were infected with dengue viruses. The most frequent 
neurological manifestations of this group were reduced consciousness and 
convulsions. Nine patients had encephalitis. No patient died, but six had 
neurological sequelae at discharge (Solomon, Dung et a1. 2000). With the 
development of more sensitive molecular diagnostic methods, the chance of 
dengue detection from cerebrospinal fluid or brain tissue has increased; however, 
the question of contamination with blood has been raised or passage of the dengue 
virus through a leaky blood brain barrier. It is possible that haemorrhage or 
leakage through the blood-brain barrier enables antibody and virus present in the 
blood to move into the cerebrospinal fluid, or dengue virus could cross the blood-
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brain barrier and infect the cerebrospinal fluid. Therefore, more pathological 
studies are needed. 
3.3.2 Dengue classification and case definitions 
Recommendations for the classification and management of DHF were developed 
following key findings in Bangkok in the 1960s. In particular, a study in 1964 of 
123 Thai children admitted to hospital with dengue, researchers identified that 
clinically important loss of fluid from the vascular compartment was indicated by a 
20% increase in haematocrit (Cohen and Halstead 1966). The recommendations 
evolved into the WHO guidelines of 1974, updated in 1986, 1994, and 1997 
«WHO) 1997). Undoubtedly, widespread adoption of the WHO system, together 
with implementation of the accompanying management guidelines, contributed to 
the striking initial fall in case-fatality rates. However, after the recent global 
expansion in dengue disease, several groups in Asia and Latin America have 
reported difficulties in using the system (Bandyopadhyay, Lum et al. 2006). 
In this present study, an elevated heamatocrit above 20% of baseline (i.e. 
heamatocrit ~45%) as indicator of hemoconcentration was only present in 43% and 
63% of patients on admission without and with DSS, respectively. Moreover, there 
were also 10% of patients who did not meet WHO criteria for thrombocytopenia 
on admission, even in the DSS group. 
In terms of management, WHO clinical criteria are inadequate to classify adult 
Vietnamese patients, particularly those with 01 bleeding. As a consequence, blood 
transfusion might be delayed. 
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In a study of virologically confirmed dengue deaths in Jakarta, Indonesia 
(Sumanno, Wulur et al. 1983), nine (30%) patients had gastrointestinal bleeding 
before the onset of shock with no evidence of haemoconcentration during the 
hospital stay, so they did not meet the WHO criteria for DHF. Reports from the 
Philippines (Hayes, Manaloto et al. 1988) and Kuala Lumpur (Ibrahim and Cheong 
1995) also showed significant haemoconcentration in only 39.5% and 22% of the 
patients respectively. 
In a recent study in Viet Nam (Phuong, Nhan et al. 2004) of the 712 children with 
confirmed dengue infection, bleeding and thrombocytopenia were almost as 
common in the 312 children classified as having dengue fever and in the 319 
classified as having DHF. In addition, of the 310 children with shock and 
laboratory-confirmed dengue, 57 (18%) did not meet all four WHO criteria for 
DHF and were thus classified as having DF by default. Among those, 22 failed 
because they had a negative tourniquet test result and no bleeding manifestations 
throughout the hospital stay, 15 because the platelet count was never less than 
100,000/mm3 and the remaining 20 because they did not reach the predefined 
hematocrit cut-off value of~ 45% . 
Current WHO classification system and case definitions distinguishes rigorously 
between dengue fever, DHF, and DSS, but there is much overlap between the 
three. Possibly, as previously suggested (Gubler 1998), dengue disease exists as a 
continuous range rather than as distinct clinical entities. In addition, this system 
excludes severe dengue disease associated with "unusual manifestations". New 
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categories as "dengue fever with unusual hemorrhagic manifestations" or "dengue 
with signs associated with shock" have appeared. Therefore, a large multi centre 
descriptive study is needed to obtain the evidence to establish a robust dengue 
classification scheme for use by clinicians, epidemiologists, public-health 
authorities, vaccine specialists, and scientists involved in dengue pathogenesis 
research. Dengue case definitions derived in this way might prove more useful for 
presumptive diagnosis, management, and final diagnosis, than the existing scheme 
(Deen, Harris et al. 2006). 
Recently, a revised system of dengue classification was proposed at an October 
2008 meeting of experts at WHO headquarters, Geneva, Switzerland. The 
revisions are based upon a review of clinical data from multicentre studies known 
as "DEN CO" (DENgue COntrol) in seven countries across Southeast Asia 
(included Hospital for Tropical Diseases, Ho Chi Minh city Viet Nam), Latin 
America and Western Pacific, which was supported by TOR/WHO with funding 
by the European Union and the Wellcome Trust. This new simplified dengue 
classification system that groups dengue cases into just two major categories of 
severity - dengue (with or without warning signals) and severe dengue, will now 
be tested and validated in studies in dengue endemic regions over the coming years 
(TDRNews N081 November 2008). 
3.3.3 Plasma leakage 
The cardinal feature in DHF is a transient increase in vascular permeability that 
results in the leakage of fluid from the plasma to the interstitium (Halstead 1989). 
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The circulating blood volume is reduced, hemoconcentration occurs, and, in severe 
cases, hypovolemic shock develops. After a few days, the increase in permeability 
resolves spontaneously, the leaked fluid is reabsorbed, and the patient recovers 
quickly. 
Microvascular permeability can be assessed noninvasively in humans by use of 
mercury-in-silastic strain gauge plethysmography (MSG). The MSG assessments 
were made at the midcalf of thigh and analysis of a continuous recording of limb 
circumference, obtained during a specific venous congestion pressure protocol, 
enables the quantitation of the changes in peripheral microvascular parameters, 
including permeability and blood flow (Gamble, Gartside et al. 1993). 
In study of 89 healthy Vietnamese subjects aged 5 to 77 years, the mean 
coefficient of microvascular permeability (K(f)) was highest in the youngest 
children then 3- to 4-fold lower towards the end of the second decade (Gamble, 
Bethell et aI. 2000). Moreover, other study of Vietnamese children with DSS (n = 
19), DHF without shock (n = 16), and healthy control children (n = 15) showed 
that the mean of K(f) for the patients at admission and after fluid resuscitation was 
approximately 50% higher than that for the control patients (P=0.02). There was 
no significant difference in K(f) between the 2 groups of patients - DHF without 
shock and DSS groups; this suggests the same underlying pathophysiology 
(Bethell, Gamble et al. 2001). Perhaps the fluctuations in K(f) in patients with DSS 
are larger than those in patients with DHF, which leads to short-lived peaks of 
markedly increased microvascular permeability and consequent hemodynamic 
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shock. Young mammals are known to have a larger microvascular surface area per 
unit volume of skeletal muscle than adults. During development, the proportion of 
developing vessels is greater. In addition, the novel microvessels are known to be 
more permeable to water and plasma proteins than when mature. These factors 
may explain for the age-related trend that children more readily develop 
hypovolaemic shock than adults in dengue haemorrhagic fever and other 
conditions characterized by increased microvascular permeability. 
3.3.4 Cytokine profiles and plasma leakage 
Our present study has shown an association between elevated cytokine levels and 
the acute phase of dengue. Overall, plasma concentrations of TNFa, sTNFR75 
IL6, IL lOin both groups (DHF I&II and DSS) and sTNFR55 in DHF 1&11 group 
were significantly higher at acute presentation compared with convalescent values 
but not sTNFR55 levels ofDSS group. 
However, the study has failed to demonstrate the significantly statistical difference 
of cytokine levels between DHF without shock and DSS groups. It is likely 
affected by the capillary leak. Plasma leakage that possibly resulted from an 
alteration in the function of the endothelial glycocalyx during dengue infection, 
contributes significantly to the reduction in plasma concentrations of different 
proteins (Michel and Curry 1999). The leakiness of each molecule is determined 
by complex factors; based on molecular weight alone, it has been showed that the 
smaller proteins such as human albumin (molecular weight [MW], 66.5 kDa) and 
transferrin (MW, 79 kDa) were more affected than IgG (MW, 150 kDa) (Wills, 
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Oragui et al. 2004). Therefore, human TNFa (MW, 51 kDa), sTNFR-55 (MW, 25 
kDa), sTNFR-75 (MW, 35 kDa), IL-6 (MW, 26 kDa) and IL-IO (MW, 18.6 kDa) 
are likely to be affected by this capillary leak. The more severe disease, the more 
cytokine leakage. In consequence, clinical study that aims to compare the 
concentration of plasma proteins in different severity groups of dengue infection 
would be adjusted by correcting and providing an approximation of the level that 
might have been achieved in the absence of vascular leakage. The extend of this 
leakage can be gauged by the effect on albumin and heamatocrit which are 
apparently indirect markers of vascular permeability. Unfortunately, the leakiness 
of each molecules is also affected individually by other factors such as its 
electronic charge, magnitude of alteration of electronic charge and damage extent 
on the capillary wall (Wills, Oragui et al. 2004). Therefore, interpretation of 
statistical association between plasma protein (e.g. cytokine, NSI protein, etc) and 
severity of disease would be performed with carefulness in those group of diseases 
in which hypovolemic shock secondary to vascular leak commonly occurs such as 
DHF. 
Data from Malaysia and Tahiti have suggested that the level of TNFa production 
in DHF may be related to clinical outcome (Yadav, Kamath et al. 1991) (Hober, 
Poli et al. 1993). 
The association of 1NF a with disease severity has been confirmed independently 
in mouse model of dengue infection (Atrasheuskaya, Petzelbauer et al. 2003). In 
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this experiment, increased TNFa levels were detected In sick animals and 
antibodies to TNFa attenuated the disease phenotype. 
The combination of evidence of increased levels of TNF a, soluble tumor necrosis 
factor receptor 55 and 75 in acute phase of DHF adult patients in our study 
together with previously similar finding elsewhere (Hober, Delannoy et al. 1996) 
(Bethell, Flobbe et al. 1998) (Braga, Moura et al. 2001) and evidence in animal 
studies, strongly suggested the implication of TNFa in the pathogenesis of dengue 
infection. 
Both type I (p55) and type 2 (p75) receptors for human TNFa (TNFR) may exist 
on the cell membrane as a signal-transducing unit or in a soluble form in the 
extracellular fluid (sTNFR). Soluble receptors compete with membrane-bound 
receptors for TNF binding. High amounts of soluble TNF receptors function as 
specific inhibitors of TNF activity on target tissues. However, it should be noted 
that TNF receptors may, under certain circumstances, function as TNF agonists 
rather than 1NF antagonists (Mohler 1993). The sTNFR-75 may bind to TNFa in 
the circulation and prolong its circulating half-life. Because 'INFa may readily 
dissociate from the type 2 receptor, the end result may be prolongation of TNF 
activity in the systemic circulation with potentially detrimental effects (Evans 
1994). 
Elevated sTNFR levels could theoretically be due to increased production or to 
reduced clearance. The latter has been noted in renal failure due to septic shock 
(Froon, Bemelmans et al. 1994), but from our study, renal impairment is 
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uncommon in nonfatal DSS. We consider a more likely explanation to the 
increased shedding of sTNFR in our study due to proinflammatory stimulation. It 
may be relevant that the strong clinical association was observed for sTNFR-75, 
since this form of sTNFR appears to be preferentially over expressed on 
microvascular endothelium in persons with acute respiratory distress syndrome 
(Grau, Mili et al. 1996), and had consistent positive relationship with disease 
severity (Bethell, Flobbe et al. 1998). Possibly, sTNFR levels in DHF reflect 
inflammatory events at the endothelial level and might therefore constitute a 
specific marker of incipient microvascular pathology. 
A number of cytokines besides TNFa have been implicated in DHF IDSS, most 
commonly INFy, IL-6, and IL-IO. Interleukin (lL)-1 0 is a cytokine that inhibits the 
production of a wide range of inflammatory and proinflammatory cytokines. For 
example, human IL-IO suppresses the expression of IL-2, IL-3, interferon-y, and 
granulocyte-macrophage colony-stimulating factor in T helper type I cells 
(Fiorentino, Bond et al. 1989; Fiorentino, Zlotnik et al. 1991); IL-4 and IL-5 in T 
helper type 2 cells (Moore, O'Garra et al. 1993); IL-8 and macrophage 
inflammatory protein-l in neutrophils (Kasama, Strieter et al. 1994); IL-l, IL-8, 
and TNFa in macrophages/monocytes (Howard and O'Garra 1992) (Bogdan, 
Vodovotz et al. 1991). Hence, IL-IO is a potent anti-inflammatory cytokine that 
has an important role in balancing inflammatory responses (Wang, Wu et al. 
1994). 
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In this study, pro-inflammatory plasma cytokine IL-6 and anti-inflammatory 
plasma cytokine IL-IO levels were significantly higher at acute presentation 
compared with convalescent phase in both groups (DHF I&II and DSS). IL-6 and 
IL-IO has been found in some previous studies and significantly elevated in DHF 
versus DF patients (Hober, PoIi et al. 1993) (Green, Vaughn et al. ] 999). There is 
association of increased levels of IL-IO in dengue patients with a sequential 
infection (Perez, Garcia et al. 2004). IL-6 and IL-IO may playa role in the 
pathogenesis ofDHFIDSS in infants (Nguyen, Lei et al. 2004). 
The pro-inflammatory response is regulated by the anti-inflammatory components 
of the immune system (Gomez-Jimenez, Martin et al. 1995). A complex network 
of cytokines is generated in response to a systemic immune challenge. It is the net 
effect of interactions between these proinflammatory and anti-inflammatory 
molecules over time that determines the nature of the immune response in 
individual patients. An imbalance between these two aspects of the inflammatory 
response may be deleterious. Elevated plasma IL-I0 levels and raised IL-10 to 
TNFa. ratios have been associated with poor outcome and increased mortality in 
sepsis (Lehmann, Halstensen et al. 1995), (van Dissel, van Langevelde et al. 1998), 
it is more likely to have fatal infections in meningococcemia (Westendorp 1997). 
Similarly, patients with high ratios of TNF to soluble TNF receptors are at 
increased risk of having lethal meningococcal infections (Girardin 1992). 
Taniguchi et aI. found that an increase in the ratio of IL-6 to IL-IO correlated with 
a poor outcome in patients with systemic inflammatory response syndrome (SIRS) 
(Taniguchi, Koido et al. 1999). It therefore seems that both over-robust and 
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inadequate anti-inflammatory responses can be associated with a poor prognosis, 
although insufficient data are available to define an appropriate response in any 
individual context. 
The unresolved question is why capillary leak is such a prominent feature of DHF 
when a variety of other infectious diseases show large elevations in TNF and other 
pro inflammatory cytokines without profound alterations in capillary permeability. 
The pathophysiological mechanisms underlying the capillary leak in dengue 
infection are poorly understood. Many factors including total virus burden, viral 
virulence, host immune response (Bethell, Flobbe et a1. 1998) (Leitmeyer, Vaughn 
et a1. 1999) (Vaughn, Green et a1. 2000), and genetic predisposition (Stephens, 
Klaythong et a1. 2002) have been implicated in the pathogenesis of DHF, but the 
means by which any of these factors might influence endothelial function remain 
controversial. 
Endothelial cells can be infected by dengue virus in vitro (Bunyaratvej, Butthep et 
a1. 1997) (Avirutnan, Malasit et al. 1998) (Diamond, Edgil et al. 2000) (Huang, Lei 
et a1. 2000), but the endothelium of dengue haemorrhagic fever patients shows 
little evidence of infection or endothelial cell damage due to infection (Andrews, 
Theofilopoulos et a1. 1978) (Sahaphong, Riengrojpitak et a1. 1980) (Killen and 
O'Sullivan 1993) (Kurane 1997). This suggests the endothelium is not a site for 
direct viral replication or cytolysis in vivo; however, alterations in endothelial cell 
penneability induced after infection of other cell types may contribute to vascular 
leakage. 
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There are many known modulators of endothelial cell permeability, included 
cytokines, thrombin, cytotoxic factors, sVCAM-I, that regulate the endothelium to 
maintain an active barrier between blood and tissues (Royall JA 1989) (Rabiet M-J 
1996). Cytotoxic factor has been described that is produced from dengue virus-
infected peripheral blood mononuclear cells (PBMC) is present in dengue patient 
sera (Shaio, Cheng et al. 1995; Agarwal, Chaturvedi et al. 1998), and can induce 
leakage in the peritoneal cavity of mice. Peak leakage occurred 30 min after 
inoculation of cytotoxic factor and the vascular integrity was restored by 2 hours 
(Khanna, Chaturvedi et al. 1990). TNF-alpha released from dengue virus-infected 
monocytes in supernatants can induce TNF- alpha dependent activation of 
endothelial cells, as measured by upregulation of endothelial cell expression of 
VCAM-I and ICAM-l (Anderson, Wang et al. 1997). Plasma soluble vascular cell 
adhesion molecule-l (sVCAM-l) concentration, markers of endothelial damage, 
were significantly higher in severe disease of dengue haemorrhagic fever (Murgue, 
Cassar et al. 2001). Similarly, studies with Marburg virus, which causes a more 
severe haemorrhagic fever than dengue virus, have shown that supernatants from 
infected monocyte-derived macrophages can rapidly induce TNF - alpha dependent 
changes in endothelial cell permeability (Feldman H 1996). Recently, Lin et al. 
showed that in vitro, antibodies against dengue virus nonstructural protein I (NS I ) 
act as autoantibodies that cross-react with noninfected endothelial cells and trigger 
the intracellular signaling leading to the production of nitric oxide and to apoptosis 
(Lin, Lei et al. 2002). Activation and damage of human microvascular endothelial 
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cells could be induced in vitro by inflammatory mediators present in sera from 
patients with acute dengue infection (Cardier, Marino et al. 2005). 
The difference in pathogenesis of prominent feature of cytokine - associated 
capillary leakage in dengue infection and non-profound alterations in capillary 
permeability in other systemic infections, that all show large elevations in 
cytokines, could be possibly explained from the result of Carr's experiment. In 
vitro, Carr et al. showed that supernatants from dengue virus type 2-infected 
monocyte-derived macrophages increased permeability in human umbilical vein 
endothelial cell monolayers without inducing endothelial cell infection. 
Interestingly, in their experiment, induction of endothelial cell permeability by 
supernatants from dengue virus infected monocyte-derived macrophages did not 
coincide with the timing at the peak of TNF-alpha release from the latter cells. 
Permeability changes in endothelial cells were observed with supernatants from 
dengue virus infected monocyte-derived macrophages at 96 hr post infection, 
whereas the peaks of TNF -alpha release were biphasic, initial response at 4-24 hr 
after mock infection - that was likely a result of cell manipulation and second peak 
at 36-48 hr post infection - that represents a viral specific response. Additionally, 
pre-exposure of endothelial cells to supernatants harvested at the time of peak 
release of 1NFa, enhanced the subsequent endothelial cell permeability induction 
(Carr, Hocking et al. 2003). Clinically, this phenomenon may be compared to the 
pathophysiology of dengue haemorrhagic fever where the peak of plasma leakage 
occurs late in the course of disease, during or after the decline in fever. 
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Therefore, we speculated that the mechanisms of endothelial cell permeability in 
DHF may involve to endothelium activation induced by 1NF-alpha release from 
dengue virus-infected monocytes then followed by action of other factor(s), it is 
possibly by other types of cytokine or more likely, by another pulse of 
pro inflammatory mediators released into the peripheral circulation in later phase of 
immune responses. Pulse(s) of pro inflammatory mediators released into the 
peripheral circulation from the process of immune responses of dengue infection 
would result in sudden, rapid, massive, but self-limiting, hypovolemic shock. 
Repeated episodes of shock could be explained by further pulses of circulating 
mediators. Further studies on endothelial cell permeability in dengue infection and 
other diseases that had elevated cytokines are needed. 
In term of management and outcome of dengue infection, plasma leakage would 
allow plasma water to flood out of the intravascular compartment, that would 
result in hemoconcentration, ascites, and pleural effusions, and when the 
compensation mechanism is overridden, that would lead to hypovolemic shock. 
Failure to treat shock at this early stage leads to the development of severe shock 
disease, whereby the patient becomes into uncompensated shock syndrome with 
complications of metabolic acidosis, disseminated intravascular coagulopathy, 
edematous and had poor outcome. Unfortunately, the regimen and volume of fluid 
replacement for adult with DHF IDSS remain empirical and are not described in the 
World Health Organization Management Guidelines. In most of cases, the 
resuscitation was based on the regimen of hypovolemic shock (such as severe 
acute diarrhea) or septic shock or even based on DHFIDSS children's WHO 
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guidelines. This might explained such number of patients with fluid overloading 
and complication of pulmonary acute edema in the past. Based on ideal body 
weight and WHO guidelines (for children), clinicians from HTD has established 
the empirically volume replacement guideline for adult with different grades of 
DHF and it has been implemented into Viet Nam National Guideline for Dengue 
Heamorrhagic Fever. The preliminary effect on overall reduction of severe 
mortality and case fatality after implication of new guideline to all hospitals in 
Southern Viet Nam was presented in the annual academic conference of HTD in 
2005. Further large-scale studies of the volume replacement and resuscitation are 
needed. 
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4.1 Introduction 
Epidemiological studies suggest the frequency of DHF is substantially higher in 
individuals experiencing a secondary infection with a heterologous dengue 
serotype (Sangkawibha, Rojanasuphot et al. 1984; Burke, Nisalak et at. 1988). 
While children carry most of the symptomatic disease burden in endemic 
countries, young adults are also significantly affected. Several explanations have 
been proposed to explain the epidemiological association between DHF and 
secondary infection with a heterologous dengue virus. Viral, host genetic and 
nutritional factors have been associated with susceptibility to DHF (Thisyakom 
and Nimmannitya 1993) (Rico-Hesse, Harrison et al. 1997) (Leitmeyer, Vaughn et 
al. 1999) (Gamble, Bethell et al. 2000) (Loke, Bethell et al. 2001) (Loke, Bethell et 
al. 2002) (Stephens, Klaythong et al. 2002). 
Cytotoxic T-Iymphocytes (CTLs) play a major part in the cellular immune 
response to viruses and other intracellular infections. A role for T lymphocytes in 
DHF pathogenesis has been discussed (Kurane 1997). CD8+ T cells may 
contribute both to protection against and to development ofDHF. A protective role 
for CD8 T cells is plausible, because these cells may limit viral infection by 
cytolysis of infected cells and secretion of antiviral cytokines such as IFNy. 
However, the mechanism by which T cells contribute to DHF pathogenesis is less 
clear, although new insights have been acquired in the last few years. Serotype 
cross-reactivity is likely to be important and has been possibly implicated in the 
immunopathogenesis of dengue infection. Primary dengue virus infections induce 
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serotype-specific and serotype-cross-reactive, CD4+ and CD8+ memory cytotoxic 
T lymphocytes (CTL). In secondary infections with a virus of a different serotype 
from that which caused primary infections, the presence of cross-reactive non-
neutralizing antibodies results in an increased number of infected monocytes by 
dengue virus--antibody complexes. This in turn results in marked activation of 
serotype cross-reactive CD4+ and CD8+ memory CTL. It is hypothesize that the 
rapid release of cytokines and chemical mediators caused by T cell activation and 
by CTL-mediated lysis of dengue virus-infected monocytes triggers the plasma 
leakage and hemorrhage that occurs in DHF (Kurane, Rothman et al. 1994). 
CD4+ and CD8+ T cell responses to dengue virus in both mice (Rothman, Kurane 
et al. 1996) (Spaulding, Kurane et al. 1999) and humans (Mathew, Kurane et al. 
1998), (Zivny, Kurane et al. 1995) with cross-reactivity demonstrated to both 
completely and incompletely conserved epitopes. It had been shown that activated 
dengue serotype cross-reactive memory CD4+ T lymphocytes secrete cytokines 
including TNFa. and IFNy, which might contribute to the enhanced pathology 
manifested as DHF(Gagnon, Ennis et al. 1999). 
Inflammatory cytokines secreted by CD8+ T cells could directly affect vascular 
permeability (Kurane 1997); epitopes from dengue virus might mimic host 
proteins, reSUlting in excessive tissue damage; or more complex interactions 
between virus strains and serotypes could result in altered peptide-ligand 
antagonism, impairing protective virus-specific T cell responses (Klenerman, 
Rowland-Jones et al. 1994). 
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In order to understand these possibilities during natural dengue virus infections we 
would need to study CD8+ T cell cellular immune responses and serotype cross-
reactivity as a result of natural dengue infection. Therefore, the aim of this chapter 
was to investigate dengue-specific and cross - reactivity CD8+ T Lymphocyte 
responses during acute disease and convalescence, in a population of naturally 
immune individuals, in a dengue-endemic region. 
4.2 Methodology for this study. 
Naive Cytotoxic T-Iymphocytes (CTLs) are initially activated when their T-cell 
receptors (TCR) strongly interacts with surface class I HLA molecules on the 
target cells which have bound peptides from the pathogen or tumour antigens. 
Once activated, the CTL undergoes a process called clonal expansion in which it 
gains functionality, and divides rapidly, to produce an army of "armed"-effector 
cells and then travel throughout the body in search of cells bearing that unique 
MHC Class I - peptide complex. When exposed to these infected, effector CTLs 
release of cytokines such as IFNyand TNFex, chemokines such as RANTES and 
MIP-I ex, and causing the lysis of the target cell. Upon resolution of the infection, 
most of the effector cells will die and be cleared away by phagocytes, but a few of 
these cells will be retained as memory cells. Upon a later encounter with the same 
antigen, these memory cells quickly differentiate into effector cells, dramatically 
shortening the time required to mount an effective response. Therefore, in most 
studies of human CTLs, the aim is to detect and expand in vitro this memory-cell 
population from peripheral blood mononuclear cells (PBMCs). 
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CTLs recognize small peptides (of between 8 and 11 amino acids in length) from 
foreign proteins that have been broken down in the cytosol of infected cells. 
Peptide fragments are translocated to the endoplasmic reticulum and bind to newly 
synthesized class I molecules in a groove formed by the alpha helices of the a.l 
and a2 domains. Human HLA molecules are highly polymorphic and most of the 
polymorphism occurs in the peptide-binding groove. Therefore, different HLA 
molecules bind different kinds of peptides and a key component of CTL studies is 
to identify the dominant peptide targets of CTL recognition associated with 
individual class I HLA molecules for a particular pathogen. 
Although with limited sample size (309 dengue cases) and with not ideal controls 
(251 "healthy" control), results from a case-control study of Vietnamese patients 
with DHF possibly suggests that variation at the HLA-A locus was associated with 
susceptibility to DHF and class I restricted cellular immune responses have an 
important influence on susceptibility to DHF (Loke, Bethell et al. 2001). HLA-
A "'II is one of the most common class I alleles in worldwide populations, ranging 
from 4 to 33% depending on the particular ethnic background (Sidney, Grey et al. 
1996), and is highly prevalent in Southeast Asia. Fifteen natural variants (-A*1101 
to -A * 1115) have been reported to date, with HLA-A * 11 01 being most prevalent. 
We chose to study HLA-All, as it is one of the most common alleles in the 
Vietnamese population. 
Major Histocompatibility Complex molecules associated with peptides derived 
from endogenous or exogenous proteins serve as ligands for TCR. The MHCITCR 
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interaction is often viewed as a specific process, which involves one given TCR 
and only one MHC:peptide combination. 
The allele-specific interaction usually involves a sequence of nine to eleven amino 
acids spanning the MHC groove. For class I molecules, the entire peptide ligand is 
involved in allele-specific interaction with MHC but for class II, the peptides are 
longer and the nine amino acid sequence is roughly central to the peptide. Allele-
specific interactions are brought about by anchoring peptide side chains in 
complementary pockets in the MHC groove. The combination of allele-specific 
peptide-MHC interaction requirements can be described as a "peptide motif', 
characterized by number, spacing and specificities of anchors, as well as the more 
degenerate preferences at non-anchor positions within the nonamer stretches. 
(Rarnmensee 1995). 
Target cells are able to present 15-20mer peptides to specific CTLs, although the 
exact method of processing these longer peptides to the optimal 8-11 amino acid 
epitope remains obscure. 
In theory, there are two approaching options for epitope identification. The panels 
of overlapping peptides of 15-20 amino acids representing the sequence of the 
target protein can be used to map the approximate region recognized by a CTLs. 
The optimal epitope can then be precisely defined using truncated peptides. The 
other approach is selection of 8-11mer peptides guided by knowledge of the 
peptide-binding 'motif of the restricting class I molecule (Hill, Elvin et al. 1992) 
(Rowland-Jones, Sutton et al. 1995) or using more detailed computer algorithms. 
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peptide- binding motif in combination with computer algorithm5, 
The peptide-binding motifofHLA·A·1101 is defined by a preference for re~idue, 
with hydrophobic amino acid in position 2 (valine. threonine. or isoleucine) and 
with positively charged side chains (Lysine or Arginine) at the C terminu!I po!utjun 
(position 9 or 10) (Falk. Rotzschke et al. 1994) (Kubo. Sette et 01, 1994) t/han~. 
Gavioli et at. 1993). 
Table 4.1: HLA-A·IIOI motifs (Davenport MP 1996) 
AminO-Kid position 
~~ _______________ ~ __ ~2~ _____ ~3 ____ 4~ __ ~S __ ~6~ __ 7~ __ 1 
HLA- VllfT 
A-IIOI 
(FlYiM 
iA) 
IM/V}'I 
ItYIA) 
(L1Y 
Vll 
q 10 
-~-.--,. ~-~ .. ...,~ 
K K 
In order to meet the needs of scientists involved with Mile ·as.~()cialed peptide, 
and to provide a handy source of MHC ligands and ephopes and related cnlnell. " 
number of prediction servers are available over the World Wide Web !uJCh :tti 
SIMAS (http://thr.cit.nih.gov/molbiolhla_bindl), SYFI)I·:t 1'111 
(hnp:llwww.syfpeithi.del). etc. Therefore. the possibility of cpitope pmJiction!i rur 
a limited number of MHC motifs has been opened. Thctlretical prediction" 
potentially save time and money. Instead of synthesizing and lestint: hwldred\ nr 
even thousand of peptides, a preselection of a small set of peptide, i!' made I he 
sequence of the protein or its gene, the restriction element. and its respective m(ltif 
has to be available. Motif·based predictions result in a list of peptides that ha\'C " 
high probability of being presented by MHC class I molccu1c~, II U,\'C\' cr. 
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theoretical approaches cannot always guarantee success because not all details of 
the motifs are entirely known. The occurrence of unusual anchor amino acids can 
be compensated by refining the motif, but still a small percentage of epitopes do 
not act in accordance with any rules of the respective motif. In these cases, the 
theoretical approach will fail and experimental epitope mapping is unavoidable 
(Rammensee J 999). 
4.3 Peptide panel of epitope prediction 
Peptides that were selected from the amino-acid sequence of dengue virus serotype 
2 (DV2) isolate (strain 16681) based on published peptide-binding motifs for 
HLA-A * I I (Lysine or Arginine at the C terminus position) and by using 
SYFPEITHI website, an HLA peptide binding prediction offered by the National 
Institute of Health - USA. Dengue serotype 2 virus (D2V) has been circulating and 
dominated over last few years in Viet Nam (Pasteur Institute of HeMe data). The 
D2V strain 16681 sequence was chosen because it is well-characterised, and is 
widely used in laboratory studies. Moreover, the strain 16681 is closely related to 
the circulating D2V strains in Viet Nam (Twiddy, Farrar et al. 2002). 
A total of 61 peptides were synthesized by standard, solid phase Fmoc chemistry at 
the Weatherall Institute of Molecular Medicine, Oxford UK using a semi-
automated peptide synthesizer (Zinnser Analytical, Germany). The purity ranged 
between 30-90% as determined by high performance liquid chromatography and 
the concentrations were estimated using BeA protein assay kit. These 61 peptides 
(28 nonamers and 33 decamers) corresponded to the amino acid sequence of the 
capsid (J peptide), preM (l peptide), Env (13 peptides), NSI (7 peptides), NS2 (4 
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peptides), NS3 (lO peptides) and NS4 (6 peptides) viral antigens from D2V. (See 
Appendix 1) 
They were arranged into 19 peptide pools and constructed a matrix of peptides. 
and the list is as below: 
Pool 1 to 12: 
PooII3-14: 
Pool 15: 
Pool 16: 
Pool 17: 
Poo/18: 
Poo119: 
5 - 6 peptides in each pool (less or equal 1 NS3 peptide/pool) 
NS3 peptides (5 peptides in each pool) 
C + preM + NSI (9 peptides/pool: 1 C, 1 preM, 7 NSI) 
E (13 peptides/pool) 
NS2 + NS4 (10 peptides/pool) 
NS5 (lO peptides of 9mers/pooI) 
NS5 (9 peptides of 10mers/pool) 
In this matrix arrangement, each peptide is present in two different pools. This 
allows rapid identification of the peptide within a pool that is responsible for 
evoking a response in the IFN-y ELI SPOT assay, since this peptide should drive a 
response in two different pools. PBMC were initially tested against 19 different 
peptide pools. The peptides from pools that evoked an IFN-y response were 
subsequently tested individually using IFN-y enzyme-linked immunospot assay 
(ELISPOT) (see Chapter 2). 
In our present study, ELI Spot assays were used to screen for peptide-specific 
responses and to quantify these in PBMCs from patients with dengue (this 
chapter). Later, tetramer assays and CTL lysis assays will be used for further study 
on functional phenotype of CD8+ CTLs, CTL lines and clones (chapter 5) against 
relevant immunodominant peptide(s) discovered from this current works. 
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4.4 Results 
4.4.1 Patient population 
Thirty-one HLA-A * 11 patients with laboratory-confirmed dengue of varying 
clinical disease severity, attending the Hospital for Tropical Diseases in Ho Chi 
Minh City, Viet Nam, from year 2002 to 2004 were recruited into this prospective 
study of cellular immune responses. Molecular HLA typing was performed by Tim 
Rostron from WIMM Oxford using amplification refractory mutation system PCR 
(ARMS-PCR) with sequence specific primers, as described previously (Bunce, 
O'Neill et al. 1995). Written informed consent was obtained from the patient. The 
study protocol was approved by the Scientific and Ethical Committee at The 
Hospital for Tropical Disease and Oxford Tropical Research Ethical Committee 
(OXTREC) UK. Approximately 10 mL of venous blood samples were collected 
between 8 and 11 am on the first morning after admission (study day 1), and again 
on study day 5 unless the patient was discharged earlier. Convalescent samples 
were obtained at 2 weeks and 1 month post-admission. The mean age was 21 years 
(range 15-31 years) and the mean length of illness before admission was 5 days 
(SD, 1 day, range 3 - 6 days). Serology on paired plasma samples indicated all 
patients were experiencing a secondary dengue infection. Among 31 patients, 12 
patients had DSS, 19 patients had DHF grade I or II. There were 4 patients with 
DEN-2, 3 with DEN-4, 1 with DEN- and 1 with mixed DEN-l & DEN-4 
infections. DEN-3 was not be detected by RT-PCR in this group of patients. It was 
not possible to identify the infecting serotype by RT-PCR in the remaining 22 
patients, presumably because they had already resolved their viraemia when 
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admitted. The average haematocrit on hospital admission was 45% (SD, 5.1 %, 
range, 38 -57%), the mean of the platelet count was 50,903 (lmm3) (SD, 40,519; 
range 14,000-155,000) and the mean of the white blood cells was 4,784 (lmm3) 
(SD 1,831; range 1,400-8,540). (Appendix 2) 
4.4.2. IFN"( ELISPOT responses against a panel of peptides 
PBMCs from convalescence samples (3 - 4 weeks after hospital admission) of 
those 31 adults experiencing a secondary dengue infection were assayed by IFN-y 
ELISPOT. The number of spot-forming units (SFU) in each well was counted and 
was subtracted the background (no antigen stimulation). The range of spots in 
negative control was less than 20 (SFU)/million PBMCs. The criteria for a positive 
ELIspot are ~ 100 spot forming units (SFU)/million PBMCs. 
In 14 patients (45%), one or more individual peptides reproducibly evoked an IFN-
,,(response in the ELISPOT assay. 
In total, 6 different peptides were recognized by T cells from 14 patients. A 
summary of the peptides contained potentially novel T-cell epitopes that evoked 
responses in the IFN-"( ELISPOT assay is provided in Table 4.2. The magnitude of 
the response varied by patient and by peptide. Of 14 patients who had ELISPOT 
responses, DEN-2 was detected by RT-PCR in 3, DEN-4 in 3 patients. 
There were nine patients who made responses to one peptide and five patients who 
made response to two or more individual peptides (Figure 4.1). 
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Table 4.2: List of peptides that evoked responses in IFN-y ELlS POT assays. 
D2V Peptides Sequence Magnitude Number of patients Note 
(SFU/I06 PBMCs) (14 positive /31 screened pts) 
Average Range Total Dl D2 D3 D4 Unknown 
(31) (1) (4) (0) (4) (22*) 
Env226-234 TQGSNWIQK 850 100 - 1705 6 0 1 0 2 3 
NS1161-170 GVFTTNIWLR 186 100 - 506 9 0 2 0 3 4 
NS3s2-61 VTRGAVLMHK 435 nla 1 0 1 0 0 0 
NS3133-142 GTSGSPIIDK 384 109 - 1005 8 1* 1 0 3* 4 *One DVI & DV4 co-infection 
NS412-20 RLPTFMTQK 296 215-377 2 0 0 0 2 0 
NS5362-371 RTQEPKEGTK 760 nla 1 0 0 0 0 1 
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Figure 4.2: Magnitude ofT cell re ponses from dengue infected patients to HLA-A * II 
dengue 2 erotype peptide. 
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Interestingly, all of four DEN-4 infected patients (including 1 patient with mixed 
DEN-I&DEN-4 infection) and 3 among four DEN-2 infected patients made 
responses to one or more individual HLA-A * 11 DEN-2 peptides. The magnitude 
ofT cell responses to peptide EnV226-234, NS1 161 _ 170, and NS3 m -142 in DEN-2 
infected patients varied amongst individuals. Responses against these same 
peptides in patients infected with an unknown serotype are also presented for 
comparison (Figure 4.2). 
At the time this work was conducted, other scientists at the Wetherall Institute of 
Molecular Medicine, Oxford had identified NS3 133 -142 as dominant dengue CD8+ 
T cell epitope by using an overlapping peptide approach in ELI SPOT assays. 
Peptide-HLA tetrameric complexes of this NS3 133 _ 142 peptide have been also 
folded successfully. Moreover, NS3 133 - 142 peptide was the only peptide 
recognized by subjects infected with all three serotypes identified in our study, an 
indication that there may be serotype cross-recognition. Given the strength of 
evidence implicating NS3 133 _ 142 as a T cell epitope, we decided to focus on the 
immune response of CD8+ T cells of this epitope in term of specificity and cross-
reactivity between the four dengue serotypes. 
4.4.3. Cross reactivity of the CD8+ T cell response to NS3133 - 142 
Sequence analysis of the decamer NS3 133 _ 142 suggested there were 4 major 
variants among the published dengue NS3 sequences (Table 4.3). 
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Table 4.3: Main variants of Dengue NS3/33-142 peptides. 
Peptide Serotype of dengue viru Amino acid equences 
pDI DEN-I GTSGSPI VN R 
pD2.1 DEN-2 GTSGSPII DK 
pD2.2 DE -2 GTSGSPI VD K 
pD3/4 DEN-3 and 4 GTSGSPII NR 
The NS3133_142 sequence in pD I (GTSGSPIVNR) differed by three amino acids 
from previous predicted pD2 peptide (GTSGSPII DK). The NS3 133_142 equence in 
DEN-3 and DEN-4 are identical (GTSGSPIIN R) and they differed by one amino 
acid from pD 1 (Isolec ine in replaced for Valine at position 8) and two last amino 
acids from C-tenninal anchor from previou predicted pD2 peptide. There is also 
an other variant of NS3 133_142 sequence in DEN-2 that differed from previous 
predicted pD2 peptide by 1 amino acid at position 8 (Valine was replaced by 
Isoleucine) and named as variant pD2.2 (GTSGSPIVDK). 
Acute phase PBMCs (day 6 - 7 of the illness) of 15 adults expenencmg a 
secondary dengue infection with known dengue serotypes from prospective study 
of cellular immune responses were tested by JFNy ELlSPOT assays against 4 
variants of S3/33-142 decamers. In those 15 patients, there were 3 donor with 
dengue serotype I infection (20%), 7 donors with dengue serotype 2 infection 
(47%), 1 donor with dengue serotype 3 infection (7%) and 4 donors with dengue 
serotype 4 infection (26%) (see Appendix 3). 
123 
Chapter 4 Cellular Immune Responses in Dengue Patients 
The magnitude of IFNy ELISPOT assays responses varied by patient, by serotype 
and by variant of NS3JJJ..Ul peptide as showed in Table 4.4. (The number of spot-
forming units in each well was counted and was subtracted the background). 
There were few differences between ELISPOT responses to pDl and pD3/4 10 
each individual with DEN-lor DEN-3, 4 infections. However, in those groups of 
patients, responses to the pD2.1 were weaker, and particularly, responses to pD2.2 
variants were comparabJy low (in BC395, DFllO and BC428) or even negative. 
Interestingly, the magnitude of CD8+ T cell responses to cognate peptide variants 
corresponding to the current infecting DEN-2 infected patients (i.e. pD2.1 and 
pD2.2 against DEN-2 patients) were significantly weaker compared with those in 
patients infected by other serotypes (i.e. pDI in DEN-l and pD3, 4 in DEN-3/4 
infections respectively). Moreover, except patient DFl29 who had positive 
response to pDI and pD3/4, ELISPOT responses to pDI and pD3/4 in patients 
with dengue serotype 2 infection were all negative. 
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Table 4.4: IFNy ELISPOT assays of acute phase PBMCs (day 6 - 7 of illnes ) with 
different serotype infection againts variants of Dengue NS313J_141 peptides. 
/
patient I Dengue 
Serotype 
RESULTS (SFU/J 06 PBMC )* 
2 egative (0) 
2 
2 egative (4) 
2 egative (8) 
Positive (152) Positive 
3 PO 'itive ( 1376) [Positive (828) egative (56) 
4 Positive (1240) Positive (616) Negative (44) 
I 4 Positive (1665) Ipo itive (550) egative (30) 
;----
4 :Po itive (1708) Positive (500) rPositive (108) 
Positive 
/POSltlve 
/Posltlve 
Positive 
(30) 
(0) 
(0) 
(0) 
(0) 
(1432) 
( 1268) 
(1655) 
(1662) I 
r 4 Positive (2080) Positive (990) INegative (75) Positi\c (2240) 
* The number of spotforming units (SFU) in each well was counted and wa 
subtracted the background (no antigen stimulation). The range 0/ spots in negative 
control was less than 20 (SFU)/million PBMe . The criteria/or a positive ELlspo/ 
are 2: 100 spot forming units (SFU)/million PBMes. 
4.4.4 Ex - vivo cell surface staining for PBMC with NS3 133 - 142 
As ELISpot does not distingue between responses to the individual erotypc 
peptides of the same population of T cells in term of the cro s reactivity, we went 
on to perform tetramer cell surface staining. 
Acute and convalescent PBMC from 31 HLA-A * 11 01 po itive dengue patient 
were re-screened for responses to the previously defined HLA-A 11 dengue N 3133 _ 
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142 epitope using tetramer staining with a panel of peptides representing the main 
serotype variants of this epitope. In this tudy, for pD2, we concentrated on 
variants 2.1 as it seems make more responses than variant 2.2 (results from Table 
4.4). Summary of three variants of HLA-All dengue NS3 J33 _142 epitope i 
described in Table 4.5 
Table 4.5: Panel of pep tides from dengue S3 133-1 42 epitope using in tetramer study. 
Peptide tetramers Serotype Amino acid sequences 
pDl Dengue 1 GTSGSPIVNR 
pD2 Dengue 2 GTSGSPJl DK 
pD3/4 Dengue 3 and 4 GTSGSPJl NR 
The HLA-A * 1101 tetramers a sembled with NS3 133-142 peptides from different 
serotypes were conjugated with different fluorochromes in order to be ab le to 
examine the ability of CD8+ T-cells to recognize more tban one dengue variant by 
co-staining ofT-ceil populations. Cell surface staining was carried out on carefu ll y 
thawed cryo-preserved PBMCs. Titrated tetramers (PE conjugated or quantum-red 
conjugated) were added for 15 min at 3rC, then the cells were incubated with 
Anti-CD8-APC and anti-CD38-FITC antibodies (Becton Dickinson - San Diego, 
California) for 15 min at room temperature (RT). Ce lls were then washed and 
stored in Cell Fix ™ buffer (Becton Dickinson) at 4°C until flow cytometry 
analy is was perfonned. Samples were analyzed on a Becton Dickinson 
FACSCalibur (Chapter 2). 
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Although one adult DHF grade II patient (BC307), a 17 year old woman admitted 
on day 6 of illness with confmned secondary acute dengue infection (unknown 
serotype) had HLA-AII restricted NS3 133_142 -specific responses detected in both 
the acute and convalescent samples were selected for this study. The rest majority 
of patients showed much less significant staining. 
This patient had a high frequency of ex-vivo tetramer positive populations in both 
acute and convalescent samples allowing direct analysis without the need for in-
vitro expansion. In contrast, the majority of the rest of HLA-A * 11 0 I positive 
dengue patients were screened by tetramer staining showed much less significant 
staining. 
In-patient 8C307, approximately 18% of NS3 133_142 -tetramer positive cells in 
acute PBMC were cross-reactive, recognizing both the pD2 and pD3/4 tetramers; 
73% were p03/4 specific and 9% were pD2 specific. The cross - reactive 
population was not detectable in the convalescent (day 27) sample (Figure 4.3). 
The frequency of tetramer positive C08+ T lymphocytes from PBMC samples 
incrementally declined from day 6 to day 9 and day 27. C08+ T cell populations 
binding the pDI and pD3/4 tetramers were present in higher frequencies compared 
with T cells binding p02 tetramer (Figure 4.4). 
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Figure 4.3: Ex vivo pD2 and pD3/4 tetramer staining ofPBMC from patient BC3071 
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Freshly thawed cryopreserved PBMCs from BC307 were stained with AJ J pD3/4 and 
pD2 tetramers and CD8 antibody. The plots are gated on CD8 positive lymphocytes. The 
majority of cells in the acute ample (left) are specific for pD3/4 but there is a significant 
population cross-reactive with thi and pD2. The convalescent sample (right) shows only 
pD3/4 specific cells. 
Figure 4.4: Frequency of Dengue pecific CTL from PBMC on acute and convalescent 
phase. 
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CD38+ is a marker of lymphocyte activation. Ex vivo staining of PBMC from 
patient BC307 demonstrated equally high levels of CD38 staining among all 
tetramer positive cells in the acute phase. By three weeks after the acute sample 
CD38 expression had fallen markedly (Figure 4.5.a). At this time point CD8 cells 
recognizing the two similar peptide variants, pDI and pD3/4, were present (Fig 
4.5.b). Interestingly, there were relatively different levels of binding to the pOl 
and pD3/4 tetramers, with a population of cells showing high cross-reactivity to 
the two tetramers (gate R7 in Fig. 4.5.b) and second population showing relatively 
less cross-reactivity (gate R6 in Fig. 4.5.b). 
CD38 expression was greater on those T cells with the highest level of cross-
reactivity to the pDI and pD3/4 tetramers (57% CD38 high - Figure 4.5.c - Right) 
compared to cells with relatively less cross-reactivity to the pOl and pD3/4 
tetramers (19% CD38 high - Figure 4.5.c - Left). This suggests that highly cross-
reactive T cell populations are more activated than cells exhibiting low levels of 
cross-reactivity . 
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Figure 4.5: Highly cross-reactive CTL are more activated than partially cross-reactive 
CTL. 
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(a) Frozen PBMC from patient BC307 on acute and day 21 a/illness were. The cells 
showed in the plot were gated on tetramer positive CD8+ cells. 
(b)&(e) Convalescent sample from this patient were co-stained with CD38 (FL1), pD1 
(FL2), pD3/4 (FL3) fetramers and CD8. (b) Lymphocytes gated on tetramer positive 
CD8+ cells. Cross-reactivity population with pD1 and pD3/4 tetramers were divided into 
2 sub-groups. (e) Highly cross-reactive cells (Gate R7) show higher levels of expression 
ofCD38 (right) than partially cross-reactive cells (Gate R6) (left)· 
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4.5 Discussion 
4.5.1 Epitope prediction using IFNy ELISPOT with predicted peptides 
T cell responses to viral pathogens provide important direct and indirect assistance 
in the control of viral replication and viral eradication. In the context of dengue, 
the breadth and specificity of in vivo T cell responses to dengue viral antigens 
remains relatively poorly characterized. Most studies of dengue-specific T cells 
have occurred in the context of T cell clones generated from live attenuated dengue 
virus vaccines, or less frequently, from dengue patients (Kurane, Brinton et al. 
1991) (Green, Kurane et al. 1993) (Dharakul, Kurane et al. 1994) (Kurane, 
Okamoto et al. 1995) (Gagnon, Zeng et al. 1996) (Mathew, Kurane et al. 1996). 
Analysis of T-cell responses in patients after natural secondary infections is 
therefore important because it may provide insights into the mechanisms ofT-cell-
mediated immunopathology. 
In this chapter, we sought to identify HLA-A'" 11 restricted dengue-specific CD8+ 
T lymphocyte responses in a more direct fashion by combining the sensitive IFN-y 
ELI SPOT assay with freshly collected PBMC from serologically- and 
virologically-defined natural secondary dengue cases using motif-based predicted 
peptides. This approach has the advantages of speed, simplicity and the avoidance 
of artifacts generated by lengthy in vitro restimulation. 
With the screening over 31 patients experiencing a secondary dengue infection, we 
identified 6 peptides that could evoke T cell responses in interferon-gamma 
ELISPOT assay. D2V _NS1161-170 epitope is recognized by 2 out of 4 DEN2- and 
by 3 out of 4 DEN4-infeted patients; Env226-234 peptide is also recognized by 6 
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patients. Further work will be required to determine if all of these peptides are 
genuine HLA-A * 11 restricted CD8+ T cell epitopes. 
However, multiple lines of evidence indicate that the DV2 NS3w-142 peptide 
(GTSGSPIIDK) is indeed a HLA-A * 11 restricted CD8+ T cell epitope. First, in 
this present study we demonstrated that the NS3/33-142 peptide could be folded into 
a MHC-class I complex tetramer and that this could be used to stain specific CD8 
T cell populations in PBMC of dengue patients. Secondly, Mongkolsapaya et aI, 
using an overlapping peptide approach then a set of truncated peptides, also 
identified NS3u3-142 as a CD8+ T cell epitope restricted through HLA-A * 11 
(Mongkolsapaya, Dejnirattisai et al. 2003). Mongkolsapaya et at found that the 
optimal peptide for the NS3JJ3-142 serotype 2 variant to be the II-mer peptide 
GTSGSPIIDKK, although there were also responses to the 10-mer peptide 
GTSGSPIIDK, truncated by one amino acid at the C terminus. However, IO-mers 
were optimal for the NS3 JJ3-U2 serotype 1, 2 and 3 variants than II-mers (extra C-
terminal amino acid), suggesting they were using the arginine at position 10 as the 
C-terminal anchor. 
The NS3JJ3-142 epitope is one of several epitopes located within the NS3 protein. 
The importance of NS3 as a target of T cell responses has been demonstrated in 
parallel studies at the Hospital for Tropical Diseases (Simmons, Dong et at. 2005). 
These studies identified thirty-four peptides containing potentially novel T-cell 
epitopes, with peptides from NS3 being over-represented. These results highlight 
the importance of NS3 and T cells during acute secondary infection. 
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4.5.2 Cross reactivity of predicted peptides 
After acute dengue infection, PBMCs from convalescence samples (3 - 4 weeks 
after admission) were able to be stimulated by DEN-2 A * 11 restricted peptides by 
ELI SPOT assays. The magnitudes of responses varied by patient and by peptide 
and there was cross-reactive responding of PBMCs from non-DEN-2 infected 
patients to pD2 peptide stimulation. 
There are 4 variants of the sequence of Env226 -234 when performing sequence 
analysis: TQGSNWIQK ofD2V; TKTPTWNRK ofD3V, TSQETWNRQ ofDIV 
and TSEVHWNYK of D4V. In this study, the D2V _Env226 -234 peptide could 
stimulate ELI SPOT responses in convalescence PBMCs from two DEN-4 infected 
patients and one DEN-2 infected patients. Therefore, further analysis with all 4 
variants of this suspected epitope is needed for confirmation the cross-reactivity of 
this epitope. 
In term of cross-reactivity of NS3133-141 epitope variants, NS3 JJJ-142 pD2 was 
recognised by convalescent PBMCs (3 - 4 weeks after hospital admission) from 
one DEN-I, one DEN-2 and four DEN-4 infected patients. Interestingly, PBMCs 
from acute phase (day 6 - 7 of the illness) in either DEN-lor DEN-3 or -4 
infection showed relatively strong responses to NS3133_U1 pDt and NS3w -J41 
pD3/4 and weaker responses to pD2. These results could possibly be explained by 
the high sequence similarity in peptide sequence between NS3l33-J41 pD 1 and 
NS3 l33-142 pD3/4 (only one amino acid at position 8 - Valine was replaced by 
Isoleucine) and the different of 2 or 3 amino acid in those respectively peptide 
sequences versus NS313J-141 pD2. 
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In our study, in convalescent phase (3 - 4 weeks after hospital admission), the 
NS3 IJJ_uz pD2 gave strong responses in PBMCs of DEN-2 infected (serotype _ 
specific) and from DEN-4 infected patients (cross - reactive) (see Tab 4.2 and Fig 
4.2); in acute phase (day 6 - 7 of illness), responses to pD2 variants (including 
pD2.1 and pD2.2) are weak or negative in patients with DEN-2 (serotype _ 
specific) but stronger in patients with Dengue I, 3 or 4 infections (cross - reactive) 
(see Table 4.4). There were three out of seven DEN-2 infected patients reacted to 
pD2 in acute phase, among those, only one patient (DF129) showed cross-
reactivity against pDt and pD3/4 with this was of low magnitude. In contrast, 
although only one of four DEN-2 infected samples from the convalescent phase 
responded to pD2.1, the response magnitude was high. 
Mongkolsapaya et al found low or absent ELISpot responses against those HLA-
A 11_ NS3 JJJ-UZ peptides in samples taken during acute hospital admission and 
peak responses were observed at 2 weeks to 2 months follow-up (Mongkolsapaya, 
Dejnirattisai et al. 2003). Similar finding also reported in ELI Spot responses 
against HLA-A24_NS3556-564 peptides (Mongkolsapaya, Duangchinda et al. 2006). 
In contrast to other virus infections such as HIV or Epstein - Barr virus (Appay, 
Dunbar et al. 2002), the absence of responses in acute secondary dengue 2 
infection in our study and the low frequencies of antigen - specific T cells in 
Mongkolsapaya's studies could be explained by one of three possibility, or the 
combination of them. Firstly, these epitope specific cells may not have had time to 
proliferate fully at the time of sample was collected. Secondly, they may have been 
sequestered in peripheral tissues or in lymphoid organs. Lastly, these cells may 
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have been over-activated and the cells may have been dying at an increased rate 
due to activation - induced cell death (AICD). 
Mongkolsapaya et oj showed that there is a degree of cross-reactivity between the 
different epitopes. After secondary infection with DEN-lor 3 (and 4) serotypes, in 
acute phase of currently DEN-2 infection, T cells reacted better with the HLA-
All_NS31J3_u2 pDl and NS3133-U2 pD3 but lesser with NS3133-142 pD2. The 
finding that secondary infection with a virus carrying a similar but distinct epitope 
can stimulate the proliferation of cross-reacting, low-affinity clones is interpreted 
as "original antigenic sin" phenomenon ofT cells. 
However, we could not generally reproduce this finding in our acute samples of 8 
adult Vietnamese patients with DEN-l and DEN-3, -4 infections. We speculated 
that an additional mechanism by which the order of sequential dengue serotype 
infections might influence phenotypic manifestations. In theory, a second dengue 
infection may occur in any of 12 possible sequences (1-2, 1-3, 1-4, etc.). 
Epidemiologic studies have suggested that the order of acquisition of dengue virus 
infections might be important. Classical DHFIDSS has occurred with infections in 
the sequence DEN-l followed by DEN-2 (Guzman, Kouri et al. 1990), DEN-3-
DEN-2, or DEN-4-DEN-2 (Sangkawibha, Rojanasuphot et al. 1984), and DEN-l-
DEN-3 (Endy, Nisalak et al. 2004). Other sequences may also exist but have not 
been reported. Infections caused by the sequence DEN-I-DEN-3 were 
accompanied by DHFIDSS cases, whereas in the Americas from 1963 to 1977, 
many persons must have been infected in the sequence DEN-2- DEN-3 genotype 
V, but without developing DHFfDSS (Alvarez, Rodriguez-Roche et al. 2006). 
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Experimentally, by analyzing of murine CD8+ T cell clones specific for the 
dengue virus NS3 protein, Spaulding found that the patterns of dengue virus 
serotype cross-reactivity in short-term T cell lines and clones differed in mice 
immunized with different dengue serotypes. CTL responses are influenced by the 
order of acquisition of serotypes of dengue virus (Spaulding, Kurane et al. 1999). 
In addition, Brehm, Welsh et al showed that previous viral infection markedly 
altered the establishment of virus specific memory CD8+ T cells for subsequent 
infection with a heterologous virus encoding a cross-reactive peptide (Brehm, 
Pinto et al. 2002). Collectively these observations suggest that particular sequences 
of infection can have different biological phenotypes and this might extend to the 
characteristics of the acute T cell response to NS3 133-142 peptides. 
4.5.3 Ex - vivo cell surface staining for PBMCs & Over activation of cross-
reactive CTL 
Although one adult patient (BC307) demonstrated a larger ex-vivo NS3 133_142 -
specific tetramer positive population in acute samples, the rest (majority) of 
patients showed much less significant staining. 
Ex vivo staining ofPBMC from patient BC307 demonstrated equally high levels of 
CD38+ staining among all tetramer positive cells in the acute phase. By three 
weeks after the acute sample CD38 expression had fallen markedly. At this time 
point CD8+ cells recognizing the two similar peptide variants, pDt and pD3/4, 
were present (partially cross-reactive) but cells cross-reactive between the more 
heterologous peptides, pD2 and pD3/4 could not be detected (highly cross-reactive 
cells). CD38 expression was greater on those T cells recognizing both pDt and 
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pD3/4 (57%) than upon partially or non cross-reactive T cells (19%). This suggests 
that highly cross-reactive T cell populations are more activated than cells 
exhibiting low levels of cross-reactivity. 
These observations, albeit limited to one patient, led us to the hypothesis that high 
levels of T cell activation in the acute phase of dengue are possibly associated with 
activation - induced cell death. 
Others have found that tetramer staining of fresh blood does not always 
demonstrate large numbers of virus specific CD8 T cells in acute dengue infection 
(Mongkolsapaya, Dejnirattisai et al. 2003). As discussed in 4.5.2, this phenomenon 
may be a consequence of the timing of cell proliferation, the sequestration of T 
cells in infected peripheral tissues or in lymphoid organs, or the massive apoptosis 
of stimulated T cells or perhaps, the combination of them. The enhancement of 
viral replication caused by antibody-mediated immune enhancement may drive the 
T cells with highest affinity for the infecting virus into apoptosis, through the 
process of activation-induced cell death (Mongkolsapaya, Dejnirattisai et al. 2003). 
The over-activation of CD8+ T Lymphocyte could possibly be associated with 
serotype cross - reactive T cells. Excessive immune activation may contribute to 
clinical disease during secondary infection. In particular, the rapid mobilization of 
serotype cross-reactive memory T cells that release vasodilator inflammatory 
molecules has been suggested to explain some aspects of the clinical syndrome 
(Kurane, Rothman et al. 1994). Relatively higher frequencies of activated, cross-
reactive CD8+ T cells (Zivna, Green et al. 2002; Mongkolsapaya, Dejnirattisai et 
al. 2003), and a range of direct and indirect markers of cellular immune activation 
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have been associated with severe disease during secondary infection (Kurane, Innis 
et al. 1991) (Kittigul, Temprom et al. 2000) (Green, Pichyangkul et al. 1999) 
(Green, Vaughn et al. 1999) (Green, Vaughn et al. 1999) (Gagnon, Mori et al. 
2002) (Juffiie, Meer et al. 2001). 
To gain further insight around this phenomenon, we generated CTL lines and 
clones stimulated with different variants of NS3133-J42 peptide from acute and 
convalescence PBMCs of secondary DHF patients then evaluated the functional 
phenotype of these cross-reactivity CD8+ T cells (next chapter). 
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5.1 Introduction 
In order to assess the fine specificities of dengue-specific CTL with limited cell 
numbers, and in the face of the possible down-regulation of cell-surface TcR 
expression in acute samples, we have studied further the specificity and cross 
reactivity of CD8+ T-cells by generating short-term CD8+ CTL lines and clones 
stimulated with the different variants of the immunodominant NS3 133-142 peptide 
(Table 4.5) from acute and convalescence PBMCs of DHF patients with secondary 
dengue. The functional phenotype of these cross-reactivity CD8+ CTL lines and 
clones was then evaluated. 
5.2 Results 
5.2.1 Highly cross-reactive CTL can be expanded from bulk culture of PBMC 
in acute infection but are less abundant in convalescence. 
PBMCs collected acutely (day 4-7 of illness) and during convalescence (3 months 
after illness onset) from three patients were used in this study. The details of the 
patients are summarized in (Table 5.1). 
Acute and convalescence PBMC samples (5-10 x 106cells/sample) from these 
patients were incubated with each of the dengue NS3 133-142 variant epitope 
peptides (Table 4.5) at 2J.tM concentration for 1 hour, after which IL-7 
(PeproTech) was added at 25 ng/ml. On day 3, 25 to 50 U of recombinant 
interleukin-2 was added. On day 14 and 20, CTL were double-stained with HLA-
A II tetramers assembled with different epitopes and labeled with different 
fluorophores (see chapter M&M). 
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Table 5.1: Acute secondary dengue infected paients had HLA-All restricted NS3 133-142 
specific responses_ 
Patient Age Infecting Days of illness at the time of Clinical Diagnosis 
ID serotype enrollment 
BC 307 17 Unknown 6 Secondary DHF III 
MD893 14 04 3 Secondary DHF I 
MD856 11 04 5 Secondary 0 HF I 
We conSIdered such T cell lInes - those recognizing both pD2 and pD3/4 - to be 
highly cross-reactive given their equal recognition of both tetramers despite 
significant peptide sequence variation. T cell lines recognizing pD 1 usually 
recognized pD3/4 - a reflection of their greater similarity in peptide epitope 
sequence. 
The pattern of staining differed slightly in each patients but all three patients 
demonstrated expansions of highly cross - reactive T cell lines (Le. binding both 
pD2 and pD3/4 tetramers equally well) from acute samples after stimulation with 
each of the dengue NS3 133-142 variant epitope peptides (Fig. 5.1). In contrast to T 
cell lines generated from acute samples, those from convalescent samples did not 
contain the same proportion of T cells that were highly cross-reactive with the pD2 
and pD3/4 tetramers (Figure 5.1). Serotype specific CTL lines (i.e. strong binding 
of the tetramer folded with the peptide of one serotype, weak binding of the other) 
were detected from acute and convalescent samples after stimulation with variants 
of epitope peptides. 
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Figure 5.1: Highly cro s-reactive T cells can be expanded from acute but not 
convalescent PBMC from dengue-infected patients. 
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(b) Short term CTL lines from MD856 PBMCs 
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(c) Short term CTL lines from MD893 PBM Cs 
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Interestingly, in patient MD 893, after pD2 stimulation, there was a single 
population of cross-reactive cells acutely but in convalescence there were two 
population of cells: one had pD3/4 serotype specificity (i.e. strong binding of 
pD3/4 and weak binding of pD2 tetramers) and the other had pD2 serotype 
specificity. (Figure 5.l-c). These data suggest there are differences between acute 
and convalescent samples in terms of the repertoire of dengue NS3133-142 specific T 
cells that proliferate in response to pD2 stimulation in vitro. 
In addition, the double tetramer staining is a competition assay and can be 
considered as a measure of relative avidity between the two competing tetramer 
peptides than of absolute serotype specificity. Therefore, we went on to generate T 
cells clones to further examine the fine phenotypic differences between dengue 
NS3 133-142 specific T cells in acute and convalescent samples. 
5.2.2 Dengue specific cross-reactive CTL clones. 
Dengue specific Cytotoxic T Lymphocyte clones were generated by the limiting 
dilution ofT cell Jines generated as described in chapter 2. Briefly, CTL lines from 
three above donors (stimulated with each of the 3 dengue NS3 133-142 peptide 
variants - acute and convalescent) were plated out in flat - bottom 96-well 
microtitre plate at a concentration of 1 cell/well in cloning mixture containing 
irradiated mixed allogeneic PBMCs, irradiated autologous peptide -pulsed BCLs, 
phytohaemagglutinin and 10% pooled human AB serum in RPM!. On day 4, 50 U 
of recombinant interleukin-2 per ml of 10% pooled human AB serum in RPMI 
was added. Wells demonstrating sufficient growth and cell density (very obvious 
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on micro copy of flat-bottomed plate) at each 7-day period were screened for their 
specificity u ing dengue S3 133-142 tetramer staining and selected clones were 
expanded into 48-well (then 24-well) plate tissue culture plates with autologou , 
irradiated, peptide-pul ed EB -tran formed B-Iymphoblastoid cells (B-LCL). An 
example of dual tetramer taining for a diver e selection of the clones was shown 
in Figure 5.2. 
Figure 5.2: n example of dual tetramer taining for clone selection. 
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Candidate 0/ dengue pecijic CTL clones from the limiting dilution ofT eel! lines were co-
stained with pDf, pD2 and pD3/4 tetramers and CD8 antibody. The plots are gated on 
CD po itive cells. (a) clone £5: cross-reactivity to pDf - pD2 and pD34, (b) clone D9: 
pD3/5 serotype specijic, (c) clone C4-8: partially cross-reactive to pDf and pD3/4. 
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The expanded clones were cultured for 14 days and were screened for their 
specificity using pD2 and pD3/4 tetramer staining. 
Specific clones were maintained by weekly restimulation with autologous, 
irradiated, peptide-pulsed EBV-transformed B-Iymphoblastoid cells (B-LCL) and 
also could be kept frozen and stored in liquid nitrogen. Specific clones were 
studied for their lytic activity in a CTL assay and their cytokine expression profile 
measured by cytokine beads assays and intra-cellular Cytokine Staining assays 
(ICS). 
Although there were populations of CTL lines that showed tetramer binding 
positive on either 14th or 20th day after stimulation, except BC307, specific 
cytotoxic T Lymphocyte clones could not be generated from MD 856 or MD 893. 
Table 5.2: Dengue HLA-AII restricted NS3133-142 specific CD8+ T cell clones. 
CD8+ T cells clones from: Acute Sample Convalescent Sample 
pOl stimulated I 4 
pD2 stimulated 3 0 
pD3+4 stimulated I 7 
Total 5 11 
5.2.3 Specificity of CTL clones using CTL lysis assays. 
To determine the specificity of the 16 clones, we tested their capacity to recognize 
peptides corresponding to the three variant NS3 133-142 epitopes by using CTL lysis 
assays. CTL lysis assays were performed using standard slChromium release 
assays. Briefly, HLA-AII matched B-cell lines (BCL) were labeled with 
slChromium for 1 hour, and then washed three times: target cells were then 
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divided and pulsed with each of a panel of three variants of NS3 133-142 peptide at 
different concentrations (0.1, 1 and 10 f.lM). After another hour of incubation at 
37°C, the peptide solution was then washed off and cells were counted and co-
cultured with CTL clones at appropriate effector to target (E: T) ratios (10:1) in 96 
well plates. The plates were incubated at 37°C for 4 hours, supernatants were 
harvested and radioactivity measured using a Beta-plate counter. 
CTL clones generated by limiting dilution of short-term T cell lines derived from 
both acute and convalescent PBMC stimulated with either PDl, pD2 or pD3/4 had 
a heterogenous range of cytolytic activity. The percentage of lysis of these clones 
to target cells pulsed with either of three variants of NS3 133-142 peptide at 0.1 f.lM, 
1 J.1M and 10 J.1M are shown in Figure 5.3. 
Interpretation of T cell clone reactivity 
The spectrum of cross-reactivity displayed by different CD8+ T cell clones is 
summarized in Table 5.3. Overall, most CD8+ clones recognized at least 2 peptide 
variants of the NS3133-142 epitope. In particular, a large proportion of clones 
recognized the highly sequence similar NS3 133-142 epitopes pD1 and pD3. This 
was independent of the type of peptide used for stimulation- for example several T 
cells clones elicited by in vitro stimulation with pD2 nonetheless recognized both 
pD1 and pD3 in the chromium-release assay. With the exception of one clone 
(C3), all clones recognized the peptide used for stimulation of the PBMC. 
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pecificity and cytolytic efficacy in chromium-release a says. 
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Target cells were pulsed with either pD1 (blue - horizontal lines), pD2 (pink-noline) or pD3 
(yellow - vertical lines) at difJerent concentration: 0.1JiM, f J1M and 10J1M The E:T ratio was 
10:1 for all clones. (a) Clones (C9, E5. C3, Cll, D9) derived from acute PBMC by 
stimulating with pDf, pD2 and pD3/4. respectively. (b) Clones (C9 _8, C4_1, C4_10, C4_8) 
derived/rom convalescent PBMC by stimulating with pDl. (c) Clones (C19_2, CI2_1, C4 6, 
C4_5 C4_ 4 C4_3 C4_2) derived/rom convalescent PBMC by stimulating with pD3/4. -
Thu , p02 timulation elicited cro -reactive T cell clones that recognized all 
sequence variant of the 3 133-142 epitope. It was not possible to unequivocally 
detennine whether the T cell clone derived from this patient (BC307) repre ented 
T cell elicited de novo by the current DEN infection, or were memory cross-
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reactive T cells originally elicited by a previous DEN infection and re-stimulated 
by the current infection. 
Table 5.3: Recognition of Oengue specific Clones generated from PBMC of acute dengue 
infected patient by stimulating with different variants ofNS3 133.142 epitope.(+) 
Serotype Recognition Phase of illness Clone name 
Stimulation 
01 02 03/4 
Acute C9 ++ + + 
C4 1 +++ + +++ 
pDI C48 +++ ++ +++ Convalescent 
C4 10 ++ 
-
+++ 
C9 8 +++ + +++ 
E5 +++ +++ +++ 
pD2 Acute C3 - - + 
Cll +++ + ++ 
Convalescent 
Acute 09 + - +++ 
C4_2 +++ - +++ 
C4_3 ++ 
-
+++ 
pD3/4 C44 +++ - +++ 
Convalescent C4 5 ++ - +++ 
C46 ++ + +++ 
C12_1 + - ++ 
C19_2 ++ 
-
+++ 
.. PeptIde recogmtlOn IS classIfied by the percentage of specIfic lYSIS of B cells loaded 
with IJ.lM of peptide in a standard chromium release assay. +++ 50% or greater lysis, ++ 
between 20 and 50% lysis, + less than 20% lysis, - less than 5% or no lysis 
5.2.4 Further functional characterization of NS3133-142 specific CD8+ T cell 
dones. 
Subsets of clones were selected for further study in the basis of their peptide 
recognition patterns in chromium-release assay. Thus, clones E5 and C4.8 were 
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selected because they recognized all three of the common NS3 133-142 variant 
epitopes, with C4.8 being slightly less cross-reactive for pD2. Clones CII and 
C4.6 were selected because although reactive with all NS3 133_142 variant epitopes 
at high peptide concentrations, they failed to recognize pD2 at low concentrations. 
Finally, clone D9 was selected because of its relatively specific recognition of 
pD3/4. This subset of clones were tested for their CTL activity against peptide 
variants across a range of peptide concentrations, including low concentrations as 
might be found in vivo. In the same experiments, further functional analyses of the 
clones were performed by measuring cytokines in supernatants from co-cultures of 
clones and target cells. A schematic summarizing the methodology used to 
characterize these clones is shown in Figure 5.4. 
In parallel with the CTL lysis assays, we performed a duplicate set of experiments 
using the scheme described above but without stCr labeling of the BCL. 
Supernatant from the CTL and target cell co-culture was harvested after overnight 
incubation, and cytokines were measured by standard Cytokine Beads Array 
analysis. By using this model, we are able to compare between clones in term of 
cytolytic activity and cytokine production activity. 
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Figure 5.4: Experiment to correlate and compare Cytolytic and Cytokine production activities 
of Clones 
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+ 
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Cytokine Measurement 
Highly cro -reactive clone E5 maintained high levels of cytolytic activity against 
B-cell pul ed with all three peptide variants at concentrations as low as O.lJlM 
(Figure 5.5). 
Partially cro -reactive clone CII, C4.6 and C4.8 
Cl] (delived from acute PBMC with pD2 stimulation) howed robust killing 
acti ity again t pO 1 and p03/4, but no measurable activity against pD2 at 
concentrations below 10 llM concentration. Clone C4.6 (derived from 
con ale cent PBMC with pD3 stimulation) was lytic for cells pulsed with p03/4 
and to a Ie er xtent, pD1 , but had minimal activity against pD2 (Figure 5.5). 
Partially cro -reactive clone C4.8 (derived from convalescent PBMC with pO I 
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stimulation) howed good lytic activity again t cells pulsed with p03/4 and pO I 
but activity against pD2 decrea ed in a peptide concentration dependent manner. 
Relatively serotype specifi c clones 
Serotype specific clone 09 was lytic for target cell pulsed with its cognate peptide 
(pD3/4) but had minimal or absent activity against pD I and pD2 respectively at 
peptide concentrations less than 10 11M (Figure 5.5). 
Figure 5.5: Cytolytic activity of Highly Cro reactive Clone (ESt Serotype pecific Clone 
(09) and Partially Cro Reactive Clones. 
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Target cells were pulsed with either pDf (blue - round lines), pD2 (square line) or pD3 
(yellow - triangle lines) at different concentration. The E:T ratio wa 10: I for all clones 
These data on lytic activity amongst T cell clones sugge ted heterogeneity in the 
way these T cells re ponded to NS31 33-142 peptide valiants . To fu l1her exp lore 
functional differences between the clones, we analyzed cytokine respon es by 
clone in re ponse to pecific antigenic timulation, especially focus on IFNy and 
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1NFa as they have been implicated in the pathogeneses of the capillary leak 
syndrome in DHF. 
Patterns of cytokine release from CTL clones correlate with cytolytic activity. 
For many clones, IFNyand TNFa production by the clones correlated with their 
cytolytic activity. The higher cytolytic activity does, the higher of cytokine release 
is. 
For example, clone C4.6 had highest lytic activity against pD3/4 (Figure 5.6 d-f) 
and also produced higher levels of lNFa. and IFNyafter stimulation with pD3/4 
peptide. 
Cytokine secretion profiles are consistent with CTL phenotype for partially cross-
reactive T cell clones 4.6, 4.S and Cll. Shown are concentrations of TNFa and 
IFNy in supernatants of co-cultures containing peptide-pulsed target cells and 
CDS T cell clones 4.6 (Figure 5.6 d-f), 4.8 (Figure 5.6 g-j) and CII (Figure 5.6 k-
m). In these assays, TNFa and IFNy were good correlates of the T cell clones lytic 
activity. 
Serotype specific clone D9 showed intermediate activity and produced 1NFa and 
IFNyagainst its cognate peptide (PD3/4) and failed to recognize target cells pulsed 
with other peptide variants and they not produced cytokines. (Figure 5.6 n-p). 
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Figure 5.6: Cytokine relea e from CTL clones and Cytolytic ac tivity. 
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Target cells were pulsed with either pD I (blue round lines), pD2 (square line) or pD3 (yellow triangle 
lines) at different concentration. The £ :T ratio was 10: I for all clones. CytolytiC activity per peptide 
concentration of target cells were shown on left panel, cytokine release activity per peptide concentration of 
target cells were shown on middle (TNFa) and right( IFNr} panel. (a-c) Highly cross-reactive clone £5 
showed good lytic activit)' against cells pulsed with all three peptide variants and also prod/lced high levels of 
TNFaand IFNr. el'en at low peptide concentrations (0.01 pM). (d-m) Partially cross reactive clones. (Il-p) 
Serotype specific clone. 
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Cross-reactive CTL dones produce higher levels and different patterns of 
cytokine release than serotype-specific CTL 
A feature of the highly cross-reactive clone E5 was that it consistently produced 
higher levels of TNFa and IFNy than the other clones when stimulated with 
different peptide variants across a range of peptide concentrations (Figure S.7.a). 
Clones E5 and D9 produced similar quantities of IFN-y when stimulated by 
cognate peptide at high concentrations. At lower concentrations cross-reactive 
clone ES produces up to twice as much IFN-y than serotype specific D9 or 
partially cross-reactive clones. Clone E5 also produces up to 4 times more TNFa 
than serotype specific D9 or partially cross-reactive clones (Figure 5.7.a). These 
data suggest that clone E5 is broadly able to recognize NS3 133-142 variant peptides 
and in response to cognate antigen stimulation secretes relatively high levels of 
pro-inflammatory cytokines. 
To explore whether other patterns of cytokine secretion were associated with these 
T cell clones, concentrations of IL-4, IL-6, IL-2 and IL-IO were measured in 
culture supernatants. Along with TNFa and IFNy. clone ES produced relatively 
high levels of IL-I 0 and IL-2 whereas the other clones secreted either very low 
levels or not all (Figure S.7.b and c). 
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Figure 5.7: Cross-reactive CTL clones produce higher levels ofCytokine 
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(a) TNF a and IFNyproduction of clones at different concentration (0.1 to10JiM) of different peptide 
variants (PDl - blue horizontal lines; pD2 - pink 110 line: pD3/4 - yellow vertical lines). (b) IL 10 
production by highly cross - reactive clone E5 when incubated with difJerent peptide variant - pulsed 
target cell at different concentration (0.1 to10flM) of peptide (left)· IL-IO was produced in high 
levels by clone E5. Other clones produced 1L-10 in only very low levels if al all (right). (c) IL2 
production by these clones. 
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Intracellular cytokine secretion in antigen-stimulated clones 
We had thus far shown that T cell clones from a patient with secondary dengue 
were heterogenous with respect to their lytic activity for target cells and secretion 
of cytokines previously associated with dengue pathogenesis. To better understand 
whether the increased cytokine secretion by the cross-reactive clone ES was a 
result of more cells secreting cytokine, or perhaps more cytokine secreted per cell, 
we perfonned intracellular cytokine staining for TNF ex and IFNyon antigen 
stimulated clones. High cross-reactive clone (E5), partially cross-reactive clone 
(C4_8) and serotype specific clone (09) were stimulated with l/lM of different 
peptide variant pulsed HLA-matched BCL and incubated for 6 hours in the 
presence of brefeldin A. Cells were washed with F ACS buffer and were fixed and 
penneabilized with F ACSTM permeabilizing solution (80). This was followed by 
a wash and intracellular staining with antibodies for TNFex_FITC, IFNy_PE, 
C08+APC and pD3/4QR then analyzed by FACS machine (chapter 2). 
The frequency of TNFex+ CD8+ T cells and IFNy+-CD8+T cells following 
stimulation with l/lM p03/4 to high cross-reactive clone (ES) was higher than 
those of partially cross-reactive clone (C4_8) and serotype specific clones (09). 
(Figure S.8, Table 5.4 and Figure 5.9). 
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Table 5.4 : Double intracellular staining for TNFa, IFNyand C08+. Cytokine exprcs ion 
following timulation with 111M of djfferent peptide variant to high cross-reactive (E5), 
partiallyero -reactive (C4_ 8) and erotype specific clone (0 9). 
Clones % positive C08+ CTL 
TNFa INFy 
Unstimulation 0.56 0.48 
C4_8 p01 61 72 p02 13 29 
p034 59 71 
Unstimulation 0.25 0.22 
09 p01 3 10 pD2 5 11 
pD34 13 29 
Unstimulation 2 3 
ES pD1 52 72 p02 37 51 
pD3/4 67 80 
Figure 5. : Intracellular cytokine secretion in antigen-stimulated clones 
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Figure 5.9: An example of Intracellular cytokine ecretion in alltigen- timulated clone by 
F ACS IC plotting 
Nopoplclo 
~~ ____ ~D~~~ ______ ~ 
TNFIIIpba 
7: F a+ CD8+ T cells /0110 wing stimulation with with I jlMpD3/4 to high cross-reactive 
clone £5 (Right) and no timulation (Left). 
5.3 Discu sion 
In this chapter, we have performed ex vivo characterization of N 313). 142 specific 
T cell by timulation of PBMC then identified and characterized a panel of 
N 3133-142 specific CD + T cell clones. A feature of the T cell clones wa their 
heterogeneity in lytic activity and cytokine secretion when stimulated with NS3 133-
142 variant epitope . 
we ob erved that hort-term timulation of PBMCs with epitope peptidcs 
produced large e pan ion in the tetramer positive populations, in order to asse 
the fine pecificitie of dengue-specific CTL with limited cell number , we grew 
hort-term CTL line by stimulating PBMCs with each of the A II N 3133- 142 
epitope variant. 
We howed that the highly cross-reactive populations again t p02 and p03/4 
apparent in the acute pha e with high frequency but in the convale cent sample 
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with very low frequency or not detectable when more serotype specific populations 
have appeared. 
We considered such CTL - those recognizing both pD2 and pD3/4 - to be highly 
cross-reactive given their equal recognition of both tetramers despite significant 
sequence variation. CTL recognizing pDl usually recognized pD3/4 - it might be 
explained as a reflection of their greater homology. Cells showing high cross-
reactivity between pD2 and pD3/4 always cross-reacted with pD 1. Interestingly, in 
convalescent samples, these highly cross-reactive CTL were at low frequency or 
undetectable. 
The previous chapter showed that ex vivo staining of PBMC from patient BC307 
demonstrated equally high levels of CD38+ staining among all tetramer positive 
cells in the acute phase. CD38 expression was greater on those highly cross-
reactive T cells than partially or non cross-reactive T cells. This suggested that 
highly cross-reactive T cell populations are more activated than cells exhibiting 
low levels of cross-reactivity. Therefore, we went on further assessment the cross-
reactivity of de~gue-specific CTL by exploring the cytotoxic characteristics of 
CTL clones. 
Five CTL clones were isolated from PBMes in acute sample from donor BC307 
by stimulation with each of three variants of NS3J33-J42 peptide. In convalescent 
cells from the same donor only pDl and pD3&4 stimulation generated NS3 133_142 
specific clones (11 clones). 
CTL clones stimulated with each variants of peptide showed were either serotype 
specific (i.e. only strong recognition for a single variant peptide tetramer), partial 
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cross-reactivity (both showing strongest recognition for pD3/4 and differing 
recognition of pDl or vice versa) or highly cross-reactivity between pD2 and 
pD3/4 (PD 1) tetramers. Highly cross-reactive clone showed high levels of cytolytic 
activity at low peptide concentrations with all three peptide variants in a standard 
chromium release assay. Partially cross-reactive clones varied in the extent to 
which they recognized the epitope variants on pulsed B-cells in CTL lysis assays. 
They were grown from lines derived from acute and convalescent samples. 
Partially cross-reactive clones derived by either pDl or pD3/4 stimulation showed 
strongest lytic activity against cells pulsed with corresponding sequence ofNS3 133_ 
142 peptide that stimulated the memory cells in PBMC (cognate stimulator), 
respectively but varied lower activity against other reciprocal peptide. All cross-
reactive or partially cross-reactive clones maintained lytic activity against B-cells 
pulsed with peptide concentrations as low as O.Ol~M. In this study, there was only 
one serotype specific clone (ES) that showed intermediate activity against its 
cognate (stimulation) peptides but failed to recognize target cells at these low 
levels. 
Our cloning phenotypes are similar to our previous finding that large expansions of 
highly cross-reactive CTL (binding to both pD2 and pD3/4 tetramers equally well) 
were seen in pD2 stimulated cultures of acute but not convalescent PBMC samples 
from the same patient. They are also comparable with results of ex vivo staining of 
PBMC from patient BC307 that could showed pDl-pD3/4 cross-reactive cells at 3 
weeks after illness but not pD2-pD3/4 cross-reactive cells. 
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In this study, we could isolate only one good D3/4 serotype specific clone (D9) 
from acute PBMC with NS3 133_142 peptides_ Clone C3 was another D3/4 serotype 
specific but with low lysis activity (5%) at concentration of 1 J.lM of peptide in a 
standard chromium release assay; at higher concentration of stimulation, it showed 
approximately 20% cross-reactivity lysis activity against both pD3/4 and pDI, 5% 
lysis activity against pD2. It would emphases that this C3 clone was generated by 
challenge with pD2. Challenge with pD2 could expand three clones from acute 
PBMCs but not convalescent; among those, one was highly cross-reactive against 
all four serotypes (E5), one was partial cross-reactivity (CII) and one was serotype 
specific with low lysis activity (C3). Whereas, almost the rest of clones that 
stimulated by either pD I or pD3/4 were partial cross-reactivity against only those 
two peptides with relatively equal magnitudes. Regarding our experiment as an 
alternately way of T cell clone expansion ex-vivo in sequential challenge from 
acute secondary dengue infected PBMCs, "original antigenic sin" phenomenon 
have been seen in pD2 stimulation. These pattern of dengue specific responses also 
suggested that this patient might be acutely infected by DEN-3 or Den-4 serotype. 
In addition, original antigenic sin could be explain why highly cross-reactivity and 
serotype specific clones were not likely generated from challenging convalescent 
PBMCs. It is possible that serotype specific precursor memory CTLs are in very 
low frequency in convalescent samples in comparison with the partially cross-
reactive memory CTLs. 
Recently, my colleague Dr Tao Dong established a clone from an acute dengue 
patient as part of our collaborative research project, also found a similar 
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phenomenon in three highly cross-reactive clones of one 10-year-old dengue 2 
infected child (MD 1413). These clones were grown from short term lines derived 
from acute samples but not convalescent samples, and produced high levels of both 
type 1 and type 2 cytokines than serotype specific clones (Dong, Moran et a1. 
2007). Therefore, we have demonstrated that in hospitalized Vietnamese patients 
with acute dengue virus infection, a population of high cross-reactivity CTLs 
between all four dengue serotypes and a significant degree of activation could be 
detected in peripheral PBMCs. High cross-reactivity CTL clones also could be 
expanded by ex-vivo challenging with HLA-All_NS3\33.142 pD2, which is 
possibly not the current serotype infection (suggested DEN-3/4 serotype as 
discussion above). 
In this study, we reported that the highly cross-reactive clone grown from acute 
samples may secrete IL-I0 and produce more high levels of TNFa. even at low 
peptide concentrations (0.0 I JlM), whereas serotype specific clones do not secrete 
any IL-IO and produce much less 1NFa., IFN-y. 
As discussed in Chapter 3, Type 1 cytokines (IFN-y, TNF-a) exhibit vasoactive 
properties and are likely to participate in the pathogenesis of vascular leak. In 
addition TNF-a. can mediate activation-induced cell death in some T cells (Zheng, 
Fisher et al. 1995) and has been implicated in peripheral T-cell deletion (Speiser, 
Sebzda et al. 1996; Sytwu, Liblau et a1. 1996). Type 2 cytokines such as IL-I 0 also 
have been implicated in the pathogenesis of severe dengue (Mustafa, Elbishbishi et 
al. 2001; Perez, Garcia et al. 2004). IL-IO can be produced by distinct CD4+ and 
CD8+ T cell populations and has the ability to suppress T cell function (Tanchot, 
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Guillaume et al. 1998; Pestka, Krause et al. 2004). The net effect of interactions 
and balance between pro inflammatory and anti-inflammatory molecules over time 
determines the nature of the immune response in individual patients. It could be 
postulated that certain type 2 cytokines such as IL-1 0 produced in acute disease by 
a subset of highly cross-reactive CTL might exert an inhibitory effect on dengue 
specific effector T cells. 
These findings could be interpreted as implicating highly cross-reactive CTLs in 
the pathogenesis of severe dengue disease through differential release of 
vasoactive and pro-inflammatory factors. We propose that during the acute illness 
of secondary infection with a heterologous strain of dengue virus, high cross-
reactive CTLs may be generated for some epitopes that produce high levels of 
TNFa and IL-I 0 and may contribute to plasma leakage and cell death. 
Our study had several limitations. Although there were populations of CTL lines 
that showed positive tetramer binding on either the 14th or 20th day after 
stimulation, with the exception of BC307, dengue specific Cytotoxic T 
Lymphocyte clones could not be generated from patients MD856 and MD893. In 
our experiment, T cell clones were generated from the portion of PBMCs 
(approximately 107 cells for each cloning process) that were taken from peripheral 
blood samples at a certain time point during the acute phase and during the follow-
up phase of one severe patient, and therefore might not be representative of other 
time points in the illness process. More generally, the patients who were admitted 
into our study are not representative of the whole population of individuals with 
dengue in the community. The cloning progress was also likely influenced by 
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varied factors that might impact on the generation of the clones, e.g. cell 
concentration, culture conditions, timing of stimulations. 
To further understand the role of highly cross-reactive CD8 T cell that produce 
high levels of cytokines in the pathogenesis of dengue, further work is needed. 
Such studies should include larger numbers of patients across a range of disease 
severities that are followed early in their illness with specific tetramer reagents 
until convalescence. 
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Transient increase in vascular permeability is the cardinal pathological feature in 
DHF that results in the leakage of plasma to the interstitial space. Many factors 
including total virus burden, viral virulence, host immune response (Bethell, 
Flobbe et al. 1998) (Leitmeyer, Vaughn et al. 1999) (Vaughn, Green et al. 2000), 
and genetic predisposition (Stephens, Klaythong et al. 2002) have been implicated 
in the plasma leakage. The findings in my thesis strongly implicates vaso-active 
cytokines such as TNFa, soluble TNF receptors, IFNy, IL-2, IL-6, IL-I0 and 
possibly, the imbalance between these proinflammatory and anti-inflammatory 
cytokines of immune system in the pathogenesis of dengue infection (Kurane, 
Innis et al. 1991) (Hober, Poli et al. 1993) (Hober, Delannoy et al. 1996) (Bethell, 
Flobbe et al. 1998) (Hober, Nguyen et al. 1998) (Green, Vaughn et al. 1999) 
(Braga, Moura et al. 2001) (Perez, Garcia et al. 2004). 
For many years, the prevailing mechanism proposed to link immunological cross-
reactivity with the pathogenesis of severe disease has been antibody-dependent 
enhancement (ADE) (Halstead 1989) (Morens 1994), in which partially cross-
reactive antibodies generated against one dengue serotype fail to provide 
protection against other serotypes but enhance macrophage infection by 
heterologous virus. The mechanism of action of ADE is thought to involve 
formation of complexes of dengue virus and pre-existing, non-neutralizing 
antibody against a different dengue serotype; these complexes is then endocytosed 
by Fe receptor baring cells (such as monocytes) (Littaua R 1990). This allows for 
the infection of greater numbers of cells, which can lead to a greater viral load, 
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particularly early in infection. High viremia titres during dengue infection, peaking 
2 days before defervescence, have been shown to correlate with progression to 
DHF at defervescence (Vaughn DW 2000) (Libraty DH 2002). 
Recent reports have linked cross-reactive cellular immune responses to dengue 
virus with pathogenesis (Zivny, DeFronzo et al. 1999) (Mongkolsapaya, 
Dejnirattisai et al. 2003). Using HLA class I peptide tetrameric complexes 
("tetramers") to identify HLA-All-restricted CD8+ T-cells specific for an 
immunodominant epitope in the dengue protein NS3 133_142 that varies between 
dengue virus subtypes, it was observed that in acute secondary dengue infection 
with a particular serotype, low affinity T-cells were preferentially expanded which 
showed greater specificity for NS3 variant epitopes from previous infecting 
serotypes, an immunological phenomenon termed "original antigenic sin". It was 
proposed that these cross-reactive cytotoxic T-cells (CTL) which had been raised 
against a previous dengue strain would be less efficient in eliminating newly 
encountered dengue virus serotypes, and that this could lead to increased virus 
replication and more severe disease (Mongkolsapaya, Dejnirattisai et al. 2003) 
In my thesis, I provide further evidence of the potential pathogenic role for CTL in 
Vietnamese patients with acute dengue virus infection, a population of high avidity 
CTLs that show substantial cross-reactivity between all four dengue serotypes and 
a significant degree of activation can be detected. However, these highly activated 
cross-reactive cells cannot be detected in convalescent samples. The failure to 
expand these cells from convalescent samples suggests they are absent or greatly 
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reduced in number by this time point. This may be a consequence of the large 
ADE-augmented antigen load combined with the high avidity of the T cells 
leading to over-activation, T cell exhaustion and cell death presumably as a 
consequence of activation-induced cell death (Green, Droin et al. 2003). Newly 
generated CTLs therefore dominate that show a much greater degree of serotype 
specificity. 
When CTL clones are expanded from either acute or convalescent samples, 
significant differences in the cytokine profile are seen: cross-reactive clones grown 
from acute samples may secrete IL-IO and produce high levels of TNFa., whereas 
serotype specific clones do not secrete any IL-IO and produce much less TNFa. and 
IFNy. These findings have significant implications for understanding the role of 
highly cross-reactive CTLs in the pathogenesis of severe dengue disease through 
differential release of vasoactive, pro-inflammatory factors and possibly anti-
inflammatory factors. 
Discussion surrounds the precise roles of antibody and cellular immunity in term 
of overall immune system in dengue infection. Antibody enhancement of 
secondary infection facilitates viral infection of cells leading to high viraemia, 
antigen loading of antigen-presenting cells and a consequently vigorous cellular 
immune response. My observations outlined here suggest that not only the 
magnitude, but the specific "style" of the immune response could be of 
significance. Memory CTL demonstrating both serotype-cross reactivity (a pre-
requisite for expansion from the memory pool in secondary infection) and higher 
levels production activity of inflammatory cytokines than their serotype specific 
170 
Chapter 6 Discussion 
peers. In vivo this may contribute to the level of those vasoactive cytokines shown 
to have an association with plasma leakage and disease severity. Moreover, as 
discussion about Carr's experiment (Carr, Hocking et a1. 2003) in chapter 3, 
vasoactive cytokines released from cellular immune response possibly enhance 
further the permeability of activated endothelial cells that were pre-exposured by 
TNF-alpha released from dengue virus-infected monocytes in early phase of 
infection. Those former cytokines possibly act as another pulse of vaso-actice 
factor(s) in the "later phase" of the illness-immune responses and reinforce the 
circulation system overdrive their threshold of compensation, thus shock syndrome 
is developed. This hypothesis could be applied to the manifestation of plasma 
leakage in dengue haemorrhagic fever clinically. All DHF patients had 
progressively increased endothelial permeability with variety of degree when 
present at the clinics and the peak of plasma leakage occurs late in the course of 
disease, usually after the decline in fever, at day 4 to day 5 after onset. It is 
possibly that plasma leakage pathogenesis is a complex, multifactorial process, in 
that, in early phase of dengue infection (i.e. viremia and fever), cytokine cascades 
released mainly by the activation of monocytes/macrophages and possibly by 
complement activation, the interaction of other vaso-mediators such as histamine, 
tissue plasminogen activator (tP A), macrophage migration inhibitory factor (MIF). 
In later phase, cytokine response is clearly closely linked to T-cell activation and 
the complex interaction of antibody - dependent enhancement - viral replication -
T cell activation - cytokine release interplays of self-reinforcing pathological 
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events which ultimately increases further vascular permeability and leads 
circulatory failure. 
In term of cardinal feature of plasma leakage and immunopathogenesis in dengue 
infection, we postulated that dengue disease exists as a continuous spectrum of 
clinical manifestation rather than classical distinct clinical entities such as dengue 
fever, dengue haemorrhagic fever and dengue shock syndrome. A new dengue 
classification scheme based on an understanding of the pathophysiology is 
therefore necessary in order to help in defining the direction of epidemiology and 
pathogenesis research, and to improve clinical diagnosis and management. 
On limitation of my studies was the relatively small number of patients to allow 
firm conclusions to be drawn regarding disease pathogenesis. Nonetheless these 
findings have potentially significant implications for understanding the role of 
virus-specific CTL in immunity to dengue virus infection and in the pathogenesis 
of severe dengue disease. Further work is needed to extend them and relate the 
presence or absence of such high-avidity cross-reactive cells to clinical spectrum. 
The significant problems of multiple serotypes of dengue virus, ADE with cross-
reactive antibody, serotype cross-reactive T cells are important challenges in 
furthering our knowledge of dengue infection. Management of dengue infection 
currently relies on symptomatic treatment with fluid replacement that aims to 
compensate the plasma leakage and resuscitation if circulation failure occurs. 
Radical therapy with a specific treatment, administered in the early stages of 
dengue infection, which prevents viral replication and thus reduces the high viral 
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load associated with severe disease, represents an attractive option in the fight 
against dengue in future. Greater understanding of the immune mechanism 
underlying the disease may help us design rational immune modulatory treatment 
and aid in the development of vaccines. 
In recent years there has been considerable progress in the production of a vaccine 
against dengue with advanced candidates undergoing Phase II and soon Phase III 
clinical trials (Bhamarapravati and Sutee 2000) (van Der Most, Murali-Krishna et 
al. 2000) (Kochel, Raviprakash et al. 2000) (Guirakhoo, Pugachev et al. 2002). 
Unfortunately, knowledge that cross-reactive immune responses between dengue 
serotypes may play a part in the pathogenesis of severe disease has been a 
substantial obstacle to dengue vaccine development. It is important to assess not 
only the nature of the antibody response but the fine specificity, and effector 
function of T -cells elicited by putative dengue vaccine candidates in order to aid 
the development of a vaccine that produces pan-serotype protective immunity 
without the risk of iatrogenically excessive vaso-active cytokine release. 
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Appendix 1: List ofHLA-All predicted pep tides (nonamers & decamers) 
of serotype 2 dengue (strain 16681) 
Start Subsequence Residue 
ID Position * Location Listing Type 
1 36 C GMLQGRGPLK 10 mers 
2 163 preM ITYKCPFLK 9 mers 
3 318 E KPTLDFELI K ]0 mers 
4 394 E VTCAMFTCKK )0 mers 
5 399 E FTCKKNMEGK 10 mers 
6 506 E TQGSNWIQK 9 mers 
7 518 E VTFKNPHAK 9 mers 
8 518 E VTFKNPHAKK 10 mers 
9 566 E RLRMDKLQLK 10 mers 
10 576 E GMSYSMCTGK )0 mers 
11 582 E CTGKFKVVK 9 mers 
12 632 E TTVNPIVTEK )0 mers 
13 665 E GQLKLDWFK 9 mers 
14 665 E GQLKLDWFKK 10 mers 
15 666 E QLKLDWFKK 9 mers 
16 835 NSI VTRLENLMWK 10 mers 
J7 860 NSI KLTIMTGDIK 10 mers 
18 861 NSI LTIMTGDIK 9 mers 
19 887 NSI RYSWKTWGK 9mcrs 
20 936 NSI GVFTTNIWLR 10 mers 
21 949 NSI KQDAFCDSK 9 mers 
22 1038 NSI QTAGPWHLGK )0 mers 
23 1217 NS2 GLLLRKLTSK ]0 mers 
24 1335 NS2 LTTLSRTSK 9 mers 
25 ]335 NS2 LTTLSRTSKK 10 mers 
26 1336 NS2 TTLSRTSKK 9 mers 
27 1509 NS3 SQIGAGVYK 9 mers 
28 1527 NS3 VTRGAVLMHK 10 mers 
29 1570 NS3 VQVLALEPGK 10 mers 
30 1583 NS3 AVQTKPGLFR 10 mers 
31 1608 NS3 GTSGSPIIDK 10 mers 
32 1692 NS3 RTLILAPTR 9 mers 
33 1832 NS3 KTVWFVPSIK 10 mers 
34 1863 NS3 KTFDSEYVK 9 mers 
35 1990 NS3 KVDAIDGEYR ]0 mers 
36 2006 NS3 KTFVDLMRR 9 mers 
37 2102 NS4 RLPTFMTQK 9 mers 
38 2161 NS4 FLMSGRGIGK 10 mers 
39 2312 NS4 ATVLMGLGK 9 mers 
40 2317 NS4 GLGKGWPLSK 10 mers 
41 2398 NS4 IPYDPKFEK 9 mers 
42 2472 NS4 GAGLLFSIMK 10 mers 
43 2521 NS5 IQEVDRTLAK 10 mers 
44 2526 NS5 RTLAKEGIK 9 mers 
45 2526 NS5 RTLAKEGIKR 10 mers 
46 2564 NS5 KVVDLGCGR 9 mers 
47 2581 NS5 GLKNVREVK 9 mers 
48 2841 NS5 RVFKEKVDTR 10 mers 
49 2850 NS5 RTQEPKEGTK 10 mers 
50 2880 NS5 RMCTREEFTK 10 mers 
51 2882 NS5 CTREEFTKK 9 mers 
52 3004 NS5 GYILREVSK 9 mers 
53 3004 NS5 GYILREVSKK 10 mers 
54 3041 NS5 ITNHMAGEHK 10 mers 
55 3075 NS5 GTVMDIISR 
56 3109 NS5 RQMEGEGIFK 
57 3137 NS5 RVGRERLSR 
58 3166 NS5 LTALNDMGK 
59 3340 NS5 GLTSRATWAK 
60 3341 NS5 LTSRATWAK 
61 3367 NS5 YTDYMPSMK 
Note: • position from the beginning of the viral genome. 
capsid protein C 
Pre M 
M 
E 
NS1 
NS2A 
NS2B 
NS3 
NS4a 
NS4b 
NS5 
1-114 
115-205 
206-280 
281-775 
776-1127 
1128-1345 
1346-1474 
1475-2093 
2094-2243 
2244-2491 
2492 3391 
9 mers 
10 mers 
9 mers 
9 mers 
10 mers 
9 mers 
9 mers 
Appendix 2: List of patients in tbe screening for Dengue serotype 2 HLA-A 11 epitope peptides (Cbapter 4) 
ID HospNo Age Gender Adm date Day of Illness DHFgrade Serotype Ret Platelet WBC N% L% 
BCOOI 18615 28 F 02-06-02 3 2 1,4 42 142000 6100 51.8 36.3 
BC303 22611 25 M 01-07-02 6 2 unknown 41 17000 5840 58.9 16.4 
BC304 23403 36 F 04-07-02 4 3 unknown 42 56000 7100 75.7 23.8 
BC306 31142 17 M 27-08-02 6 2 unknown 49 22600 3810 67.4 25.4 
BC307 31918 17 F 04-09-02 6 2 unknown 44 48000 7500 50.3 36.1 
BC310 33951 17 F 20-09-02 3 3 unknown 38 106000 4090 70.6 12.3 ! 
BC322 45756 26 M 12-12-02 3 3 unknown 52 25000 4080 50.2 25.5 
BC323 46074 31 M 16-12-02 4 3 unknown 53 75000 8540 29.5 24.0 
BC328 2073 15 F 05-02-03 5 1 unknown 42 36000 8430 32.0 56.0 
BC330 3320 16 M 09-02-03 6 3 4 46 46500 3080 59.8 20.7 
BC332 4274 16 M 13-03-03 5 3 unknown 51 45800 4870 73.7 17.2 
BC357 11690 26 M 30-06-03 5 3 2 50 40000 6120 40.0 43.0 
BC363 12686 31 F 15-07-03 5 3 unknown 41 36000 1400 51.0 42.0 
BC375 14349 16 M 10-08-03 4 2 unknown 38 38800 3870 60.3 16.4 
BC378 14576 21 M 13-08-03 5 2 2 57 49000 3800 42.2 45.5 
BC380 14710 17 M 15-08-03 5 2 1 48 144000 4300 72.1 22.9 
BC395 15503 23 F 26-08-03 5 2 2 46 18000 4400 36.0 55.0 
BC412 16686 23 F 11-09-03 5 3 unknown 41 19100 5900 42.0 55.0 
BC418 17050 21 M 16-09-03 3 2 unknown 43 155000 5990 79.2 19.0 
- -
-
------ -
BC419 17116 22 M 17-09-03 5 3 4 49 20100 2870 46.1 24.0 
BC420 17262 21 M 18-09-03 4 2 unknown 55 24000 3600 21.0 31.0 
BC423 14252 18 F 18-09-03 5 I unknown 41 28000 1900 61.0 23.0 
! BC428 17644 17 M 24-09-03 6 3 4 43 27900 5980 34.7 28.9 
BC437 18155 15 M 01-10-03 6 2 3 44 96600 3220 59.4 21.7 
BC439 18162 15 F 01-10-03 4 2 2 40 88500 2600 34.6 39.3 
BC440 18258 16 F 02-10-03 6 3 unknown 39 26000 7600 52.3 35.6 
BC441 18199 21 F 01-10-03 4 2 unknown 45 20000 5100 20.0 70.0 
BC444 18490 17 M 06-10-03 5 2 unknown 50 14000 3470 38.0 50.0 
BC467 20919 19 F 06-11-03 4 2 unknown 41 18500 3620 33.3 36.3 
BC494 23601 25 F 07-12-03 4 2 unknown 40 31000 2670 34.0 54.0 
BC703 24673 15 M 19-12-03 4 2 unknown 41 55900 5850 50.8 26.5 
--
Appendix 3: List of patients with acute phase PBMCs using in IFNl ELISPOT assays ae;ainst variants of 
NS313J-141 peptides. (Chapter 4) 
ID HospNo Age Gender Adm date Day of Illness DHFgrade Serotype Het Platelet WBC N% 
BC337 6089 16 M 06-04-03 4 3 1 46 17300 5090 44.1 
BC354 11229 17 F 24-06-03 4 2 1 50 30000 6600 72.0 
BC392 15403 20 M 25-08-03 4 0 1 46 51200 1750 53.2 
BC338 6758 22 F 15-04-03 3 2 2 42 33900 2490 51.0 
BC378 14576 21 M 13-08-03 5 2 2 57 49000 3800 42.2 
BC393 15424 17 F 26-08-03 4 3 2 49 46200 3650 68.9 
BC395 15503 23 F 27-08-03 5 2 2 46 18000 4400 36.0 
BC514 24292 18 F 15-12-03 6 1 2 38 44600 5600 79.0 
DF110 14909 9 M 18-08-03 5 3 2 41 49200 3100 71.8 
DF129 16162 8 F 05-09-03 3 3 2 41 53400 3700 56.2 
DF141 16321 7 M 07-09-03 6 3 3 41 60000 8150 52.0 
BC383 14927 16 M 18-08-03 6 2 4 40 31100 6100 30.7 
BC390 14932 18 M 22-08-03 2 1 4 41 90000 4200 75.2 
BC428 17644 17 M 24-09-03 6 3 4 34 41400 11800 26.8 
DF135 16034 12 F 03-09-03 6 3 4 40 88500 11700 82.6 
--- ---
L% 
27.5 
21.0 
32.1 ! 
31.1 
45.5 
21.6 
55.0 
21.0 
12.0 
37.5 
7.2 
33.8 
18.6 
36.7 
4.6 
